Compositions for the treatment of hypertension
Patent Information
- Application Number
- HK42026126512
- Authority / Receiving Office
- HK · HK
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2018-07-26
- Filing Date
- 2021-10-21
- Publication Date
- 2026-09-11
Smart Images

Figure 00000086_0000 
Figure 00000087_0000 
Figure 00000088_0000
Abstract
Description
(19) State Intellectual Property Office (12) Invention Patent Application (10) Application Publication Number (43) Application Publication Date (21) Application Number 202511608430.6 (22) Application Date 2019.07.26 (30) Priority Data 62 / 703,802 2018.07.26 US (62) Divisional Application Data 201980063218.2 2019.07.26 (71) Applicant George Global Health Institute Address Sydney, New South Wales, Australia (72) Inventors Stephen McMahon Anthony Rogers (74) Patent Agency Beijing Anxin Fangda Intellectual Property Agency Co., Ltd. 11262 Patent Attorneys Wei Changjin Wujingjing (51) Int.Cl. A61K 31 / 4422 (2006.01) A61K 31 / 4184 (2006.01) A61K 31 / 404(2006.01) A61K 45 / 06(2006.01) A61K 31 / 505(2006.01) A61K 31 / 397(2006.01) A61P 9 / 12(2006.01) (54) Invention Title Composition for the Treatment of Hypertension (57) Abstract This document provides a pharmaceutical composition for the treatment of hypertension, comprising an angiotensin II receptor blocker, a diuretic and a calcium channel blocker. Claims 2 pages, Description 83 pages, Drawings 3 pages, CN 122272578 A 2026.06.26 CN 1 22 27 25 78 A 1. A pharmaceutical composition comprising: (a) telmisartan; (b) indapamide; and (c) amlodipine besylate; wherein the dose of telmisartan is 8-12 mg or 12-16 mg; the dose of indapamide is 0.5-0.75 mg or 0.75-1.0 mg; the dose of amlodipine besylate is 1-1.5 mg or 1.5-2 mg; and wherein the pharmaceutical composition further comprises one or more cholesterol-lowering active agents. 2. The pharmaceutical composition of claim 1, wherein the dose of indapamide is about 0.625 mg. 3. The pharmaceutical composition of claim 1 or 2, wherein the dose of amlodipine besylate is 1 to 1.5 mg. 4. The pharmaceutical composition according to claim 1 or 2, wherein the dose of amlodipine besylate is 1.5 to 2 mg. 5. The pharmaceutical composition according to any of the preceding claims, wherein the dose of telmisartan is about 10 mg. 6. The pharmaceutical composition according to any of the preceding claims, wherein the dose of indapamide is about 0.625 mg, the dose of amlodipine besylate is 1.5-2 mg, and the dose of telmisartan is about 10 mg.7. A pharmaceutical composition comprising: (a) telmisartan; (b) indapamide; and (c) amlodipine besylate; wherein the dose of telmisartan is 16-30 mg, 16-24 mg, 18-22 mg, or 30-50 mg; the dose of indapamide is 1-1.875 mg, 1-1.5 mg, 1.125-1.375 mg, or 1.875-3.125 mg; wherein the dose of amlodipine besylate is 2-3.75 mg, 2-3 mg, 2.25-2.75 mg, or 3.75-6.25 mg; and wherein the pharmaceutical composition further comprises one or more cholesterol-lowering active agents. 8. The pharmaceutical composition of claim 7, wherein the dose of amlodipine besylate is 2-3.75 mg. 9. The pharmaceutical composition of claim 7 or 8, wherein the dose of amlodipine besylate is 2-3 mg. 10. The pharmaceutical composition according to any one of claims 7-9, wherein the dose of amlodipine besylate is 2.25-2.75 mg. 11. The pharmaceutical composition according to any one of claims 7-10, wherein the dose of amlodipine besylate is 3.75-6.25 mg. 12. The pharmaceutical composition according to any one of claims 7-11, wherein the dose of indapamide is about 1.25 mg. 13. The pharmaceutical composition according to any one of claims 7-12, wherein the dose of telmisartan is about 20 mg. 14. The pharmaceutical composition according to any one of claims 7-13, wherein the dose of indapamide is about 1.25 mg, the dose of amlodipine besylate is 2 mg-3.75 mg, and the dose of telmisartan is about 20 mg. 15. The pharmaceutical composition according to claim 1 or 7, wherein the pharmaceutical composition is a pill, tablet, or capsule. 16. The pharmaceutical composition according to any one of the preceding claims, wherein the one or more cholesterol-lowering drugs are rosuvastatin, ezetimibe, or a combination thereof. Claims 1 / 2 Page 2 CN 122272578 A 17. The pharmaceutical composition of claim 16, wherein one or more cholesterol-lowering active agents are rosuvastatin. 18. The pharmaceutical composition of claim 16 or 17, wherein the dose of rosuvastatin is 10 mg. 19. The pharmaceutical composition of claim 16, wherein one or more cholesterol-lowering active agents are ezetimibe. 20. The pharmaceutical composition of claim 16 or 19, wherein the dose of ezetimibe is 10 mg.Claims 2 / 2 Page 3 CN 122272578 A Composition for Treating Hypertension
[0001] This application is a divisional application of Chinese Patent Application No. 201980063218.2, filed on July 26, 2019, entitled "Composition for Treating Hypertension" (the corresponding PCT application was filed on July 26, 2019, and has the application number PCT / IB2019 / 000923). Cross-Reference to Related Applications
[0002] This application claims the benefit of U.S. Provisional Application No. 62 / 703,802, filed on July 26, 2018, which is incorporated herein by reference. Background Art
[0003] High blood pressure, also known as hypertension, is the leading cause of preventable morbidity and mortality, and treatment to lower blood pressure (BP) has been found to be beneficial. However, despite the availability of a large number of antihypertensive drugs, blood pressure control remains poor in many patients, as demonstrated by several large-scale population studies. Factors contributing to poor blood pressure control include poor adherence, complex guidelines suggesting multiple up-titration steps, and treatment inertia. Furthermore, most treated patients receive only single-drug therapy, which remains limited in efficacy even at high doses with increased side effects and decreased tolerability. Therefore, there is a need for effective and tolerable new treatments to lower hypertension. Summary of the Invention
[0004] In one aspect, this document provides a pharmaceutical composition comprising: (a) an angiotensin II receptor blocker; (b) a diuretic; and (c) a calcium channel blocker, wherein each of (a), (b), and (c) is at a dose of about 40% to about 80% of the lowest hypertension treatment dose (LHTD), wherein the pharmaceutical composition further comprises at least one cholesterol-lowering active agent. In some embodiments, the pharmaceutical composition is substantially free of angiotensin-converting enzyme inhibitors or pharmaceutically acceptable salts thereof, beta-blockers or pharmaceutically acceptable salts thereof, platelet function modifiers, serum homocysteine-lowering agents, or combinations thereof.
[0005] In some embodiments, the diuretic is a thiazide-like diuretic. In some embodiments, the thiazide-like diuretic is quetiapine, clopamine, chlorthalidone, mefcitabine, chlorfenapyramide, metoprazine, meteclaron, sipamine, indapamine, chlorothiazide, fenquinazole, or a pharmaceutically acceptable salt or hydrate thereof. In some embodiments, the thiazide-like diuretic is indapamide or its hydrate. In some embodiments, the thiazide-like diuretic is indapamide.
[0006] In some embodiments, the calcium channel blocker is amlodipine, nifedipine, diltiazem, nimodipine, verapamil, isradipine, felodipine, nicardipine, nisoldipine, clovidipine, dihydropyridine, lercanidipine, nifedipine, cilnidipine, manidipine, miradipine, benprodil, barnidipine, nivardipine, golopamil, lidocaine, areradipine, dotalizine, dipropionyl, or a pharmaceutically acceptable salt or hydrate thereof. In some embodiments, the calcium channel blocker is amlodipine or a pharmaceutically acceptable salt thereof. In some embodiments, the calcium channel blocker is amlodipine besylate.
[0007] In some embodiments, the angiotensin II receptor blocker is irbesartan, telmisartan, valsartan, candesartan, eprosartan, olmesartan, azilsartan, losartan, or a pharmaceutically acceptable salt or hydrate thereof. In some embodiments, the angiotensin II receptor blocker is telmisartan.
[0008] In some embodiments, the doses of (a), (b), and (c) are each about 40% to about 60% of the lowest therapeutic dose (LHTD) of hypertension. In some embodiments, the diuretic is a thiazide-like diuretic, and the dose of the thiazide-like diuretic is about 50% of the lowest therapeutic dose (LHTD) of the thiazide-like diuretic. In some embodiments, the thiazide-like diuretic is indapamide, and the dose of indapamide is about 0.625 mg. In some embodiments, the calcium channel blocker is administered at approximately 50% of the lowest therapeutic high blood pressure (LHTD) dose of the calcium channel blocker. In some embodiments, the calcium channel blocker is amlodipine besylate, and the dose of amlodipine besylate is approximately 1.25 mg. In some embodiments, the angiotensin II receptor blocker is administered at approximately 50% of the lowest therapeutic high blood pressure (LHTD) dose of the angiotensin II receptor blocker. In some embodiments, the angiotensin II receptor blocker is telmisartan, and the dose of telmisartan is approximately 10 mg. In some embodiments, the angiotensin II receptor blocker is telmisartan, the diuretic is indapamide, and the calcium channel blocker is amlodipine besylate. In some embodiments, the dose of telmisartan is about 8 mg to about 12 mg, the dose of indapamide is about 0.5 mg to about 0.75 mg, and the dose of amlodipine besylate is about 1 mg to about 1.5 mg. In some embodiments, the dose of telmisartan is about 10 mg, the dose of indapamide is about 0.625 mg, and the dose of amlodipine besylate is about 1.25 mg.
[0009] In one aspect, a pharmaceutical composition is provided comprising: (a) telmisartan; (b) a thiazide-like diuretic; and (c) a calcium channel blocker, wherein each of (a), (b), and (c) is at a dose of about 80% to about 150% of the lowest therapeutic dose for hypertension (LHTD), wherein the pharmaceutical composition further comprises at least one cholesterol-lowering active agent.
[0010] In some embodiments, the pharmaceutical composition is substantially free of angiotensin-converting enzyme inhibitors or pharmaceutically acceptable salts thereof, beta-blockers or pharmaceutically acceptable salts thereof, platelet function modifiers, serum homocysteine lowering agents, or combinations thereof.
[0011] In some embodiments, the thiazide-like diuretic is quinethane, clopamine, chlorthalidone, mefcitrate, chlorfenapyramide, metoprazone, meteclaron, sipamine, indapamine, lorsolon, fenquinazole, or a pharmaceutically acceptable salt or hydrate thereof. In some embodiments, the thiazide-like diuretic is indapamine or its hydrate. In some embodiments, the thiazide-like diuretic is indapamide.
[0012] In some embodiments, the calcium channel blocker is amlodipine, nifedipine, diltiazem, nimodipine, verapamil, isradipine, felodipine, nicardipine, nisoldipine, clovidipine, dihydropyridine, lercanidipine, nifedipine, cilnidipine, manidipine, miradipine, benprodil, barnidipine, nivardipine, golopamil, lidocaine, areradipine, dotazine, dipropionylene, or a pharmaceutically acceptable salt or hydrate thereof. In some embodiments, the calcium channel blocker is amlodipine or a pharmaceutically acceptable salt thereof. In some embodiments, the calcium channel blocker is amlodipine besylate.
[0013] In some embodiments, the doses of (a), (b), and (c) are each about 80% to about 120% of the lowest hypertension treatment dose (LHTD). In some embodiments, the dose of the thiazide-like diuretic is about 100% of the lowest hypertension treatment dose (LHTD) of the thiazide-like diuretic. In some embodiments, the thiazide-like diuretic is indapamide, and the dose of indapamide is about 1.25 mg. In some embodiments, the dose of the calcium channel blocker is about 100% of the lowest hypertension treatment dose (LHTD) of the calcium channel blocker. In some embodiments, the calcium channel blocker is amlodipine besylate, and the dose of amlodipine besylate is about 2.5 mg. In some embodiments, the dose of telmisartan is about 100% of the lowest hypertension treatment dose (LHTD) of telmisartan. In some embodiments, the dose of telmisartan is about 20 mg. In some embodiments, the thiazide-like diuretic is indapamide, and the calcium channel blocker is amlodipine besylate.In some embodiments, the dose of telmisartan is about 16 mg to about 24 mg, the dose of indapamide is about 1 mg to about 1.5 mg, and the dose of amlodipine besylate is about 2 mg to about 3 mg. In some embodiments, the dose of telmisartan is about 20 mg, the dose of indapamide is about 1.25 mg, and the dose of amlodipine besylate is about 2.5 mg.
[0014] In some embodiments of the pharmaceutical compositions disclosed herein, (a), (b), and (c) are provided in one formulation. In some embodiments, (a), (b), and (c) are each provided in a separate formulation. In some embodiments, two of (a), (b), and (c) are provided in one formulation. In some embodiments, the pharmaceutical composition is in the form of a pill, tablet, or capsule. In some embodiments, the pharmaceutical composition is suitable for oral administration.
[0015] This document also provides a method of treating hypertension in a subject of need, comprising administering any of the pharmaceutical compositions disclosed herein. In some embodiments, the treatment results in a systolic blood pressure (SBP) below about 140 mmHg. In some embodiments, the treatment results in a SBP reduction of about 10 mmHg or more. In some embodiments, the treatment results in a diastolic blood pressure (DBP) below about 90 mmHg. In some embodiments, the treatment results in a DBP reduction of about 5 mmHg or more. In some embodiments, the treatment results in a SBP reduction greater than that achieved with the lowest complete hypertension treatment dose of any of (a), (b), and (c) of the pharmaceutical composition. In some embodiments, the treatment results in a DBP reduction greater than that achieved with the lowest complete hypertension treatment dose of any of (a), (b), and (c) of the pharmaceutical composition. In some embodiments, the treatment results in greater long-term tolerability and a reduced risk of side effects compared to treatment with the lowest complete hypertension treatment dose of any of (a), (b), and (c) of the pharmaceutical composition. In some embodiments, the treatment is an initial or first-line treatment for hypertension. In some embodiments, the subject has not received any prior hypertension therapy prior to treatment.
[0016] In another aspect, this document provides a pharmaceutical composition comprising essentially the following components: (a) an angiotensin II receptor blocker; (b) a diuretic; and (c) a calcium channel blocker, wherein each of (a), (b), and (c) is in a dose of about 40% to about 80% of the lowest hypertension treatment dose (LHTD), wherein the pharmaceutical composition further comprises at least one cholesterol-lowering active agent.
[0017] In another aspect, this document provides a pharmaceutical composition comprising essentially the following components: (a) an angiotensin II receptor blocker, such as telmisartan; (b) a thiazide-like diuretic; and (c) a calcium channel blocker wherein each of (a), (b), and (c) is at a dose of about 80% to about 150% of the lowest therapeutic dose (LHTD). In some embodiments, each of (a), (b), and (c) is at a dose of about 80% to about 120% of the lowest therapeutic dose (LHTD), wherein the pharmaceutical composition further comprises at least one cholesterol-lowering active agent. In some embodiments, each of (a), (b), and (c) is at a dose of about 90% to about 110% of the lowest therapeutic dose (LHTD).
[0018] In some embodiments, the at least one cholesterol-lowering active agent is selected from NPC1L1 inhibitors, statins, or combinations thereof. Instructions for Use, Page 3 / 83, CN 122272578 A
[0019] In some embodiments, the at least one cholesterol-lowering active agent is selected from NPC1L1 inhibitors, statins, or combinations thereof.
[0020] In some embodiments, the at least one cholesterol-lowering active agent is a combination of NPC1L1 inhibitors and statins.
[0021] In some embodiments, the at least one cholesterol-lowering active agent is ezetimibe, rosuvastatin, or a combination thereof.
[0022] In some embodiments, the at least one cholesterol-lowering active agent is a combination of ezetimibe and rosuvastatin.
[0023] In some embodiments, the dose of ezetimibe is about 10 mg, and the dose of rosuvastatin is about 10 mg.
[0024] In some embodiments, (a), (b), and (c) are provided in a single formulation.
[0025] In some embodiments, (a), (b), (c), and the at least one cholesterol-lowering active agent are provided in a single formulation.
[0026] In another aspect, this document also provides a method for treating at least one of hypertension and dyslipidemia in a subject in need, comprising administering the pharmaceutical composition disclosed herein. In an improvement, this method is a first-line therapy.
[0027] In another aspect, this document also provides a method for treating a combination of hypertension and dyslipidemia in a subject in need, comprising administering the pharmaceutical composition disclosed herein. In an improvement, this method is a first-line therapy.
[0028] All publications, patents, and patent applications mentioned in this specification are incorporated herein by reference to the extent that each individual publication, patent, or patent application is specifically and individually indicated to be incorporated herein by reference.
[0029] The novel features of this disclosure are set forth in the appended claims.The features and advantages of this disclosure will be better understood by referring to the following detailed description of illustrative embodiments utilizing the principles of this disclosure, along with the accompanying drawings, in which: Figure 1 shows the mean systolic blood pressure (mmHg) during the treatment period.
[0030] Figure 2 shows the mean diastolic blood pressure (mmHg) during the treatment period.
[0031] Figure 3 shows the mean heart rate during the treatment period. Detailed Description
[0032] This document provides pharmaceutical compositions for treating hypertension, comprising an angiotensin II receptor blocker, a diuretic, and a calcium channel blocker. In some embodiments, the dose of each component is below the lowest dose approved for the treatment of hypertension. This disclosure recognizes the technical effects of the low-dose combination therapies described herein, including, but not limited to, using low doses to avoid or reduce side effects while maintaining or improving benefits, the synergistic therapeutic benefits of certain drug combinations, and the early introduction of combination therapies to improve treatment outcomes. In one aspect, this document describes low-dose combination compositions for treating hypertension, including initial or first-line treatment of hypertension.
[0033] Certain terms, as used herein and in the appended claims, the singular forms “a,” “an,” and “the” include plural references unless the context clearly indicates otherwise. Thus, for example, reference to “a pharmaceutical agent” includes multiple such pharmaceutical agents, and reference to “the composition” includes reference to one or more compositions and their equivalents known to those skilled in the art, etc. When the scope is used herein with respect to physical properties such as molecular weight or chemical properties such as chemical formula, it is intended to include all combinations and sub-combinations of the scope and specific embodiments herein. The term “about” as used when referring to a number or numerical range means that the number or numerical range mentioned is an approximation within the range of experimental variability (or within the range of statistical experimental error), and thus in some embodiments, the number or numerical range varies between 1% and 10% of the number or numerical range. The term “comprising” (and related terms such as “including”, “having”, or “containing”) is not intended to exclude the fact that in some other embodiments, for example, embodiments of any of the material compositions, compositions, methods, or processes described herein may “consist of” or “substantially consist of” the described features.
[0034] Definitions as used herein and in the appended claims, unless indicated otherwise, have the meanings described below.
[0035] “Pharmaceutically acceptable salt” as used herein includes acid addition salts and base addition salts. In some embodiments, a pharmaceutically acceptable salt of any of the compounds described herein is in a form approved for use by the U.S. Food and Drug Administration.Preferred pharmaceutically acceptable salts of the compounds described herein are pharmaceutically acceptable acid addition salts and pharmaceutically acceptable base addition salts.
[0036] "Pharmaceutically acceptable acid addition salts" refers to those salts that retain the bioavailability and properties of the free base, are not biologically or otherwise undesirable, and are formed from inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, hydroiodic acid, hydrofluoric acid, and phosphorous acid. It also includes salts formed from organic acids such as aliphatic monocarboxylic acids and dicarboxylic acids, phenyl-substituted alkanes, hydroxyalkanes, alkanedioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, etc., and includes, for example, acetic acid, trifluoroacetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, etc. Therefore, exemplary salts include sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, nitrates, phosphates, monohydrogen phosphates, dihydrogen phosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, trifluoroacetates, propionates, caprylates, isobutyrates, oxalates, malonates, succinates, caprylates, sebacic acid salts, fumarates, maleates, mandelates, benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates, phthalates, benzenesulfonates, toluenesulfonates, phenylacetates, citrates, lactates, malates, tartrates, methanesulfonates, etc. Salts of amino acids such as arginine salts, gluconates, and galacturons are also involved (see, for example, Berge S.M. et al., “Pharmaceutical Salts,” Journal of Pharmaceutical Science, 66:1–19 (1997), which is incorporated herein by reference in its entirety). Acid addition salts of basic compounds can be prepared by contacting a free base in sufficient quantity with the desired acid to produce a salt, according to methods and techniques familiar to a skilled craftsman.
[0037] "Pharmaceutically acceptable base addition salts" are those salts that retain the biological effectiveness and properties of the free acid and are not biologically or otherwise undesirable. These salts are prepared by adding an inorganic or organic base to the free acid. Pharmaceutically acceptable base addition salts can be formed from metals or amines such as alkali metals and alkaline earth metals or organic amines. Salts derived from organic bases include, but are not limited to, sodium salts, potassium salts, lithium salts, ammonium salts, calcium salts, magnesium salts, iron salts, zinc salts, copper salts, manganese salts, aluminum salts, etc.Salts derived from organic bases include, but are not limited to, salts of the following organic bases: primary, secondary, and tertiary amines; substituted amines (including naturally occurring substituted amines); cyclic amines; and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, diethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, N,N-dibenzylethylenediamine, chloroprocaine, hydrabamine, choline, betaine, ethylenediamine, ethylenediphenylamine, N-methylglucosamine, glucosamine, methylglucosamine, theobromine (see page 5 / 83 of the specification, CN 122272578 A), purines, piperazine, piperidine, N-ethylpiperidine, polyamine resins, etc. See Berge et al., ibid.
[0038] As used herein, a “hydrate” is a compound containing a stoichiometric or non-stoichiometric amount of water, and in some embodiments, it is formed during crystallization with water. Hydrates are intended to include hydrates of any of the compounds described herein that are approved for use by the U.S. Food and Drug Administration.
[0039] As used herein, the term “acceptable” in relation to a formulation, composition, or ingredient means that it has no lasting adverse effect on the general health of the subject being treated.
[0040] As used herein, the terms “administration,” “dosing,” and similar terms refer to methods that can be used to enable the delivery of a compound or composition to the desired site of biological action. These methods include, but are not limited to, oral, duodenal, parenteral (including intravenous, subcutaneous, intraperitoneal, intramuscular, intravascular, or infusion), local, and rectal administration. Those skilled in the art are familiar with drug delivery techniques that can be used with the compounds and methods described herein. In some embodiments, the compounds and compositions described herein are administered orally.
[0041] The terms “subject” or “patient” include mammals. Examples of mammals include, but are not limited to, any member of the class Mammalia: humans, non-human primates such as chimpanzees and other ape and monkey species; livestock such as cattle, horses, sheep, goats, and pigs; domestic animals such as rabbits, dogs, and cats; laboratory animals, including rodents such as rats, mice, and guinea pigs, etc. In one respect, the mammal is human.
[0042] As used herein, “treatment” or “manipulation” or “relief” or “improvement” are used interchangeably herein. These terms refer to the means of obtaining a beneficial or desired outcome (including, but not limited to, therapeutic benefits and / or preventive benefits). A “therapeutic benefit” means the elimination or improvement of the underlying condition being treated. In addition, a therapeutic benefit may also be achieved as follows: one or more physiological symptoms associated with the underlying condition are eradicated or improved, resulting in an improvement observed in the patient, although the patient may still be suffering from the underlying condition.For preventative benefits, the composition may be administered to patients at risk of developing a particular disease or to patients who have reported one or more physiological symptoms of the disease, even if a diagnosis of the disease may not have been made.
[0043] Triple Composition This article describes a pharmaceutical composition comprising (a) an angiotensin II receptor blocker, (b) a diuretic, and (c) a calcium channel blocker; wherein each of (a), (b), and (c) is at a dose of about 40% to about 80% of the lowest therapeutic dose (LHTD). In some embodiments, each of (a), (b), and (c) is at a dose of about 40% to about 60% of the lowest therapeutic dose (LHTD). In some embodiments, each of (a), (b), and (c) is at a dose of about 50% of the lowest therapeutic dose (LHTD). In some embodiments, each of (a), (b), and (c) is at a dose of about 60% to about 80% of the lowest therapeutic dose (LHTD). In some embodiments, each of (a), (b), and (c) is at a dose of about 66% of the lowest therapeutic dose (LHTD).
[0044] In some embodiments, the pharmaceutical composition comprises a combination of antihypertensive agents, wherein the antihypertensive agent comprises an angiotensin II receptor blocker, a diuretic, and a calcium channel blocker.
[0045] In another aspect, pharmaceutical compositions comprising (a) an angiotensin II receptor blocker such as telmisartan, (b) a thiazide-like diuretic, and (c) a calcium channel blocker are described herein; wherein each of (a), (b), and (c) is at a dose of about 80% to about 150% of the lowest therapeutic dose (LHTD). In some embodiments, each of (a), (b), and (c) is at a dose of about 80% to about 120% of the lowest therapeutic dose (LHTD). In some embodiments, each of (a), (b), and (c) is at a dose of about 90% to about 110% of the lowest therapeutic dose (LHTD). In some embodiments, each of (a), (b), and (c) is at a dose of about 95% to about 105% of the lowest therapeutic dose (LHTD). In some embodiments, the doses of (a), (b), and (c) are each approximately 100% of the lowest hypertension treatment dose (LHTD).
[0046] In some embodiments, the pharmaceutical compositions disclosed herein are substantially free of angiotensin-converting enzyme inhibitors (ACE inhibitors) or pharmaceutically acceptable salts thereof. In some embodiments, the angiotensin-converting enzyme inhibitor includes, but is not limited to, benazepril, captopril, enalapril, fosinopril, lisinopril, moxipril, perindopril, quinapril, ramipril, trandopril, or pharmaceutically acceptable salts or hydrates thereof.
[0047] Additionally, this document describes a pharmaceutical composition substantially consisting of (a) an angiotensin II receptor blocker, (b) a diuretic, and (c) a calcium channel blocker; wherein each of (a), (b), and (c) is at a dose of about 40% to about 80% of the lowest therapeutic dose (LHTD). In some embodiments, each of (a), (b), and (c) is at a dose of about 40% to about 60% of the LHTD. In some embodiments, each of (a), (b), and (c) is at a dose of about 50% of the LHTD. In some embodiments, each of (a), (b), and (c) is at a dose of about 60% to about 80% of the LHTD. In some embodiments, each of (a), (b), and (c) is at a dose of about 66% of the LHTD.
[0048] Additionally, this document describes a pharmaceutical composition substantially consisting of (a) an angiotensin II receptor blocker such as telmisartan, (b) a thiazide-like diuretic, and (c) a calcium channel blocker; wherein each of (a), (b), and (c) is at a dose of about 80% to about 150% of the lowest therapeutic dose (LHTD). In some embodiments, each of (a), (b), and (c) is at a dose of about 80% to about 120% of the lowest therapeutic dose (LHTD). In some embodiments, each of (a), (b), and (c) is at a dose of about 90% to about 110% of the lowest therapeutic dose (LHTD). In some embodiments, each of (a), (b), and (c) is at a dose of about 95% to about 105% of the lowest therapeutic dose (LHTD). In some embodiments, each of (a), (b), and (c) is at a dose of about 100% of the lowest therapeutic dose (LHTD).
[0049] In some embodiments, the pharmaceutical compositions disclosed herein achieve a significant reduction in blood pressure in subjects with moderately elevated blood pressure. In some embodiments, the pharmaceutical compositions disclosed herein achieve a significant reduction in blood pressure in subjects with moderately elevated blood pressure with minimal, insignificant, or no side effects.
[0050] β-blockers In some embodiments, the pharmaceutical compositions disclosed herein are substantially free of β-blockers or pharmaceutically acceptable salts thereof. In some embodiments, β-blockers are compounds that inhibit receptor sites on adrenergic β-receptors of the sympathetic nervous system targeting endogenous catecholamines adrenaline (epinephrine) and noradrenaline (norepinephrine). In some embodiments, β-blockers include, but are not limited to, β-adrenergic blockers, β-receptor antagonists, β-adrenergic antagonists, β-adrenergic receptor antagonists, or β-adrenergic receptor antagonists. In some embodiments, β-blockers inhibit the activation of all types of β-adrenergic receptors.In some embodiments, the β-receptor blocker inhibits both β-adrenergic receptors and α-adrenergic receptors. In some embodiments, the β-receptor blocker is selective for one of the following β-receptors: β1 receptor, β2 receptor, and β3 receptor.
[0051] In some embodiments, the β-receptor blocker is a non-selective β-adrenergic receptor antagonist. Examples of non-selective β-adrenergic receptor antagonists include, but are not limited to, indolol, propranolol, oxenolol, sotalol, timolol, carteolol, pentbuprofenolol, and naldolol. In some embodiments, the β-receptor blocker is a compound having combined β-adrenergic receptor and α-adrenergic receptor blocking effects. Suitable examples include, but are not limited to, carvedilol, bucetinol, and labetalol. In some embodiments, the β-receptor blocker is a β1-selective adrenergic receptor antagonist. Examples of β1-selective adrenergic receptor antagonists include, but are not limited to, atenolol, bisoprolol, betalol, metoprolol, celilol, esmolol, nebivolol, and acebutolol. In some embodiments, the β-receptor blocker is a β2-selective adrenergic receptor antagonist, such as butaxamine.
[0052] In some embodiments, the β-receptor blocker is acebutolol, atenolol, betalolol, bisoprolol, carbendazimol, esmololol, pentbuprofenolol, metoprolol, naldololol, nebivololol, indololol, sotalolol, propranolol, carvedilol, labetalolol, timololol, esmololol, celylololol, oxenololol, levobenolol, pralololol, metenololol, landilolol, bolinolol, propranololol, butaxamine, bevanolol, tertalolol, aprololol, levobenolol, benzylololol, amisulolol, teliololol or a pharmaceutically acceptable salt or hydrate thereof. In some embodiments, the beta-blocker is acebutolol, atenolol, betalolol, bisoprolol, carteolol, esmolol, pentbuprofen, metoprolol, naldolol, nebiolol, indololol, sotalolol, propranolol, carvedilol, labetalol, or a pharmaceutically acceptable salt or hydrate thereof. In some embodiments, the beta-blocker is acebutolol, atenolol, betalolol, bisoprolol, celylolol, oxenolol, metoprolol, naldolol, nebiolol, indololol, propranolol, carvedilol, labetalol, timolol, or a pharmaceutically acceptable salt or hydrate thereof. In some embodiments, the beta-blocker is atenolol. In some embodiments, the beta-blocker is bisoprolol or a pharmaceutically acceptable salt thereof.
[0053] Platelet-modifying agents In some embodiments, the pharmaceutical compositions disclosed herein are substantially free of platelet-modifying agents. In some embodiments, the platelet-modifying agents are aspirin, ticlopidine, dipyridamole, or clopidogrel.In some embodiments, the platelet function modifier is a glycoprotein IIb / IIIa receptor inhibitor, such as abciximab. In some embodiments, the platelet function modifier is a nonsteroidal anti-inflammatory drug, such as ibuprofen. In some embodiments, the platelet function modifier is aspirin, ticlopidine, dipyridamole, clopidogrel, abciximab, or ibuprofen. In some embodiments, the platelet function modifier is aspirin.
[0054] Serum homocysteine lowering agent In some embodiments, the pharmaceutical compositions disclosed herein are substantially free of serum homocysteine lowering agents. In some embodiments, the serum homocysteine lowering agent is folic acid, vitamin B6, or vitamin B12, or a combination thereof. In some embodiments, the serum homocysteine lowering agent is folic acid.
[0055] Angiotensin II receptor antagonist / blocker As used herein, angiotensin II receptor antagonist or blocker (ARB) is a compound that modulates the action of angiotensin II by preventing the binding of angiotensin II to angiotensin II receptors on perivascular muscle. In some embodiments, the angiotensin II receptor blocker is olmesartan, azilsartan, losartan, valsartan, candesartan, eprosartan, irbesartan, telmisartan, or a pharmaceutically acceptable salt or hydrate thereof. In some embodiments, the angiotensin II receptor blocker is losartan. In some embodiments, the angiotensin II receptor blocker is valsartan. In some embodiments, the angiotensin II receptor blocker is candesartan. In some embodiments, the angiotensin II receptor blocker is eprosartan. In some embodiments, the angiotensin II receptor blocker is irbesartan. In some embodiments, the angiotensin II receptor blocker is telmisartan.
[0056] Diuretics, as used herein, refer to compounds that increase urine flow. Diuretics are classified according to their chemical structure (thiazide diuretics and thiazide-like diuretics), site of action (e.g., loop diuretics), or pharmacological action (e.g., osmotic diuretics, carbonic anhydrase inhibitors, and potassium-sparing diuretics).
[0057] In some embodiments, the pharmaceutical compositions disclosed herein comprise thiazide diuretics. In some embodiments, the pharmaceutical compositions disclosed herein comprise thiazide-like diuretics. In some embodiments, the pharmaceutical compositions disclosed herein comprise loop diuretics. In some embodiments, the pharmaceutical compositions disclosed herein comprise osmotic diuretics. In some embodiments, the pharmaceutical compositions disclosed herein comprise carbonic anhydrase inhibitors. In some embodiments, the pharmaceutical composition disclosed herein (page 8 / 83, CN 122272578 A) comprises potassium-sparing diuretics.
[0058] Thiazide diuretics, as used herein, refer to compounds containing a benzothiadiazine molecular structure.In some embodiments, thiazide diuretics inhibit the reabsorption of sodium and chloride in the distal tubules of the kidney, resulting in increased urinary excretion of sodium and water. Examples of thiazide diuretics include, but are not limited to, albithiazide, benzylfluthiazide, chlorothiazide, cyclopenthiazide, cyclothiazide, epithiazide, hydrochlorothiazide, hydrofluorothiazide, mebthiazide, methamphethiazide, porithiazide, and trichlorothiazide.
[0059] In some embodiments, the thiazide diuretic is albithiazide, benzylfluthiazide, chlorothiazide, cyclopenthiazide, cyclothiazide, epithiazide, hydrochlorothiazide, hydrofluorothiazide, mebthiazide, methamphethiazide, porithiazide, trichlorothiazide, or a pharmaceutically acceptable salt or hydrate thereof. In some embodiments, the thiazide diuretic is albithiazide. In some embodiments, the thiazide diuretic is benzylfluthiazide. In some embodiments, the thiazide diuretic is chlorothiazide. In some embodiments, the thiazide diuretic is cyclopentathiazide. In some embodiments, the thiazide diuretic is cyclothiazide. In some embodiments, the thiazide diuretic is epithiazide. In some embodiments, the thiazide diuretic is hydrochlorothiazide. In some embodiments, the thiazide diuretic is hydrofluorothiazide. In some embodiments, the thiazide diuretic is mebbutazide. In some embodiments, the thiazide diuretic is methachlorthiazide. In some embodiments, the thiazide diuretic is porithiazide. In some embodiments, the thiazide diuretic is trichlorothiazide.
[0060] Thiazide-like diuretics, as used herein, are sulfonamide diuretics that have similar physiological properties to thiazide diuretics but do not have the chemical properties of thiazides (i.e., do not have a benzothiadiazine core). Examples of thiazide-like diuretics include, but are not limited to, quinacrine, clopamine, chlorthalidone, mefcitabine, chlorfenapyramide, metoprazine, meteclaron, sipamide, indapamide, chloroquine, and fenquinazole.
[0061] In some embodiments, the thiazide-like diuretic is quinacrine, clopamine, chlorthalidone, mefcitabine, chlorfenapyramide, metoprazine, meteclaron, sipamide, indapamide, chloroquine, fenquinazole, or a pharmaceutically acceptable salt or hydrate thereof. In some embodiments, the thiazide-like diuretic is quinacrine. In some embodiments, the thiazide-like diuretic is clopamine. In some embodiments, the thiazide-like diuretic is chlorthalidone. In some embodiments, the thiazide-like diuretic is mefcitabine. In some embodiments, the thiazide-like diuretic is chlorfenapyramide. In some embodiments, the thiazide-like diuretic is metoprazine. In some embodiments, the thiazide-like diuretic is meteclaron. In some embodiments, the thiazide-like diuretic is sipamide. In some embodiments, the thiazide-like diuretic is indapamide or its hydrate. In some embodiments, the thiazide-like diuretic is indapamide. In some embodiments, the thiazide-like diuretic is chlorosolone. In some embodiments, the thiazide-like diuretic is fenquinazole.
[0062] Loop diuretics, as used herein, are compounds that act on the Na+ / K+ / 2Cl- cotransporter in the thick ascending limb of the loop of Henry's loop to inhibit the reabsorption of sodium, chloride, and potassium. Examples of loop diuretics include, but are not limited to, furosemide, bumetanide, ethacrynic acid, etorazoline, mozolomide, oxazolinone, pyrrolizidine, tenacrylic acid, and torasemide. In some embodiments, the loop diuretic is furosemide, bumetanide, ethacrynic acid, etorazoline, mozolomide, oxazolinone, pyrrolizidine, tenacrylic acid, torasemide, or a pharmaceutically acceptable salt or hydrate thereof.
[0063] Other diuretics Osmotic diuretics are compounds that cause water to be retained within the proximal tubule and the descending limb of the loop of Henry's loop. In some embodiments, osmotic diuretics expand fluid and plasma volume and increase blood flow to the kidneys. Examples include, but are not limited to, mannitol and glycerol. Specification 9 / 83 pages 12 CN 122272578 A
[0064] Carbonic anhydrase inhibitors As used herein, carbonic anhydrase inhibitors are compounds that act as inhibitors of carbonic anhydrase. In some embodiments, carbonic anhydrase inhibitors increase the excretion of bicarbonate along with sodium, potassium, and water, resulting in an increased alkaline urine flow. In some embodiments, carbonic anhydrase inhibitors inhibit the transport of bicarbonate from the proximal convoluted tubule into the interstitium, resulting in less sodium reabsorption and providing greater loss of sodium, bicarbonate, and water in the urine. Examples of such compounds include, but are not limited to, acetazolamide, diclofenac, and metronidazole.
[0065] Potassium-sparing diuretics Potassium-sparing diuretics are compounds that compete with aldosterone for intracellular cytoplasmic receptor sites or directly block sodium channels, particularly epithelial sodium channels (ENaC). Examples of potassium-sparing diuretics include, but are not limited to, amiloride, spironolactone, eplerenone, triamterene, and potassium canileate.
[0066] Other diuretics considered for use include, but are not limited to, caffeine, theophylline, theobromine, tolvaptan, conivovatan, dopamine, and pamabrom.
[0067] In some embodiments, the diuretic is diclofenac, amiloride, pamabrom, mannitol, acetazolamide, methazoline, spironolactone, triamterene, or a pharmaceutically acceptable salt or hydrate thereof. In some embodiments, the diuretic is diclofenac. In some embodiments, the diuretic is amiloride. In some embodiments, the diuretic is pamabrom. In some embodiments, the diuretic is mannitol. In some embodiments, the diuretic is acetazolamide. In some embodiments, the diuretic is methazoline. In some embodiments, the diuretic is spironolactone. In some embodiments, the diuretic is triamterene.
[0068] Calcium channel blockers, as used herein, are compounds that promote vasodilation by reducing calcium inflow into vascular smooth muscle cells.In some embodiments, the calcium channel blocker is amlodipine, nifedipine, diltiazem, nimodipine, verapamil, isradipine, felodipine, nicardipine, nisoldipine, clovidipine, dihydropyridine, lorcanidipine, nicardipine, cilnidipine, manidipine, miradipine, bepridil, barnidipine, nivadipine, golopamil, lidocaine, areradipine, dotalizine, dipropionyl, or a pharmaceutically acceptable salt or hydrate thereof. In some embodiments, the calcium channel blocker is amlodipine, nifedipine, diltiazem, nimodipine, verapamil, isradipine, felodipine, nicardipine, nisoldipine, clovidipine, or a pharmaceutically acceptable salt or hydrate thereof. In some embodiments, the calcium channel blocker is amlodipine or a pharmaceutically acceptable salt thereof. In some embodiments, the calcium channel blocker is amlodipine besylate. In some embodiments, the calcium channel blocker is nifedipine. In some embodiments, the calcium channel blocker is diltiazem. In some embodiments, the calcium channel blocker is nimodipine. In some embodiments, the calcium channel blocker is verapamil. In some embodiments, the calcium channel blocker is isradipine. In some embodiments, the calcium channel blocker is felodipine. In some embodiments, the calcium channel blocker is nicardipine. In some embodiments, the calcium channel blocker is nisoldipine. In some embodiments, the calcium channel blocker is clovidipine.
[0069] Lowest Hypertension Treatment Dose As used herein, the Lowest Hypertension Treatment Dose (LHTD) refers to the lowest intensity dose of a single antihypertensive agent approved by the U.S. Food and Drug Administration and which, as of the date of this application, is not marked as "discontinued" in the Orange Book database (http: / / www.accessdata.fda.gov / scripts / cder / ob / ). In cases where the minimum hypertension treatment dose differs from the minimum manufacturing dose, the minimum hypertension treatment dose does not include the minimum manufacturing dose. Furthermore, in cases where the minimum hypertension treatment dose differs from the physician-recommended dose, the minimum hypertension treatment dose does not include the physician-recommended dose. Additionally, the minimum hypertension dose, as defined in the instructions for use of the angiotensin II receptor blocker, diuretic, or calcium channel blocker described herein (page 10 / 83, CN 122272578 A), refers to the dose of angiotensin II receptor blocker, diuretic, or calcium channel blocker form approved for use by the U.S. Food and Drug Administration, including its free base, pharmaceutically acceptable salt, or hydrate.
[0070] In some embodiments, the dose of the angiotensin II receptor blocker is about 40% to about 80% of the minimum hypertension treatment dose. In some embodiments, the dose of the angiotensin II receptor blocker is about 40% to about 70% of the minimum hypertension treatment dose.In some embodiments, the dose of the angiotensin II receptor blocker is about 40% to about 60% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the angiotensin II receptor blocker is about 40% to about 50% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the angiotensin II receptor blocker is about 45% to about 55% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the angiotensin II receptor blocker is about 50% to about 80% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the angiotensin II receptor blocker is about 50% to about 70% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the angiotensin II receptor blocker is about 50% to about 60% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the angiotensin II receptor blocker is about 60% to about 80% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the angiotensin II receptor blocker is about 60% to about 70% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the angiotensin II receptor blocker is about 70% to about 80% of the lowest hypertension treatment dose.
[0071] In some embodiments, the dose of the angiotensin II receptor blocker is about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, about 50%, about 51%, about 52%, about 53%, about 54%, about 55%, about 56%, about 57%, about 58%, about 59%, about 60%, about 61%, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71%, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, or about 80% of the lowest hypertension treatment dose. In some embodiments, the dose of the angiotensin II receptor blocker is about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, about 50%, about 51%, about 52%, about 53%, about 54%, about 55%, about 56%, about 57%, about 58%, about 59%, or about 60% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the angiotensin II receptor blocker is about 45%, about 46%, about 47%, about 48%, about 49%, about 50%, about 51%, about 52%, about 53%, about 54%, or about 55% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the angiotensin II receptor blocker is about 50% of the lowest therapeutic dose for hypertension.In some embodiments, the dose of the angiotensin II receptor blocker is about 60%, about 61%, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71%, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, or about 80% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the angiotensin II receptor blocker is about 61%, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, or about 71% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the angiotensin II receptor blocker is about 66% of the lowest therapeutic dose for hypertension.
[0072] In some embodiments, the dose of the diuretic is about 40% to about 80% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the diuretic is about 40% to about 70% of the lowest therapeutic dose for hypertension. In some embodiments, the diuretic is administered at a dose of about 40% to about 60% of the lowest therapeutic dose for hypertension. In some embodiments, the diuretic is administered at a dose of about 40% to about 50% of the lowest therapeutic dose for hypertension. In some embodiments, the diuretic is administered at a dose of about 45% to about 55% of the lowest therapeutic dose for hypertension. In some embodiments, the diuretic is administered at a dose of about 50% to about 80% of the lowest therapeutic dose for hypertension. In some embodiments, the diuretic is administered at a dose of about 50% to about 70% of the lowest therapeutic dose for hypertension. In some embodiments, the diuretic is administered at a dose of about 50% to about 60% of the lowest therapeutic dose for hypertension. In some embodiments, the diuretic is administered at a dose of about 60% to about 70% of the lowest therapeutic dose for hypertension. In some embodiments, the diuretic is administered at a dose of about 70% to about 80% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the diuretic is about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, about 50%, about 51%, about 52%, about 53%, about 54%, about 55%, about 56%, about 57%, about 58%, about 59%, about 60%, about 61%, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71%, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, or about 80% of the lowest hypertension treatment dose.In some embodiments, the diuretic is administered at a dose of approximately 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, or 60% of the lowest therapeutic dose for hypertension. In some embodiments, the diuretic is administered at a dose of approximately 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, or 55% of the lowest therapeutic dose for hypertension. In some embodiments, the diuretic is administered at a dose of approximately 50% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the diuretic is about 60%, about 61%, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71%, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, or about 80% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the diuretic is about 61%, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, or about 71% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the diuretic is about 66% of the lowest therapeutic dose for hypertension.
[0074] In some embodiments, the dose of the thiazide diuretic is about 40% to about 80% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the thiazide diuretic is about 40% to about 70% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the thiazide diuretic is about 40% to about 60% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the thiazide diuretic is about 40% to about 50% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the thiazide diuretic is about 45% to about 55% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the thiazide diuretic is about 50% to about 80% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the thiazide diuretic is about 50% to about 70% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the thiazide diuretic is about 50% to about 60% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the thiazide diuretic is about 60% to about 80% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the thiazide diuretic is about 60% to about 70% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the thiazide diuretic is about 70% to about 80% of the lowest therapeutic dose for hypertension.
[0075] In some embodiments, the dose of the thiazide diuretic is about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, about 50%, about 51%, about 52%, about 53%, about 54%, about 55%, about 56%, about 57%, about 58%, about 59%, about 60%, about 61%, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71%, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, or about 80% of the lowest hypertension treatment dose. In some embodiments, the dose of the thiazide diuretic is about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, about 50%, about 51%, about 52%, about 53%, about 54%, about 55%, about 56%, about 57%, about 58%, about 59%, or about 60% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the thiazide diuretic is about 45%, about 46%, about 47%, about 48%, about 49%, about 50%, about 51%, about 52%, about 53%, about 54%, or about 55% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the thiazide diuretic is about 50% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the thiazide diuretic is about 60%, about 61%, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71%, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, or about 80% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the thiazide diuretic is about 61%, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, or about 71% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the thiazide diuretic is about 66% of the lowest therapeutic dose for hypertension.
[0076] In some embodiments, the dose of the thiazide-like diuretic is about 40% to about 80% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the thiazide-like diuretic is about 40% to about 70% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the thiazide-like diuretic is about 40% to about 60% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the thiazide-like diuretic is about 40% to about 50% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the thiazide-like diuretic is about 45% to about 55% of the lowest therapeutic dose for hypertension.In some embodiments, the dose of the thiazide-like diuretic is about 50% to about 80% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the thiazide-like diuretic is about 50% to about 70% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the thiazide-like diuretic is about 50% to about 60% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the thiazide-like diuretic is about 60% to about 70% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the thiazide-like diuretic is about 70% to about 80% of the lowest therapeutic dose for hypertension.
[0077] In some embodiments, the dose of the thiazide-like diuretic is about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, about 50%, about 51%, about 52%, about 53%, about 54%, about 55%, about 56%, about 57%, about 58%, about 59%, about 60%, about 61%, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71%, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, or about 80% of the lowest hypertension treatment dose. In some embodiments, the dose of the thiazide-like diuretic is about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, about 50%, about 51%, about 52%, about 53%, about 54%, about 55%, about 56%, about 57%, about 58%, about 59%, or about 60% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the thiazide-like diuretic is about 45%, about 46%, about 47%, about 48%, about 49%, about 50%, about 51%, about 52%, about 53%, about 54%, or about 55% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the thiazide-like diuretic is about 50% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the thiazide-like diuretic is about 60%, about 61%, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71%, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, or about 80% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the thiazide-like diuretic is about 61%, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, or about 71% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the thiazide-like diuretic is about 66% of the lowest therapeutic dose for hypertension.
[0078] In some embodiments, the dosage of the loop diuretic is about 40% to about 80% of the lowest therapeutic dose for hypertension. In some embodiments, the dosage of the loop diuretic is about 40% to about 70% of the lowest therapeutic dose for hypertension. In some embodiments, the dosage of the loop diuretic is about 40% to about 60% of the lowest therapeutic dose for hypertension. In some embodiments, the dosage of the loop diuretic is about 40% to about 50% of the lowest therapeutic dose for hypertension. In some embodiments, the dosage of the loop diuretic is about 45% to about 55% of the lowest therapeutic dose for hypertension. In some embodiments, the dosage of the loop diuretic is about 50% to about 80% of the lowest therapeutic dose for hypertension. In some embodiments, the dosage of the loop diuretic is about 50% to about 70% of the lowest therapeutic dose for hypertension. In some embodiments, the dosage of the loop diuretic is about 50% to about 60% of the lowest therapeutic dose for hypertension. In some embodiments, the dosage of the loop diuretic is about 60% to about 80% of the lowest therapeutic dose for hypertension. In some embodiments, the dosage of the loop diuretic is about 60% to about 70% of the lowest therapeutic dose for hypertension. In some embodiments, the dosage of the loop diuretic is about 70% to about 80% of the lowest therapeutic dose for hypertension.
[0079] In some embodiments, the dosage of the loop diuretic is about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, about 50%, about 51%, about 52%, about 53%, about 54%, about 55%, about 56%, about 57%, about 58%, about 59%, about 60%, about 61%, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71%, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, or about 80% of the lowest hypertension treatment dose, as stated on page 13 / 83 of the specification, CN 122272578 A. In some embodiments, the dosage of the loop diuretic is about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, about 50%, about 51%, about 52%, about 53%, about 54%, about 55%, about 56%, about 57%, about 58%, about 59%, or about 60% of the lowest therapeutic dose for hypertension. In some embodiments, the dosage of the loop diuretic is about 45%, about 46%, about 47%, about 48%, about 49%, about 50%, about 51%, about 52%, about 53%, about 54%, or about 55% of the lowest therapeutic dose for hypertension. In some embodiments, the dosage of the loop diuretic is about 50% of the lowest therapeutic dose for hypertension.In some embodiments, the dosage of the loop diuretic is about 60%, about 61%, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71%, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, or about 80% of the lowest therapeutic dose for hypertension. In some embodiments, the dosage of the loop diuretic is about 61%, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, or about 71% of the lowest therapeutic dose for hypertension. In some embodiments, the dosage of the loop diuretic is about 66% of the lowest therapeutic dose for hypertension.
[0080] In some embodiments, the dosage of the calcium channel blocker is about 40% to about 80% of the lowest therapeutic dose for hypertension. In some embodiments, the dosage of the calcium channel blocker is about 40% to about 70% of the lowest therapeutic dose for hypertension. In some embodiments, the calcium channel blocker is administered at a dose of about 40% to about 60% of the lowest therapeutic dose for hypertension. In some embodiments, the calcium channel blocker is administered at a dose of about 40% to about 50% of the lowest therapeutic dose for hypertension. In some embodiments, the calcium channel blocker is administered at a dose of about 45% to about 55% of the lowest therapeutic dose for hypertension. In some embodiments, the calcium channel blocker is administered at a dose of about 50% to about 80% of the lowest therapeutic dose for hypertension. In some embodiments, the calcium channel blocker is administered at a dose of about 50% to about 70% of the lowest therapeutic dose for hypertension. In some embodiments, the calcium channel blocker is administered at a dose of about 50% to about 60% of the lowest therapeutic dose for hypertension. In some embodiments, the calcium channel blocker is administered at a dose of about 60% to about 70% of the lowest therapeutic dose for hypertension. In some embodiments, the calcium channel blocker is administered at a dose of about 70% to about 80% of the lowest therapeutic dose for hypertension.
[0081] In some embodiments, the calcium channel blocker is at a dose of about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, about 50%, about 51%, about 52%, about 53%, about 54%, about 55%, about 56%, about 57%, about 58%, about 59%, about 60%, about 61%, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71%, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, or about 80% of the lowest hypertension treatment dose.In some embodiments, the calcium channel blocker is administered at a dose of approximately 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, or 60% of the lowest therapeutic dose for hypertension. In some embodiments, the calcium channel blocker is administered at a dose of approximately 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, or 55% of the lowest therapeutic dose for hypertension. In some embodiments, the calcium channel blocker is administered at a dose of approximately 50% of the lowest therapeutic dose for hypertension. In some embodiments, the dosage of the calcium channel blocker is about 60%, about 61%, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71%, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, or about 80% of the lowest therapeutic dose for hypertension. In some embodiments, the dosage of the calcium channel blocker is about 61%, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, or about 71% of the lowest therapeutic dose for hypertension. In some embodiments, the dosage of the calcium channel blocker is about 66% of the lowest therapeutic dose for hypertension.
[0082] In some embodiments, the minimum therapeutic dose (LHTD) of the following compounds and the corresponding recommended doses and recommended dose ranges are described in the table below: Table 1. Specification 14 / 83 pages 17 CN 122272578 A
[0083] In some embodiments, the pharmaceutical composition comprises: (a) irbesartan as an angiotensin II receptor blocker; (b) hydrochlorothiazide as a thiazide diuretic; and (c) amlodipine besylate as a calcium channel blocker. In some embodiments, the dose of irbesartan is about 30 mg to about 45 mg, the dose of hydrochlorothiazide is about 5 mg to about 7.5 mg, and the dose of amlodipine besylate is about 1 mg to about 1.5 mg. In some embodiments, the dose of irbesartan is about 37.5 mg, the dose of hydrochlorothiazide is about 6.25 mg, and the dose of amlodipine besylate is about 1.25 mg.
[0084] In some embodiments, the pharmaceutical composition comprises: (a) telmisartan as an angiotensin II receptor blocker; (b) hydrochlorothiazide as a thiazide diuretic; and (c) amlodipine besylate as a calcium channel blocker.In some embodiments, the dose of telmisartan is about 8 mg to about 12 mg, the dose of hydrochlorothiazide is about 5 mg to about 7.5 mg, and the dose of amlodipine besylate is about 1 mg to about 1.5 mg. In some embodiments, the dose of telmisartan is about 10 mg, the dose of hydrochlorothiazide is about 6.25 mg, and the dose of amlodipine besylate is about 1.25 mg.
[0085] In some embodiments, the pharmaceutical composition comprises: (a) irbesartan as an angiotensin II receptor blocker; (b) indapamide as a thiazide-like diuretic; and (c) amlodipine besylate as a calcium channel blocker. In some embodiments, the dose of irbesartan is about 30 mg to about 45 mg, the dose of indapamide is about 0.5 mg to about 0.75 mg, and the dose of amlodipine besylate is about 1 mg to about 1.5 mg. In some embodiments, the dose of irbesartan is about 37.5 mg, the dose of indapamide is about 0.625 mg, and the dose of amlodipine besylate is about 1.25 mg.
[0086] In some embodiments, the pharmaceutical composition comprises: (a) telmisartan as an angiotensin II receptor blocker; (b) indapamide as a thiazide-like diuretic; and (c) amlodipine besylate as a calcium channel blocker. In some embodiments, the dose of telmisartan is about 8 mg to about 12 mg, the dose of indapamide is about 0.5 mg to about 0.75 mg, and the dose of amlodipine besylate is about 1 mg to about 1.5 mg. In some embodiments, the dose of telmisartan is about 10 mg, the dose of indapamide is about 0.625 mg, and the dose of amlodipine besylate is about 1.25 mg.
[0087] In some embodiments, the pharmaceutical composition comprises: (a) telmisartan as an angiotensin II receptor blocker; (b) chlorthalidone as a thiazide-like diuretic; and (c) amlodipine besylate as a calcium channel blocker. In some embodiments, the dose of telmisartan is about 8 mg to about 12 mg, the dose of chlorthalidone is about 10 mg to about 15 mg, and the dose of amlodipine besylate is about 1 mg to about 1.5 mg. In some embodiments, the dose of telmisartan is about 10 mg, the dose of chlorthalidone is about 12.5 mg, and the dose of amlodipine besylate is about 1.25 mg.
[0088] In some embodiments, the pharmaceutical composition comprises: (a) irbesartan as an angiotensin II receptor blocker; (b) chlorthalidone as a thiazide-like diuretic; and (c) amlodipine besylate as a calcium channel blocker.In some embodiments, the dose of irbesartan is about 30 mg to about 45 mg, the dose of chlorothiazide is about 10 mg to about 15 mg, and the dose of amlodipine besylate is about 1 mg to about 1.5 mg. In some embodiments, the dose of irbesartan is about 37.5 mg, the dose of chlorothiazide is about 12.5 mg, and the dose of amlodipine besylate is about 1.25 mg.
[0089] In some embodiments, the pharmaceutical composition comprises: (a) irbesartan as an angiotensin II receptor blocker; (b) hydrochlorothiazide as a thiazide diuretic; and (c) amlodipine besylate as a calcium channel blocker. In some embodiments, the dose of irbesartan is about 45 mg to about 60 mg, the dose of hydrochlorothiazide is about 7.5 mg to about 10 mg, and the dose of amlodipine besylate is about 1.5 mg to about 2 mg. In some embodiments, the dose of irbesartan is about 49.5 mg, the dose of hydrochlorothiazide is about 8.25 mg, and the dose of amlodipine besylate is about 1.65 mg.
[0090] In some embodiments, the pharmaceutical composition comprises: (a) telmisartan as an angiotensin II receptor blocker; (b) hydrochlorothiazide as a thiazide diuretic; and (c) amlodipine besylate as a calcium channel blocker. In some embodiments, the dose of telmisartan is about 12 mg to about 16 mg, the dose of hydrochlorothiazide is about 7.5 mg to about 10 mg, and the dose of amlodipine besylate is about 1.5 mg to about 2 mg. In some embodiments, the dose of telmisartan is about 13.2 mg, the dose of hydrochlorothiazide is about 8.25 mg, and the dose of amlodipine besylate is about 1.65 mg.
[0091] In some embodiments, the pharmaceutical composition comprises: (a) irbesartan as an angiotensin II receptor blocker; (b) indapamide as a thiazide-like diuretic; and (c) amlodipine besylate as a calcium channel blocker. In some embodiments, the dose of irbesartan is about 45 mg to about 60 mg, the dose of indapamide is about 0.75 mg to about 1.0 mg, and the dose of amlodipine besylate is about 1.5 mg to about 2 mg. In some embodiments, the dose of irbesartan is about 49.5 mg, the dose of indapamide is about 0.825 mg, and the dose of amlodipine besylate is about 1.65 mg.
[0092] In some embodiments, the pharmaceutical composition comprises: (a) telmisartan as an angiotensin II receptor blocker; (b) indapamide as a thiazide-like diuretic; and (c) amlodipine besylate as a calcium channel blocker.In some embodiments, the dose of telmisartan is about 12 mg to about 16 mg, the dose of indapamide is about 0.75 mg to about 1.0 mg, and the dose of amlodipine besylate is about 1.5 mg to about 2 mg. In some embodiments, the dose of telmisartan is about 13.2 mg, the dose of indapamide is about 0.825 mg, and the dose of amlodipine besylate is about 1.65 mg.
[0093] In some embodiments, the pharmaceutical composition comprises: (a) telmisartan as an angiotensin II receptor blocker; (b) chlorthalidone as a thiazide-like diuretic; and (c) amlodipine besylate as a calcium channel blocker. In some embodiments, the dose of telmisartan is about 12 mg to about 16 mg, the dose of chlorthalidone is about 15 mg to about 20 mg, and the dose of amlodipine besylate is about 1.5 mg to about 2 mg. In some embodiments, the dose of telmisartan is about 13.2 mg, the dose of chlorthalidone is about 16.5 mg, and the dose of amlodipine besylate is about 1.65 mg.
[0094] In some embodiments, the pharmaceutical composition comprises: (a) irbesartan as an angiotensin II receptor blocker; (b) chlorthalidone as a thiazide-like diuretic; and (c) amlodipine besylate as a calcium channel blocker. In some embodiments, the dose of irbesartan is about 45 mg to about 60 mg, the dose of chlorthalidone is about 15 mg to about 20 mg, and the dose of amlodipine besylate is about 1.5 mg to about 2 mg. In some embodiments, the dose of irbesartan is about 49.5 mg, the dose of chlorthalidone is about 16.5 mg, and the dose of amlodipine besylate is about 1.65 mg.
[0095] In some embodiments, the dose of an angiotensin II receptor blocker, such as telmisartan, is about 80% to about 150% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of an angiotensin II receptor blocker is about 80% to about 140% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of an angiotensin II receptor blocker is about 80% to about 130% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of an angiotensin II receptor blocker is about 80% to about 120% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of an angiotensin II receptor blocker is about 80% to about 110% of the lowest therapeutic dose for hypertension.
[0096] In some embodiments, the dose of an angiotensin II receptor blocker, such as telmisartan, is about 85% to about 145% of the lowest therapeutic dose for hypertension. In some implementations, the dose of the angiotensin II receptor blocker is approximately 85% to approximately 135% of the lowest hypertension treatment dose.In some embodiments, the dose of the angiotensin II receptor blocker is about 85% to about 125% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the angiotensin II receptor blocker is about 85% to about 115% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the angiotensin II receptor blocker is about 85% to about 105% of the lowest therapeutic dose for hypertension.
[0097] In some embodiments, the dose of the angiotensin II receptor blocker, such as telmisartan, is about 90% to about 140% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the angiotensin II receptor blocker is about 90% to about 130% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the angiotensin II receptor blocker is about 90% to about 120% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the angiotensin II receptor blocker is about 90% to about 110% of the lowest therapeutic dose for hypertension.
[0098] In some embodiments, the dose of an angiotensin II receptor blocker, such as telmisartan, is about 95% to about 135% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of an angiotensin II receptor blocker is about 95% to about 125% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of an angiotensin II receptor blocker is about 95% to about 115% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of an angiotensin II receptor blocker is about 95% to about 105% of the lowest therapeutic dose for hypertension.
[0099] In some embodiments, the dose of the angiotensin II receptor blocker is about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, about 100%, about 101%, about 102%, about 103%, about 104%, about 105%, about 106%, about 107%, about 108%, about 109%, about 110%, about 111%, about 112%, about 113%, about 114%, about 115%, about 116%, about 117%, about 118%, about 119%, or about 120% of the lowest hypertension treatment dose. In some implementations, the dose of the angiotensin II receptor blocker is about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, about 100%, about 101%, about 102%, about 103%, about 104%, about 105%, about 106%, about 107%, about 108%, about 109%, or about 110% of the lowest hypertension treatment dose.In some embodiments, the angiotensin II receptor blocker is administered at a dose of about 95%, about 96%, about 97%, about 98%, about 99%, about 100%, about 101%, about 102%, about 103%, about 104%, or about 105% of the lowest therapeutic dose for hypertension. In some embodiments, the angiotensin II receptor blocker is administered at a dose of about 100% of the lowest therapeutic dose for hypertension.
[0100] In some embodiments, the thiazide-like diuretic is administered at a dose of about 80% to about 150% of the lowest therapeutic dose for hypertension. In some embodiments, the thiazide-like diuretic is administered at a dose of about 80% to about 140% of the lowest therapeutic dose for hypertension. In some embodiments, the thiazide-like diuretic is administered at a dose of about 80% to about 130% of the lowest therapeutic dose for hypertension. In some embodiments, the thiazide-like diuretic is administered at a dose of about 80% to about 120% of the lowest therapeutic dose for hypertension. In some embodiments, the thiazide-like diuretic is administered at a dose of about 80% to about 110% of the lowest therapeutic dose for hypertension.
[0101] In some embodiments, the dose of the thiazide-like diuretic is about 85% to about 145% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the thiazide-like diuretic is about 85% to about 135% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the thiazide-like diuretic is about 85% to about 125% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the thiazide-like diuretic is about 85% to about 115% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the thiazide-like diuretic is about 85% to about 105% of the lowest therapeutic dose for hypertension.
[0102] In some embodiments, the dose of the thiazide-like diuretic is about 90% to about 140% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the thiazide-like diuretic is about 90% to about 130% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the thiazide-like diuretic is about 90% to about 120% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the thiazide-like diuretic is about 90% to about 110% of the lowest therapeutic dose for hypertension.
[0103] In some embodiments, the dose of the thiazide-like diuretic is about 95% to about 135% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the thiazide-like diuretic is about 95% to about 125% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the thiazide-like diuretic is about 95% to about 115% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the thiazide-like diuretic is about 95% to about 105% of the lowest therapeutic dose for hypertension.
[0104] In some embodiments, the dose of the thiazide-like diuretic is about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, about 100%, about 101%, about 102%, about 103%, about 104%, about 105%, about 106%, about 107%, about 108%, about 109%, about 110%, about 111%, about 112%, about 113%, about 114%, about 115%, about 116%, about 117%, about 118%, about 119%, or about 120% of the lowest hypertension treatment dose. In some embodiments, the dose of the thiazide-like diuretic is about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, about 100%, about 101%, about 102%, about 103%, about 104%, about 105%, about 106%, about 107%, about 108%, about 109%, or about 110% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the thiazide-like diuretic is about 95%, about 96%, about 97%, about 98%, about 99%, about 100%, about 101%, about 102%, about 103%, about 104%, or about 105% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the thiazide-like diuretic blocker is about 100% of the lowest therapeutic dose for hypertension.
[0105] In some embodiments, the dose of the calcium channel blocker is about 80% to about 150% of the lowest therapeutic dose for hypertension. In some embodiments, the calcium channel blocker is administered at a dose of about 80% to about 140% of the lowest therapeutic dose for hypertension. In some embodiments, the calcium channel blocker is administered at a dose of about 80% to about 130% of the lowest therapeutic dose for hypertension. In some embodiments, the calcium channel blocker is administered at a dose of about 80% to about 120% of the lowest therapeutic dose for hypertension. In some embodiments, the calcium channel blocker is administered at a dose of about 80% to about 110% of the lowest therapeutic dose for hypertension.
[0106] In some embodiments, the calcium channel blocker is administered at a dose of about 85% to about 145% of the lowest therapeutic dose for hypertension. In some embodiments, the calcium channel blocker is administered at a dose of about 85% to about 135% of the lowest therapeutic dose for hypertension. In some embodiments, the calcium channel blocker is administered at a dose of about 85% to about 125% of the lowest therapeutic dose for hypertension. In some embodiments, the calcium channel blocker is administered at a dose of about 85% to about 115% of the lowest therapeutic dose for hypertension. In some embodiments, the calcium channel blocker is administered at a dose of about 85% to about 105% of the lowest therapeutic dose for hypertension.
[0107] In some embodiments, the dose of the calcium channel blocker is about 90% to about 140% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the calcium channel blocker is about 90% to about 130% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the calcium channel blocker is about 90% to about 120% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the calcium channel blocker is about 90% to about 110% of the lowest therapeutic dose for hypertension.
[0108] In some embodiments, the dose of the calcium channel blocker is about 95% to about 135% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the calcium channel blocker is about 95% to about 125% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the calcium channel blocker is about 95% to about 115% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the calcium channel blocker is about 95% to about 105% of the lowest therapeutic dose for hypertension.
[0109] In some embodiments, the calcium channel blocker is at a dose of about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, about 100%, about 101%, about 102%, about 103%, about 104%, about 105%, about 106%, about 107%, about 108%, about 109%, about 110%, about 111%, about 112%, about 113%, about 114%, about 115%, about 116%, about 117%, about 118%, about 119%, or about 120% of the lowest hypertension treatment dose. In some embodiments, the dosage of the calcium channel blocker is about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, about 100%, about 101%, about 102%, about 103%, about 104%, about 105%, about 106%, about 107%, about 108%, about 109%, or about 110% of the lowest therapeutic dose for hypertension. In some embodiments (page 18 / 83 of CN 122272578 A), the dosage of the calcium channel blocker is about 95%, about 96%, about 97%, about 98%, about 99%, about 100%, about 101%, about 102%, about 103%, about 104%, or about 105% of the lowest therapeutic dose for hypertension. In some embodiments, the dosage of the calcium channel blocker is about 100% of the lowest therapeutic dose for hypertension.
[0110] In some embodiments, the minimum therapeutic dose (LHTD) of the following compounds, along with the corresponding recommended doses and recommended dose ranges, are described in the table below: Table 2.
[0111] In some embodiments, the dose of any one of the angiotensin II receptor blocker, diuretic, and calcium channel blocker is replaced with about 80% to about 250% of the minimum therapeutic dose (LHTD) of the angiotensin II receptor blocker, diuretic, or calcium channel blocker. In some embodiments, the dose of the angiotensin II receptor blocker is replaced with about 80% to about 250% of the minimum therapeutic dose (LHTD) of the angiotensin II receptor blocker. In some embodiments, the dose of the diuretic is replaced with about 80% to about 250% of the minimum therapeutic dose (LHTD) of the diuretic. In some embodiments, the dose of the calcium channel blocker is replaced with about 80% to about 250% of the minimum therapeutic dose (LHTD) of the calcium channel blocker. In some embodiments, the dose of any one of the angiotensin II receptor blocker, diuretic, and calcium channel blocker is replaced with about 80% to about 150% of the lowest therapeutic dose (LHTD) of the angiotensin II receptor blocker, diuretic, or calcium channel blocker. In some embodiments, the dose of the angiotensin II receptor blocker is replaced with about 80% to about 150% of the lowest therapeutic dose (LHTD) of the angiotensin II receptor blocker. In some embodiments, the dose of the angiotensin II receptor blocker is replaced with about 100% of the lowest therapeutic dose (LHTD) of the angiotensin II receptor blocker. In some embodiments, the dose of the diuretic is replaced with about 80% to about 150% of the lowest therapeutic dose (LHTD) of the diuretic. In some embodiments, the dose of the diuretic is replaced with about 100% of the lowest therapeutic dose (LHTD) of the diuretic. In some embodiments, the dose of the calcium channel blocker is replaced with about 80% to about 150% of the lowest therapeutic dose (LHTD) of the calcium channel blocker. In some embodiments, the dose of the calcium channel blocker is replaced with about 100% of the lowest therapeutic dose (LHTD) of the calcium channel blocker. In some embodiments, the dose of any one of the angiotensin II receptor blocker, diuretic, and calcium channel blocker is replaced with about 150% to about 250% of the lowest therapeutic dose (LHTD) of the angiotensin II receptor blocker, diuretic, or calcium channel blocker. In some embodiments, the dose of the angiotensin II receptor blocker is replaced with about 150% to about 250% of the lowest therapeutic dose (LHTD) of the angiotensin II receptor blocker.In some embodiments, the dose of the angiotensin II receptor blocker is replaced with approximately 200% of the lowest therapeutic dose (LHTD) of the angiotensin II receptor blocker. In some embodiments, the dose of the diuretic is replaced with approximately 150% to approximately 250% of the lowest therapeutic dose (LHTD) of the diuretic. In some embodiments, the dose of the diuretic is replaced with approximately 200% of the lowest therapeutic dose (LHTD) of the diuretic. In some embodiments, the dose of the calcium channel blocker is replaced with approximately 150% to approximately 250% of the lowest therapeutic dose (LHTD) of the calcium channel blocker. In some embodiments, the dose of the calcium channel blocker is replaced with approximately 200% of the lowest therapeutic dose (LHTD) of the calcium channel blocker.
[0112] In some embodiments, the dose of any two of the angiotensin II receptor blocker, diuretic, and calcium channel blocker is replaced with about 80% to about 250% of the lowest therapeutic dose (LHTD) of the angiotensin II receptor blocker, diuretic, or calcium channel blocker. In some embodiments, the dose of the angiotensin II receptor blocker is replaced with about 80% to about 250% of the lowest therapeutic dose (LHTD) of the angiotensin II receptor blocker. In some embodiments, the dose of the diuretic is replaced with about 80% to about 250% of the lowest therapeutic dose (LHTD) of the diuretic. In some embodiments, the dose of the calcium channel blocker is replaced with about 80% to about 250% of the lowest therapeutic dose (LHTD) of the calcium channel blocker. In some embodiments, the dose of any two of the angiotensin II receptor blocker, diuretic, and calcium channel blocker is replaced with about 80% to about 150% of the lowest therapeutic dose (LHTD) of the angiotensin II receptor blocker, diuretic, or calcium channel blocker. In some embodiments, the dose of the angiotensin II receptor blocker is replaced with about 80% to about 150% of the lowest therapeutic dose (LHTD) of the angiotensin II receptor blocker. In some embodiments, the dose of the angiotensin II receptor blocker is replaced with about 100% of the lowest therapeutic dose (LHTD) of the angiotensin II receptor blocker. In some embodiments, the dose of the diuretic is replaced with about 80% to about 150% of the lowest therapeutic dose (LHTD) of the diuretic. In some embodiments, the dose of the diuretic is replaced with about 100% of the lowest therapeutic dose (LHTD) of the diuretic. In some embodiments, the dose of the calcium channel blocker is replaced with approximately 80% to approximately 150% of the lowest therapeutic dose (LHTD) of the calcium channel blocker. In some embodiments, the dose of the calcium channel blocker is replaced with approximately 100% of the lowest therapeutic dose (LHTD) of the calcium channel blocker.In some embodiments, the dose of any two of the angiotensin II receptor blocker, diuretic, and calcium channel blocker is replaced with about 150% to about 250% of the lowest therapeutic dose (LHTD) of the angiotensin II receptor blocker, diuretic, or calcium channel blocker. In some embodiments, the dose of the angiotensin II receptor blocker is replaced with about 150% to about 250% of the lowest therapeutic dose (LHTD) of the angiotensin II receptor blocker. In some embodiments, the dose of the angiotensin II receptor blocker is replaced with about 200% of the lowest therapeutic dose (LHTD) of the angiotensin II receptor blocker. In some embodiments, the dose of the diuretic is replaced with about 150% to about 250% of the lowest therapeutic dose (LHTD) of the diuretic. In some embodiments, the dose of the diuretic is replaced with about 200% of the lowest therapeutic dose (LHTD) of the diuretic. In some embodiments, the dose of the calcium channel blocker is replaced with about 150% to about 250% of the lowest therapeutic dose (LHTD) of the calcium channel blocker. In some embodiments, the dose of the calcium channel blocker is replaced with about 200% of the lowest therapeutic dose (LHTD) of the calcium channel blocker.
[0113] In some embodiments, the doses of the angiotensin II receptor blocker, the diuretic (e.g., a thiazide diuretic or a thiazide-like diuretic), and the calcium channel blocker are each independently about 80% to about 150% of the lowest therapeutic dose (LHTD) of the angiotensin II receptor blocker, the diuretic, or the calcium channel blocker. In some embodiments, the dose of the angiotensin II receptor blocker is about 80% to about 150% of the lowest therapeutic dose (LHTD) of the angiotensin II receptor blocker. In some embodiments, the dose of the diuretic is about 80% to about 150% of the lowest therapeutic dose (LHTD) of the diuretic. In some embodiments, the dose of the calcium channel blocker is about 80% to about 150% of the lowest therapeutic dose (LHTD) of the calcium channel blocker. In some embodiments, the doses of the angiotensin II receptor blocker, the diuretic, and the calcium channel blocker are each independently about 80% to about 120% of the lowest therapeutic dose (LHTD) of the angiotensin II receptor blocker, the diuretic, or the calcium channel blocker. In some embodiments, the dose of the angiotensin II receptor blocker is about 80% to about 120% of the lowest therapeutic dose (LHTD) of the angiotensin II receptor blocker. In some embodiments, the dose of the angiotensin II receptor blocker is about 100% of the lowest therapeutic dose (LHTD) of the angiotensin II receptor blocker.In some embodiments, the dose of the diuretic is about 80% to about 120% of the lowest therapeutic dose (LHTD) of the diuretic. In some embodiments, the dose of the diuretic is about 100% of the lowest therapeutic dose (LHTD) of the diuretic. In some embodiments, the dose of the calcium channel blocker is about 80% to about 120% of the lowest therapeutic dose (LHTD) of the calcium channel blocker. In some embodiments, the dose of the calcium channel blocker is about 100% of the lowest therapeutic dose (LHTD) of the calcium channel blocker. In some embodiments, the doses of the angiotensin II receptor blocker, the diuretic, and the calcium channel blocker are each independently about 90% to about 110% of the lowest therapeutic dose (LHTD) of the angiotensin II receptor blocker, the diuretic, or the calcium channel blocker. In some embodiments, the dose of the angiotensin II receptor blocker is about 90% to about 110% of the lowest therapeutic dose (LHTD) of the angiotensin II receptor blocker. In some embodiments, the dose of the angiotensin II receptor blocker is about 100% of the lowest therapeutic dose (LHTD) of the angiotensin II receptor blocker. In some embodiments, the dose of the diuretic is about 90% to about 110% of the lowest therapeutic dose (LHTD) of the diuretic. In some embodiments, the dose of the diuretic is about 100% of the lowest therapeutic dose (LHTD) of the diuretic. In some embodiments, the dose of the calcium channel blocker is about 90% to about 110% of the lowest therapeutic dose (LHTD) of the calcium channel blocker. In some embodiments, the dose of the calcium channel blocker is about 100% of the lowest therapeutic dose (LHTD) of the calcium channel blocker.
[0114] In some embodiments, the pharmaceutical composition comprises: (a) telmisartan as an angiotensin II receptor blocker; (b) indapamide as a thiazide-like diuretic; and (c) amlodipine besylate as a calcium channel blocker. In some embodiments, the dose of telmisartan is about 16 mg to about 30 mg, the dose of indapamide is about 1 mg to about 1.875 mg, and the dose of amlodipine besylate is about 2 mg to about 3.75 mg.
[0115] In some embodiments, the dose of telmisartan is about 16 mg to about 24 mg, the dose of indapamide is about 1 mg to about 1.5 mg, and the dose of amlodipine besylate is about 2 mg to about 3 mg.
[0116] In some embodiments, the dose of telmisartan is about 18 mg to about 22 mg, the dose of indapamide is about 1.125 mg to about 1.375 mg, and the dose of amlodipine besylate is about 2.25 mg to about 2.75 mg.
[0117] In some embodiments, the dose of telmisartan is about 20 mg, the dose of indapamide is about 1.25 mg, and the dose of amlodipine besylate is about 2.5 mg.
[0118] In some embodiments, the pharmaceutical composition comprises: (a) telmisartan as an angiotensin II receptor blocker; (b) chlorthalidone as a thiazide-like diuretic; and (c) amlodipine besylate as a calcium channel blocker. In some embodiments, the dose of telmisartan is about 16 mg to about 30 mg, the dose of chlorthalidone is about 20 mg to about 37.5 mg, and the dose of amlodipine besylate is about 2 mg to about 3.75 mg.
[0119] In some embodiments, the dose of telmisartan is about 16 mg to about 24 mg, the dose of chlorthalidone is about 20 mg to about 30 mg, and the dose of amlodipine besylate is about 2 mg to about 3 mg. Instructions for Use, Page 21 / 83, 24 CN 122272578 A
[0120] In some embodiments, the dose of telmisartan is about 18 mg to about 22 mg, the dose of chlorthalidone is about 22.5 mg to about 27.5 mg, and the dose of amlodipine besylate is about 2.25 mg to about 2.75 mg.
[0121] In some embodiments, the dose of telmisartan is about 20 mg, the dose of chlorthalidone is about 25 mg, and the dose of amlodipine besylate is about 2.5 mg.
[0122] Formulation In some embodiments, the angiotensin II receptor blocker, the diuretic, and the calcium channel blocker are provided in one formulation. In some embodiments, the angiotensin II receptor blocker, the diuretic, and the calcium channel blocker are each provided in a separate formulation. In some embodiments, two of the angiotensin II receptor blocker, the diuretic, and the calcium channel blocker are provided in one formulation. In some embodiments, angiotensin II receptor agonists and diuretics are provided in a single formulation. In some embodiments, angiotensin II receptor blockers and calcium channel blockers are provided in a single formulation. In some embodiments, diuretics and calcium channel blockers are provided in a single formulation. In some embodiments, angiotensin II receptor blockers, diuretics, and calcium channel blockers are provided in a single formulation. In some embodiments, the pharmaceutical composition is in the form of pills, tablets, or capsules. In some embodiments, the pharmaceutical composition is in the form of pills. In some embodiments, the pharmaceutical composition is in the form of tablets. In some embodiments, the pharmaceutical composition is in the form of capsules. In some embodiments, the pharmaceutical composition is suitable for oral administration.
[0123] Other suitable formulations include, but are not limited to, formulations suitable for rectal, topical, buccal, parenteral (e.g., subcutaneous, intramuscular, intradermal, or intravenous), rectal, vaginal, or aerosol administration, but the most suitable form of administration in any given case will depend on the extent and severity of the condition being treated and the nature of the specific compound used. For example, the disclosed compositions may be formulated into unit doses.
[0124] Exemplary pharmaceutical compositions may be used in the form of pharmaceutical articles, such as in solid, semi-solid, or liquid form, comprising one or more disclosed compounds as the active ingredient, mixed with an organic or inorganic carrier or excipient suitable for external, enteral, or parenteral application. For example, the active ingredient may be compounded with a generally non-toxic, pharmaceutically acceptable carrier for use in tablets, pellets, capsules, suppositories, solutions, emulsions, suspensions, and any other suitable form. The pharmaceutical composition contains an active target compound in an amount sufficient to produce the desired effect on the course or condition of the disease.
[0125] To prepare solid compositions such as tablets, the main active ingredient may be mixed with a pharmaceutical carrier (e.g., conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate, or gum) and other pharmaceutical diluents (e.g., water) to form a solid preformation composition comprising a homogeneous mixture of the disclosed compound or a non-toxic, pharmaceutically acceptable salt thereof. When these preformation compositions are referred to as homogeneous, it means that the active ingredient is uniformly dispersed throughout the composition, such that the composition can be readily subdivided into equivalent unit dosage forms, such as tablets, pills, and capsules.
[0126] In solid dosage forms (capsules, tablets, pills, sugar tablets, powders, granules, etc.) for oral administration, the compositions of the present invention are mixed with one or more pharmaceutically acceptable carriers such as sodium citrate or dicalcium phosphate and / or any of the following substances: (1) fillers or enriching agents such as starch, lactose, sucrose, glucose, mannitol and / or silica; (2) binders such as carboxymethyl cellulose, alginate, gelatin, polyvinylpyrrolidone, sucrose and / or gum arabic; (3) humectants such as glycerin; (4) disintegrants such as agar, calcium carbonate, potato or cassava starch, alginate, certain silicates and sodium carbonate; (5) dissolution inhibitors such as paraffin; (6) absorption accelerators such as quaternary ammonium compounds; (7) wetting agents such as cetyl alcohol and glyceryl monostearate. (8) an absorbent, such as kaolin and bentonite; (9) a lubricant, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium lauryl sulfate, and mixtures thereof; and (10) a colorant. In the case of capsules, tablets, and pills, the composition may also contain a buffer.Similar types of solid compositions can also be used as fillers in soft and hard-filled gelatin capsules using excipients such as lactose or toffee and high molecular weight polyethylene glycol.
[0127] Tablets can be made by compression or molding, optionally with one or more excipients. Compressed tablets can be prepared using binders (e.g., gelatin or hydroxypropyl methylcellulose), lubricants, inert diluents, preservatives, disintegrants (e.g., sodium glycolate starch or croscarmellose sodium), surfactants, or dispersants. Molded tablets can be prepared by molding a mixture of the subject composition wetted with an inert liquid diluent in a suitable machine. In some embodiments, capsules are prepared by encapsulating the tablets in a hard gelatin capsule (e.g., encapsulation). Tablets and other solid dosage forms, such as tablets, capsules, pills, and granules, can optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings known in the field of pharmaceutical formulation.
[0128] In some embodiments, the angiotensin II receptor blocker of the pharmaceutical composition described herein may be replaced by an angiotensin-converting enzyme inhibitor (ACE inhibitor). Examples of suitable ACE inhibitors include, but are not limited to, benazepril, captopril, enalapril, fosinopril, lisinopril, moxipril, perindopril, quinapril, ramipril, trandopril, or a pharmaceutically acceptable salt or hydrate thereof. In some embodiments, the dose of the ACE inhibitor is from about 80% to about 150% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the ACE inhibitor is from about 80% to about 120% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the ACE inhibitor is from about 90% to about 110% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the ACE inhibitor is from about 100% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the ACE inhibitor is from about 40% to about 80% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the angiotensin-converting enzyme inhibitor is about 40% to about 70% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the angiotensin-converting enzyme inhibitor is about 40% to about 60% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the angiotensin-converting enzyme inhibitor is about 40% to about 50% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the angiotensin-converting enzyme inhibitor is about 45% to about 55% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the angiotensin-converting enzyme inhibitor is about 50% to about 80% of the lowest therapeutic dose for hypertension.In some embodiments, the dose of the angiotensin-converting enzyme inhibitor is about 50% to about 70% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the angiotensin-converting enzyme inhibitor is about 50% to about 60% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the angiotensin-converting enzyme inhibitor is about 60% to about 80% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the angiotensin-converting enzyme inhibitor is about 60% to about 70% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the angiotensin-converting enzyme inhibitor is about 70% to about 80% of the lowest therapeutic dose for hypertension. In some implementations, the dose of angiotensin-converting enzyme inhibitor is approximately 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, or 80% of the lowest hypertension treatment dose. In some embodiments, the dose of the angiotensin-converting enzyme inhibitor is about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, about 50%, about 51%, about 52%, about 53%, about 54%, about 55%, about 56%, about 57%, about 58%, about 59%, or about 60% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the angiotensin-converting enzyme inhibitor is about 45%, about 46%, about 47%, about 48%, about 49%, about 50%, about 51%, about 52%, about 53%, about 54%, or about 55% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the angiotensin-converting enzyme inhibitor is about 50% of the lowest therapeutic dose for hypertension. In some implementations, the dose of the angiotensin-converting enzyme inhibitor is approximately 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, or 80% of the lowest hypertension treatment dose.In some embodiments, the dose of the angiotensin-converting enzyme inhibitor is about 61%, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, or about 71% of the lowest therapeutic dose for hypertension. In some embodiments, the dose of the angiotensin-converting enzyme inhibitor is about 66% of the lowest therapeutic dose for hypertension.
[0129] Treatment Methods The pharmaceutical compositions described herein can be used to treat hypertension in subjects of need. In some embodiments, the treatment results in a systolic blood pressure (SBP) below about 140 mmHg. In some embodiments, the treatment results in a systolic blood pressure (SBP) below about 135 mmHg. In some embodiments, the treatment results in a reduction in systolic blood pressure (SBP) of about 10 mmHg or more. In some embodiments, the treatment results in a reduction in systolic blood pressure (SBP) of about 10 mmHg to about 20 mmHg. In some embodiments, the treatment results in a reduction in systolic blood pressure (SBP) of about 10 mmHg to about 30 mmHg. In some implementations, the treatment results in a reduction in systolic blood pressure (SBP) of approximately 10 mmHg, approximately 11 mmHg, approximately 12 mmHg, approximately 13 mmHg, approximately 14 mmHg, approximately 15 mmHg, approximately 16 mmHg, approximately 17 mmHg, approximately 18 mmHg, approximately 19 mmHg, or approximately 20 mmHg. In some embodiments, the treatment results in a reduction of systolic blood pressure (SBP) of approximately 10 mmHg, approximately 11 mmHg, approximately 12 mmHg, approximately 13 mmHg, approximately 14 mmHg, approximately 15 mmHg, approximately 16 mmHg, approximately 17 mmHg, approximately 18 mmHg, approximately 19 mmHg, approximately 20 mmHg, approximately 21 mmHg, approximately 22 mmHg, approximately 23 mmHg, approximately 24 mmHg, approximately 25 mmHg, approximately 26 mmHg, approximately 27 mmHg, approximately 28 mmHg, approximately 29 mmHg, or approximately 30 mmHg. In some embodiments, the treatment results in a diastolic blood pressure (DBP) below approximately 90 mmHg. In some embodiments, the treatment results in a diastolic blood pressure (DBP) below approximately 85 mmHg. In some embodiments, the treatment results in a reduction of diastolic blood pressure (DBP) of approximately 5 mmHg or more. In some embodiments, the treatment results in a reduction of diastolic blood pressure (DBP) of approximately 5 mmHg to approximately 10 mmHg. In some embodiments, the treatment results in a reduction of diastolic blood pressure (DBP) of approximately 5 mmHg to approximately 15 mmHg. In some embodiments, the treatment results in a reduction of diastolic blood pressure (DBP) of approximately 5 mmHg, approximately 6 mmHg, approximately 7 mmHg, approximately 8 mmHg, approximately 9 mmHg, or approximately 10 mmHg.In some embodiments, the treatment results in a reduction of diastolic blood pressure (DBP) of about 5 mmHg, about 6 mmHg, about 7 mmHg, about 8 mmHg, about 9 mmHg, about 10 mmHg, about 11 mmHg, about 12 mmHg, about 13 mmHg, about 14 mmHg, or about 15 mmHg.
[0130] In some embodiments, the treatment results in a reduction of systolic blood pressure (SBP) greater than the reduction obtained with the lowest complete hypertension treatment dose of any one of the angiotensin II receptor blocker, diuretic, and calcium channel blocker in the pharmaceutical composition. In some embodiments, the treatment results in a reduction of systolic blood pressure (SBP) greater than the reduction obtained with the lowest complete hypertension treatment dose of the angiotensin II receptor blocker in the pharmaceutical composition. In some embodiments, the treatment results in a reduction of systolic blood pressure (SBP) greater than the reduction obtained with the lowest complete hypertension treatment dose of the diuretic in the pharmaceutical composition. In some embodiments, the treatment results in a reduction of systolic blood pressure (SBP) greater than the reduction obtained with the lowest complete hypertension treatment dose of the calcium channel blocker in the pharmaceutical composition.
[0131] In some embodiments, the treatment results in a reduction in diastolic blood pressure (DBP) greater than that obtained with the lowest complete hypertension treatment dose of any one of the angiotensin II receptor blocker, diuretic, and calcium channel blocker in the pharmaceutical composition. In some embodiments, the treatment results in a reduction in diastolic blood pressure (DBP) greater than that obtained with the lowest complete hypertension treatment dose of the angiotensin II receptor blocker in the pharmaceutical composition. In some embodiments, the treatment results in a reduction in diastolic blood pressure (DBP) greater than that obtained with the lowest complete hypertension treatment dose of the diuretic in the pharmaceutical composition. In some embodiments, the treatment results in a reduction in diastolic blood pressure (DBP) greater than that obtained with the lowest complete hypertension treatment dose of the calcium channel blocker in the pharmaceutical composition.
[0132] In some embodiments, the treatment results in higher long-term tolerability and a reduced risk of side effects compared to treatment with the lowest complete hypertension treatment dose of any one of the angiotensin II receptor blocker, diuretic, and calcium channel blocker in the pharmaceutical composition. In some embodiments, the treatment results in greater long-term tolerability and a reduced risk of side effects compared to treatment with the complete lowest therapeutic dose of the angiotensin II receptor blocker in the pharmaceutical composition (page 24 / 83, 27 CN 122272578 A). In some embodiments, the treatment results in greater long-term tolerability and a reduced risk of side effects compared to treatment with the complete lowest therapeutic dose of the diuretic in the pharmaceutical composition.In some embodiments, the treatment results in greater long-term tolerability and a reduced risk of side effects compared to treatment with the full lowest therapeutic dose of the calcium channel blocker in the pharmaceutical composition.
[0133] In some embodiments, the treatment results in a reduction in systolic blood pressure (SBP) greater than or equal to the reduction obtained with any combination of two of the angiotensin II receptor blocker, diuretic, and calcium channel blocker in the pharmaceutical composition, wherein each of the angiotensin II receptor blocker, diuretic, and calcium channel blocker is at approximately 50% of the lowest therapeutic dose for hypertension. In some embodiments, the treatment results in a reduction in diastolic blood pressure (DBP) greater than or equal to the reduction obtained with any combination of two of the angiotensin II receptor blocker, diuretic, and calcium channel blocker in the pharmaceutical composition, wherein each of the angiotensin II receptor blocker, diuretic, and calcium channel blocker is at approximately 50% of the lowest therapeutic dose for hypertension. In some embodiments, the treatment results in greater long-term tolerability and a reduced risk of side effects compared to treatment using a combination of any two of the angiotensin II receptor blocker, diuretic, and calcium channel blocker in the pharmaceutical composition, wherein the doses of the angiotensin II receptor blocker, diuretic, and calcium channel blocker are each about 50% of the lowest hypertension treatment dose.
[0134] In some embodiments, the treatment is initial or first-line treatment for hypertension. In some embodiments, the subject has a very slight elevation in blood pressure prior to treatment. In some embodiments, the subject has not received any prior hypertension treatment prior to treatment. In some embodiments, the subject has a very slight elevation in blood pressure prior to treatment and has not received any prior hypertension treatment prior to treatment.
[0135] This disclosure recognizes that, in some embodiments, the use of angiotensin II receptor blockers in the pharmaceutical compositions disclosed herein provides beneficial therapeutic effects, including but not limited to significant reductions in blood pressure, significant reductions in blood pressure in subjects with mild elevations in blood pressure, greater long-term tolerability, and a reduced risk of side effects. This disclosure recognizes that, in some embodiments, excluding platelet-modifying agents, serum homocysteine-lowering agents, or combinations thereof from the pharmaceutical compositions disclosed herein provides beneficial therapeutic effects, including but not limited to significant reductions in blood pressure, significant reductions in blood pressure in subjects with mildly elevated blood pressure, greater long-term tolerability, and reduced risk of side effects.
[0136] This document also recognizes that, in some embodiments, the triple combination described herein, comprising an angiotensin II receptor blocker (such as losartan), a diuretic (such as hydrochlorothiazide), and a calcium channel blocker (amlodipine besylate) (each component being 100% of the lowest hypertension treatment dose), provides significantly greater reductions in blood pressure (such as systolic, diastolic, or both) compared to a triple combination comprising an angiotensin II receptor blocker (such as losartan), a diuretic (such as hydrochlorothiazide), and a calcium channel blocker (amlodipine besylate) (each component being 100% of the lowest hypertension treatment dose). In some implementations, the triple combination described herein, comprising an angiotensin II receptor blocker (such as losartan), a diuretic (such as hydrochlorothiazide), and a calcium channel blocker (amlodipine besylate) (each component being 100% of the lowest therapeutic dose for hypertension), provides significantly greater reductions in blood pressure (such as systolic, diastolic, or both) compared to a triple combination comprising an angiotensin II receptor blocker (such as losartan), a diuretic (such as hydrochlorothiazide), and a calcium channel blocker (each component being approximately 40% to approximately 60% of the lowest therapeutic dose for hypertension).
[0137] This document also recognizes that, in some embodiments, the triple combination described herein, comprising telmisartan, a thiazide-like diuretic, and a calcium channel blocker (each component being approximately 80% to approximately 150% of the lowest hypertension treatment dose), provides significantly greater reductions in blood pressure (such as systolic, diastolic, or both), compared to a triple combination comprising losartan as an angiotensin II receptor blocker, a thiazide-like diuretic (such as hydrochlorothiazide), and a calcium channel blocker (amlodipine besylate). In some embodiments, compared to a triple combination comprising losartan as an angiotensin II receptor blocker, a thiazide diuretic (such as hydrochlorothiazide), and a calcium channel blocker (amlodipine besylate), the triple combination described herein comprising telmisartan, a thiazide-like diuretic, and a calcium channel blocker (each component at about 80% to about 120% of the lowest hypertension treatment dose) provides significantly greater reductions in blood pressure (such as systolic, diastolic, or both).
[0138] In one aspect, a method of treating hypertension and / or dyslipidemia in a subject of need is provided, comprising administering to the subject: (a) an angiotensin II receptor blocker; (b) a diuretic; and (c) a calcium channel blocker, wherein each of (a), (b), and (c) is at about 40% to about 80% of the lowest hypertension treatment dose (LHTD), and wherein said method further comprises at least one cholesterol-lowering active agent.
[0139] In some embodiments of the methods provided herein, the methods substantially do not include angiotensin-converting enzyme inhibitors or pharmaceutically acceptable salts thereof, beta-blockers or pharmaceutically acceptable salts thereof, platelet function modifiers, serum homocysteine depressants or combinations thereof.In some embodiments of the methods provided herein, the methods do not include, include, or consist of the following steps: administration of an angiotensin-converting enzyme inhibitor or a pharmaceutically acceptable salt thereof, a beta-blocker or a pharmaceutically acceptable salt thereof, a platelet function modifier, a serum homocysteine depressant, or a combination thereof.
[0140] In some embodiments of the methods provided herein, the angiotensin II receptor blocker is irbesartan, telmisartan, valsartan, candesartan, eprosartan, olmesartan, azilsartan, losartan, or a pharmaceutically acceptable salt or hydrate thereof.
[0141] In some embodiments of the methods provided herein, the angiotensin II receptor blocker is telmisartan.
[0142] In some embodiments of the methods provided herein, the doses of (a), (b), and (c) are each about 40% to about 60% of the lowest therapeutic dose for hypertension (LHTD).
[0143] In some embodiments of the methods provided herein, the diuretic is a thiazide-like diuretic, and the dose of the thiazide-like diuretic is about 50% of the lowest hypertension treatment dose (LHTD) of the thiazide-like diuretic.
[0144] In some embodiments of the methods provided herein, the thiazide-like diuretic is indapamide, and the dose of indapamide is about 0.625 mg.
[0145] In some embodiments of the methods provided herein, the dose of the calcium channel blocker is about 50% of the lowest hypertension treatment dose (LHTD) of the calcium channel blocker.
[0146] In some embodiments of the methods provided herein, the calcium channel blocker is amlodipine besylate, and the dose of amlodipine besylate is about 1.25 mg.
[0147] In some embodiments of the methods provided herein, the dose of the angiotensin II receptor blocker is about 50% of the lowest hypertension treatment dose (LHTD) of the angiotensin II receptor blocker.
[0148] In some embodiments of the methods provided herein, the angiotensin II receptor blocker is telmisartan, and the dose of telmisartan is about 10 mg.
[0149] In some embodiments of the methods provided herein, the angiotensin II receptor blocker is telmisartan, the diuretic is indapamide, and the calcium channel blocker is amlodipine besylate.
[0150] In some embodiments of the methods provided herein, the dose of telmisartan is about 8 mg to about 12 mg, the dose of indapamide is about 0.5 mg to about 0.75 mg, and the dose of amlodipine besylate is about 1 mg to about 1.5 mg.
[0151] In some embodiments of the methods provided herein, the dose of telmisartan is about 10 mg, the dose of indapamide is about 0.625 mg, and the dose of amlodipine besylate is about 1.25 mg.
[0152] This document provides a method for treating hypertension and / or dyslipidemia in a subject in need, comprising administering to the subject: (a) telmisartan; (b) a thiazide-like diuretic; and (c) a calcium channel blocker, wherein each of (a), (b), and (c) is at a dose of about 80% to about 150% of the lowest therapeutic dose for hypertension (LHTD), and wherein the method further comprises at least one cholesterol-lowering agent.
[0153] In some embodiments of the methods provided herein, the method substantially excludes angiotensin-converting enzyme inhibitors or pharmaceutically acceptable salts thereof, beta-blockers or pharmaceutically acceptable salts thereof, platelet function modifiers, serum homocysteine lowering agents, or combinations thereof.
[0154] In some embodiments of the methods provided herein, the diuretic is a thiazide-like diuretic.
[0155] In some embodiments of the methods provided herein, the thiazide-like diuretic is quetiapine, clopamine, chlorthalidone, mefcitabine, chlorfenapyramide, metoprazine, meteclaron, sipamide, indapamide, chlorothiazide, fenquinazole, or a pharmaceutically acceptable salt or hydrate thereof.
[0156] In some embodiments of the methods provided herein, the thiazide-like diuretic is indapamide or its hydrate.
[0157] In some embodiments of the methods provided herein, the thiazide-like diuretic is indapamide.
[0158] In some embodiments of the methods provided herein, the calcium channel blocker is amlodipine, nifedipine, diltiazem, nimodipine, verapamil, isradipine, felodipine, nicardipine, nisoldipine, clovidipine, dihydropyridine, lorcanidipine, nifedipine, cilnidipine, manidipine, miradipine, benprodil, barnidipine, nivardipine, golopamil, lidocaine, areradipine, dotalizine, dipropionylene, or a pharmaceutically acceptable salt or hydrate thereof.
[0159] In some embodiments of the methods provided herein, the calcium channel blocker is amlodipine or a pharmaceutically acceptable salt thereof.
[0160] In some embodiments of the methods provided herein, the calcium channel blocker is amlodipine besylate.
[0161] In some embodiments of the methods provided herein, the doses of (a), (b), and (c) are each about 80% to about 120% of the lowest hypertension treatment dose (LHTD).
[0162] In some embodiments of the methods provided herein, the dose of the thiazide-like diuretic is about 100% of the lowest hypertension treatment dose (LHTD) of the thiazide-like diuretic.
[0163] In some embodiments of the methods provided herein, the thiazide-like diuretic is indapamide, and the dose of indapamide is about 1.25 mg.
[0164] In some embodiments of the methods provided herein, the dose of the calcium channel blocker is about 100% of the lowest hypertension treatment dose (LHTD) of the calcium channel blocker.
[0165] In some embodiments of the methods provided herein, the calcium channel blocker is amlodipine besylate, and the dose of amlodipine besylate is about 2.5 mg.
[0166] In some embodiments of the methods provided herein, the angiotensin II receptor blocker is telmisartan, and the dose of telmisartan is about 100% of the lowest hypertension treatment dose (LHTD) of telmisartan.
[0167] In some embodiments of the methods provided herein, the angiotensin II receptor blocker is telmisartan, and the dose of telmisartan is about 20 mg. Instructions for Use, Page 27 / 83, 30 CN 122272578 A
[0168] In some embodiments of the method provided herein, the thiazide-like diuretic is indapamide, the calcium channel blocker is amlodipine besylate, and the angiotensin II receptor blocker is telmisartan.
[0169] In some embodiments of the method provided herein, the dose of telmisartan is about 16 mg to about 24 mg, the dose of indapamide is about 1 mg to about 1.5 mg, and the dose of amlodipine besylate is about 2 mg to about 3 mg.
[0170] In some embodiments of the method provided herein, the dose of telmisartan is about 20 mg, the dose of indapamide is about 1.25 mg, and the dose of amlodipine besylate is about 2.5 mg.
[0171] In some embodiments of the method provided herein, the at least one cholesterol-lowering active agent is selected from NPC1L1 inhibitors, statins, or combinations thereof.
[0172] In some embodiments of the methods provided herein, the at least one cholesterol-lowering active agent is a combination of an NPC1L1 inhibitor and a statin.
[0173] In some embodiments of the methods provided herein, the at least one cholesterol-lowering active agent is ezetimibe, rosuvastatin, or a combination thereof.
[0174] In some embodiments of the methods provided herein, the at least one cholesterol-lowering active agent is a combination of ezetimibe and rosuvastatin.
[0175] In some embodiments of the methods provided herein, the dose of ezetimibe is about 10 mg, and the dose of rosuvastatin is about 10 mg.
[0176] In some embodiments of the methods provided herein, (a), (b), (c), and the at least one cholesterol-lowering active agent are provided in a single formulation.
[0177] In some embodiments of the methods provided herein, (a), (b), (c) and the at least one cholesterol-lowering active agent are provided in at least two separate formulations.
[0178] In some embodiments of the methods provided herein, (a), (b), (c) and at least two of the at least one cholesterol-lowering active agent are provided in a single formulation.
[0179] In some embodiments of the methods provided herein, (a), (b), (c) and at least three of the at least one cholesterol-lowering active agent are provided in a single formulation.
[0180] In some embodiments of the methods provided herein, the at least one cholesterol-lowering active agent is a combination of ezetimibe and rosuvastatin.
[0181] In some embodiments of the methods provided herein, (a), (b), (c) are provided in a single formulation, and the combination of ezetimibe and rosuvastatin is provided in another formulation.
[0182] The present invention provides embodiments including, but not limited to, the following: 1. A pharmaceutical composition comprising: (a) an angiotensin II receptor blocker; (b) a diuretic; and (c) a calcium channel blocker, wherein each of (a), (b), and (c) is at a dose of about 40% to about 80% of the lowest therapeutic dose for hypertension (LHTD), and wherein the pharmaceutical composition further comprises at least one cholesterol-lowering active agent.
[0183] 2. The pharmaceutical composition according to embodiment 1, wherein the diuretic is a thiazide-like diuretic, and the thiazide-like diuretic is quinacrine, clopamid, chlorthalidone, mefcitabine, chlorfenapyramide, metoprazine, meteclaron, sipamid, indapamid, chlorothiazide, fenquinazole, or a pharmaceutically acceptable salt or hydrate thereof.
[0184] 3. The pharmaceutical composition according to embodiment 2, wherein the thiazide-like diuretic is indapamid. Instructions for Use, Page 28 / 83, 31 CN 122272578 A
[0185] 4. The pharmaceutical composition according to any one of Embodiments 1-3, wherein the calcium channel blocker is amlodipine, nifedipine, diltiazem, nimodipine, verapamil, isradipine, felodipine, nicardipine, nisoldipine, clovidipine, dihydropyridine, lercanidipine, nifedipine, cilnidipine, manidipine, miradipine, benprodil, barnidipine, nivardipine, golopamil, lidocaine, areradipine, dotazine, dipropionylene, or a pharmaceutically acceptable salt or hydrate thereof.
[0186] 5. The pharmaceutical composition according to any one of Embodiments 1-4, wherein the calcium channel blocker is amlodipine besylate.
[0187] 6. The pharmaceutical composition according to any one of embodiments 1-5, wherein the angiotensin II receptor blocker is irbesartan, telmisartan, valsartan, candesartan, eprosartan, olmesartan, azilsartan, losartan, or a pharmaceutically acceptable salt or hydrate thereof.
[0188] 7. The pharmaceutical composition according to any one of embodiments 1-6, wherein the angiotensin II receptor blocker is telmisartan.
[0189] 8. The pharmaceutical composition according to any one of embodiments 1-7, wherein each of (a), (b), and (c) is at about 40% to about 60% of the lowest hypertension treatment dose (LHTD).
[0190] 9. The pharmaceutical composition according to any one of claims 1-8, wherein the diuretic is a thiazide-like diuretic, and the dose of the thiazide-like diuretic is about 50% of the lowest hypertension treatment dose (LHTD) of the thiazide-like diuretic.
[0191] 10. The pharmaceutical composition according to any one of embodiments 1-9, wherein the thiazide-like diuretic is indapamide, and the dose of indapamide is about 0.625 mg.
[0192] 11. The pharmaceutical composition according to any one of embodiments 1-10, wherein the dose of the calcium channel blocker is about 50% of the lowest hypertension treatment dose (LHTD) of the calcium channel blocker.
[0193] 12. The pharmaceutical composition according to any one of embodiments 1-11, wherein the calcium channel blocker is amlodipine besylate, and the dose of amlodipine besylate is about 1.25 mg.
[0194] 13. The pharmaceutical composition according to any one of embodiments 1-12, wherein the dose of the angiotensin II receptor blocker is about 50% of the lowest hypertension treatment dose (LHTD) of the angiotensin II receptor blocker.
[0195] 14. The pharmaceutical composition according to any one of embodiments 1-13, wherein the angiotensin II receptor blocker is telmisartan, and the dose of telmisartan is about 10 mg.
[0196] 15. The pharmaceutical composition according to embodiment 8, wherein the angiotensin II receptor blocker is telmisartan, the diuretic is indapamide, and the calcium channel blocker is amlodipine besylate; and the dose of telmisartan is about 8 mg to about 12 mg, the dose of indapamide is about 0.5 mg to about 0.75 mg, and the dose of amlodipine besylate is about 1 mg to about 1.5 mg.
[0197] 16. A pharmaceutical composition comprising (a) telmisartan; (b) a thiazide-like diuretic; and (c) a calcium channel blocker, wherein each of (a), (b), and (c) is at about 80% to about 150% of the lowest therapeutic dose of hypertension (LHTD), and wherein the pharmaceutical composition further comprises at least one cholesterol-lowering active agent.
[0198] 17. The pharmaceutical composition according to embodiment 16, wherein the diuretic is a thiazide-like diuretic, and the thiazide-like diuretic is quinacrine, clopamid, chlorthalidone, mefcitabine, chlorfenapyramide, metoprazine, meteclaron, ciprofloxacin, indapamid, lorsolon, fenquinazole, or a pharmaceutically acceptable salt or hydrate thereof.
[0199] 18. The pharmaceutical composition according to embodiment 17, wherein the thiazide-like diuretic is indapamid.
[0200] 19. The pharmaceutical composition according to any one of embodiments 16-18, wherein the calcium channel blocker is amlodipine, nifedipine, diltiazem, nimodipine, verapamil, isradipine, felodipine, nicardipine, nisoldipine, clovidipine, dihydropyridine, lercanidipine, nifedipine, cilnidipine, manidipine, miradipine, benprodil, barnidipine, nivardipine, golopamil, lidocaine, areradipine, dotazine, dipropionylene, or a pharmaceutically acceptable salt or hydrate thereof.
[0201] 20. The pharmaceutical composition according to any one of embodiments 16-19, wherein the calcium channel blocker is amlodipine besylate.
[0202] 21. The pharmaceutical composition according to any one of embodiments 16-20, wherein the doses of (a), (b), and (c) are each about 80% to about 120% of the lowest hypertension treatment dose (LHTD).
[0203] 22. The pharmaceutical composition according to any one of embodiments 16-21, wherein the dose of the thiazide-like diuretic is about 100% of the lowest hypertension treatment dose (LHTD) of the thiazide-like diuretic.
[0204] 23. The pharmaceutical composition according to any one of embodiments 16-22, wherein the thiazide-like diuretic is indapamide, and the dose of indapamide is about 1.25 mg.
[0205] 24. The pharmaceutical composition according to any one of embodiments 16-23, wherein the dose of the calcium channel blocker is about 100% of the lowest hypertension treatment dose (LHTD) of the calcium channel blocker.
[0206] 25. The pharmaceutical composition according to any one of embodiments 16-24, wherein the calcium channel blocker is amlodipine besylate and the dose of amlodipine besylate is about 2.5 mg.
[0207] 26. The pharmaceutical composition according to any one of embodiments 16-25, wherein the angiotensin II receptor blocker is telmisartan, and the dose of telmisartan is about 100% of the lowest hypertension treatment dose (LHTD) of telmisartan.
[0208] 27. The pharmaceutical composition according to any one of embodiments 16-26, wherein the angiotensin II receptor blocker is telmisartan, and the dose of telmisartan is about 20 mg.
[0209] 28. The pharmaceutical composition according to embodiment 21, wherein the thiazide-like diuretic is indapamide, and the calcium channel blocker is amlodipine besylate; and the dose of telmisartan is about 16 mg to about 24 mg, the dose of indapamide is about 1 mg to about 1.5 mg, and the dose of amlodipine besylate is about 2 mg to about 3 mg.
[0210] 29. The pharmaceutical composition according to any one of the foregoing embodiments, wherein the at least one cholesterol-lowering active agent is ezetimibe, rosuvastatin, or a combination thereof.
[0211] 30. The pharmaceutical composition according to any one of the foregoing embodiments, wherein the at least one cholesterol-lowering active agent is a combination of ezetimibe and rosuvastatin.
[0212] 31. The pharmaceutical composition according to embodiment 29 or 30, wherein the dose of ezetimibe is about 10 mg, and wherein the dose of rosuvastatin is about 10 mg.
[0213] 32. A method of treating at least one of hypertension and dyslipidemia in a subject in need, comprising administering to the subject the pharmaceutical composition of any one of the foregoing embodiments.
[0214] 33. A method of treating a combination of hypertension and dyslipidemia in a subject in need, comprising administering to the subject the pharmaceutical composition of any one of the foregoing embodiments.
[0215] Example Example 1: Cardiovascular Measurements in Spontaneously Hypertensive Rats Receiving Combinations of Antihypertensive Drugs Instructions for Use 30 / 83 pages 33 CN 122272578 A Overview The purpose of this study was to evaluate the comparative effects of three different combinations of angiotensin II receptor blockers, calcium channel blockers, and diuretics (thiazide diuretics or thiazide-like diuretics) on blood pressure. The primary objective was to assess whether there were differences in efficacy between combinations of different drugs of the same class, and between combinations of the same drugs at different doses (including very low doses, i.e., doses below the lowest approved and manufactured dose, such as 50% of the lowest therapeutic dose for hypertension (LHTD)).
[0216] The specific combinations studied are as follows: Combination 1: Telmisartan, amlodipine besylate, and indapamide, all at 50% of the lowest hypertension treatment dose (LHTD) or one-quarter of the FDA-recommended maintenance dose (corresponding to telmisartan 10 mg, amlodipine besylate 1.25 mg, and indapamide 0.625 mg); Combination 2: Telmisartan, amlodipine, and indapamide, all at 100% of the lowest hypertension treatment dose (LHTD) or half of the FDA-recommended maintenance dose (corresponding to telmisartan 20 mg, amlodipine besylate 2.5 mg, and indapamide 1.25 mg); and Combination 3: Losartan, amlodipine besylate, and hydrochlorothiazide, all at 100% of the lowest hypertension treatment dose (LHTD) or half of the FDA-recommended maintenance dose (corresponding to losartan 25 mg, amlodipine besylate 2.5 mg, and hydrochlorothiazide 12.5 mg).
[0217] This study was conducted in spontaneously hypertensive rats (SHR), the most commonly used animal model for studying hypertension (see: Pinto YM, Paul M, Ganten D. "Lessons from rat models of hypertension: from Goldblatt to genetic engineering". Cardiovascular Research. 39 (1): 77–88). Drug doses were calculated using standard allometric scaling and publicly available data on Cmax and AUC from each of the six antihypertensive drugs. Each animal was exposed to a single dose of each drug combination according to a Latin square design.
[0218] Methods The following substances were used as mediators in the following studies: 0.5% methylcellulose (w / v) and 0.25% polysorbate 80 (v / v) in 25 mM phosphate buffer (pH 8 + / - 0.2).
[0219] The following animals were used in the study: spontaneously hypertensive rats (strain: SHR / NCrl). These rats were obtained from Charles River Laboratories, Inc., Kingston, New York. They were approximately 12 weeks old at the start of administration. Thirteen male rats were used for adaptation. Eight male rats were used for the study. Animals were identified by cage tags and tattoos.
[0220] Telemetry Implantation: Data Science International transmitters (HD-S10) were implanted in the animals to collect blood pressure and heart rate data. The dosage was not administered to the animals until at least 10 days after surgery.
[0221] Householding: The animals were housed separately in fixed-bottom cages with water bottles.
[0222] Diet: Unless otherwise specified, Teklad Global Diet-Rodent 2014 (Envigo RMS, Inc.) was provided on a permissible basis. In some cases, the dietary form of this diet may be fed to the animals if health conditions indicate otherwise.
[0223] Water: Greenfield municipal water was provided on a permissible basis.
[0224] Contaminants: No known contaminants were present in the diet, water, or bedding (if any) at levels that would interfere with this study.
[0225] Environment: The animal facility was controlled to maintain the following room conditions: temperature ranging from 20 to 26°C, relative humidity from 30% to 70%, and a 12-hour light / 12-hour dark cycle.
[0226] Adaptation (Pre-drug administration phase): The adaptation phase lasted a maximum of 1 week.
[0227] Environmental and dietary enrichment: Various cage enrichment devices and dietary enrichment were provided to the animals (analysis was not required). Instructions for Use, Page 31 / 83, 34, CN 122272578 A
[0228] Randomization: Animals were randomly selected based on the mean arterial pressure value at the pre-dose stage.
[0229] The following table shows the grouping of rats used in this study: Table 3.
[0230] The following table shows the dose levels administered in this study: Table 4.
[0231] Dosing procedure: For combinations 1, 2, and 3, each test combination formulation was freshly prepared on each day of administration. A portion of the mediator (approximately 80%) was added to the test combination formulation and mixed until homogeneous. If a homogeneous suspension or solution was not obtained, 1N NaOH and / or 1N HCl was added to adjust to pH 9 ± 0.2. The remaining mediator was added and mixed with a stir bar. The test combination formulation was continuously stirred at room temperature and protected from light for approximately 30 minutes before administration and throughout the administration process. The test combination formulation was stored protected from light and stirred in a refrigerator set to maintain 2 to 8°C.
[0232] Dosing Procedure: For pre-dosing treatment, allow the test combination formulation to equilibrate to approximately room temperature for at least 30 minutes before administration. Administer the drug to the animal at a volume of 10 mL / kg, with the actual dose volume based on the most recent body weight. Administer the dose orally. Dosing intervals are once daily on days 1, 8, 15, and 22. After dose administration, dispose of any remaining test combination formulation according to standard operating procedures.
[0233] Telemetry Acquisition: Animals will not be disturbed or manipulated shortly before or during telemetry data acquisition without prior approval. Such disturbances include, but are not limited to, changing cages, altering bedding, mopping, cleaning, or any operation that would disrupt a naturally quiet environment, which is essential for the acquisition of cardiovascular telemetry data.
[0234] Animal Observation: Each rat will be observed once daily in the morning. Any abnormal findings will be recorded.Observe rats for death, abnormalities, and signs of pain or distress. Any abnormal findings observed during unplanned observation periods should also be recorded.
[0235] Body weight: Obtain body weight at least once during the pre-dose phase and before each scheduled dose. If appropriate, record additional body weight to monitor animal health. Equip animals with transmitters: Detached weight using a representative transmitter and lead wire before body weight collection for dose calculation.
[0236] Telemetry data acquisition: Digitize the raw arterial pressure signal at a sampling rate of 500 Hz. The derived parameters are the same for pre-dose and dosing phases. For pre-dose data acquisition, check the signal consistency of all implanted telemetry devices and verify that the telemetry signals are acceptable for analysis. Signal checking includes acquiring at least one telemetry record from each rat considered for this study. Record telemetry data continuously for approximately 24 hours. Review the telemetry data to determine if the rats are eligible for the study. Retain the data in the study log and use them to calculate the nominal 24-hour mean arterial pressure to support randomized animal selection. For data acquisition during the dosing phase, continuous telemetry data were acquired from at least 90 minutes before dosing until approximately 48 hours after dosing.
[0237] Nominal dosing time: Telemetry acquisition time points were based on a single nominal dosing time for all animals. The nominal dosing time for each day of the dosing phase was the end time of dosing for the first half of the animals on each computer, recorded on each computer.
[0238] Evaluation of telemetry data: Telemetry parameters, including heart rate (heart beats / minute), systolic blood pressure (mmHg), diastolic blood pressure (mmHg), mean arterial pressure (mmHg), and pulse pressure (mmHg), were analyzed and reported. Telemetry data generated by Ponemah during the dosing phase were analyzed in 1-minute samples. Data were processed as 15-minute averages and provided for data review. The 15-minute average data were further averaged by binning to the following analysis periods: Phase 1: 0.5 to 2 hours post-administration; Phase 2: 2 to 4 hours post-administration; Phase 3: 4–8 hours post-administration; Phase 4: 8–12 hours post-administration; Phase 5: 12–20 hours post-administration; Phase 6: 20–32 hours post-administration (second light cycle); and Phase 7: 32–44 hours post-administration (second dark cycle).
[0239] Blood pressure was measured over a 44-hour period using an implanted telemetry device. The primary outcome measure was systolic blood pressure.
[0240] Statistical analysis was performed using all available data points and weighted to reflect the non-uniform temporal distribution of measurements. Estimates of treatment effect were calculated using estimated differences between treatments, employing a mixed model with a direct product autoregressive correlation structure (SAS 9.4, SAS Institute, Cary, NC), to account for repeated measurements within individuals over time.
[0241] As a result, eight animals were started for the study; however, the telemetry transmitter of one animal malfunctioned. As a result, complete data were obtained from seven animals.
[0242] The following table shows the differences in systolic blood pressure (mmHg) between treatments: Table 5. Specification 33 / 83 pages 36 CN 122272578 A
[0243] Figure 1 shows the mean systolic blood pressure (mmHg) during the treatment period. Figure 2 shows the mean diastolic blood pressure (mmHg) during the treatment period. Figure 3 shows the mean heart rate during the treatment period.
[0244] In this non-limiting embodiment, the results showed that combination 1 produced a significantly greater reduction in systolic blood pressure than combination 3, while combination 2 produced a significantly greater reduction in systolic blood pressure than combination 3 or 1. These differences persisted throughout the 44-hour observation period. The results showed that combinations 1 and 2 produced significantly greater reductions in systolic blood pressure than combination 3. These differences persisted throughout the 44-hour observation period. There were similar differences among the three combinations in terms of DPB reduction, while there were no differences among the combinations in terms of heart rate.
[0245] In this non-limiting embodiment, these results demonstrate unexpected differences between the combination of telmisartan, amlodipine besylate, and indapamide and the combination of losartan, amlodipine besylate, and hydrochlorothiazide. Specifically, at equal or lower doses, the combination of telmisartan, amlodipine besylate, and indapamide produced significantly greater reductions in blood pressure compared to the combination of losartan, amlodipine besylate, and hydrochlorothiazide. Since the dose of amlodipine besylate was the same in combinations 2 and 3, the results demonstrate previously unknown differences in efficacy between specific angiotensin II receptor blockers and specific diuretics (such as thiazide diuretics versus thiazide-like diuretics) when administered in parallel with amlodipine besylate.
[0246] Example 2: Triple Combination Therapy Approach for the Treatment of Hypertension This study was a randomized, placebo-controlled, double-blind, crossover trial. The study was conducted in three phases. In the first phase (4 weeks), participants were randomized (1:1) to receive either a triple combination therapy or a placebo. This was followed by a two-week washout (placebo) period, after which participants were crossed over to the control group to receive the other treatment for four weeks. Participants were recruited primarily from the community through general community practice in Western Sydney, Australia.
[0247] Participants were eligible if they met the following inclusion criteria: 1) adults aged 18 years or older; 2) clinic SBP > 140 mmHg and / or DBP > 90 mmHg on two separate readings on different dates; plus baseline dynamic SBP > 135 and / or DBP > 85; 3) not receiving medication for hypertension.Exclusion criteria included: no clear contraindications to one or more of the components of the triple combination composition; but the attending physician believed that a change in current therapy would put the patient at risk; severe or accelerating hypertension; pregnancy; inability to provide informed consent; and medical conditions with a life expectancy of less than 3 months.
[0248] Intervention For these studies, the triple combination was tested at 50% of the lowest therapeutic dose (LHTD) for each component or at 100% of the LHTD for each component, as per the instructions on page 34 / 83 of CN 122272578 A.
[0249] If the study tested a triple combination at 50% of the LHTD for each component, the composition was tested as follows. The triple combination composition was a single-packed pill containing specified amounts of the following three components: telmisartan 10 mg, amlodipine besylate 1.25 mg, and indapamide 0.625 mg. The placebo capsules look identical and contain placebo tablets with a similar weight to the pills in the triple combination composition.
[0250] If this study tests a triple combination where each component is 100% of the lowest hypertension treatment dose (LHTD), the test composition is as follows. The triple combination composition is a single-encapsulated pill containing specified amounts of the following three components: telmisartan 20 mg, amlodipine besylate 2.5 mg, and indapamide 1.25 mg. The placebo capsules look identical and contain placebo tablets with a similar weight to the pills in the triple combination composition.
[0251] Throughout the trial, participants were administered a single pill, the triple combination composition, or a placebo. Patients were instructed to take the tablets at the same time each day and were encouraged to take them in the morning, but the time of day (morning or evening) was determined according to the patient's preference.
[0252] All investigational drugs were prepared in a TGA-cGMP (Therapeutic Goods Australia – Good Manufacturing Practices Certified) accredited manufacturing facility. Where appropriate, a low-intensity dose was obtained by halving the dose using a pill-splitting device without crushing it, and the dose was weighed to ensure the accuracy of the halved dose. The low-intensity dose was then encapsulated in gelatin capsules (DBCaps-Capsugel). The capsules were stored in a cool, dry place and monitored with a temperature recorder until they were dispensed.
[0253] Treatment allocation was double-blind for both researchers and participants. In addition to the study drug, all participants received education on healthier lifestyle choices recommended in hypertension management guidelines.
[0254] Randomization: The computer-aided randomization order was generated by a statistician and provided to the drug packaging company. Research assistants, the recruitment team, and the researchers were unaware of this order.For each patient, i.e., the assigned randomization number, the pills were packaged into three pediatric safety packs corresponding to the three phases of the study. All packs had the same appearance to ensure double-blinding for both patients and researchers. The packs were then opened in an organized order.
[0255] Outcome measures and data collection The primary outcome measure was the reduction in mean 24-hour systolic blood pressure at 4 weeks using ambulatory blood pressure monitoring (ABP). Secondary outcome measures included: a. A decrease in mean 24-hour diastolic blood pressure, and a decrease in daytime and nighttime SBP and DBP at 4 weeks; b. A decrease in office SBP and DBP as measured by a standardized automated blood pressure cuff; c. The proportion of patients with controlled blood pressure at 4 weeks, defined as 24-hour blood pressure <135 / 85 mmHg and office blood pressure <140 / 90 mmHg; d. Adverse events according to laboratory parameters and pre-specified adverse events: an increase in transaminase (ALT / AST) exceeding 3x the upper limit of normal or doubling of a known baseline level; an estimated decrease in glomerular filtration rate >20% as estimated from serum creatinine, sodium, potassium, and uric acid levels; e. Assessment of acceptability and tolerability: Patients underwent four 24-hour ABP monitoring sessions: baseline (without study drug), 4 weeks (Phase 1 drug), 6 weeks (placebo), and 10 weeks (Phase 3 drug). To minimize inconvenience, patients were transferred to the laboratory for ABP monitoring. The ABP unit was calibrated periodically by the laboratory according to the manufacturer's instructions. To minimize variability, subsequent readings were repeated from the same collection center using the same brand of device. Participants were reimbursed for their travel and parking expenses. The study drug and study were provided free of charge to participants. Office blood pressure was recorded three times at each visit using an OMRON T9P (HEM-759-C1). The second and third readings were averaged for study analysis. Additionally, at weeks 4 and 10, patients underwent blood tests to assess biochemical side effects, were given a questionnaire about clinical side effects, and adherence was assessed through self-reporting and pill counting. At the time of completion of this questionnaire, patients were unaware of their treatment allocation.
[0256] Drug acceptability and tolerability were also assessed at the end of the study. All adverse events were recorded. In addition, specific inquiries were made regarding the following potential adverse clinical events associated with the antihypertensive medication: dizziness, blurred vision, syncope / collapse, chest pain / angina, shortness of breath, cough, wheezing, foot edema, rash, and pruritus.
[0257] The trial had a simplified data safety and management committee with two core members possessing expertise in clinical medicine, testing, and statistics. A meeting was held when 10 patients were randomized to the trial to review safety and recommend that the study continue.
[0258] Statistical considerations were planned with a sample size of 50 patients to provide 90% power at p=0.05 for detecting a 12 mmHg difference in SBP between the intervention and control, assuming an SD of 12 mmHg for the intra-patient difference and considering a 10% chance of loss to follow-up.
[0259] Statistical methods were performed on an intention-to-treat basis. All tests were two-tailed and the nominal level of α was 5%. All statistical analyses were not adjusted for prognostic covariates. Adherence to the study drug was reported using data on the number of pills taken (dosage) and missed doses during this period.
[0260] The effect of treatment on changes in blood pressure relative to baseline was estimated for each treatment period using a linear mixed model, following the method of Kenward and Roger (Kenward MG, Roger JH. The use of baseline covariates in crossover studies. Biostatistics 2010; 11(1): 1–17). To allow for appropriate adjustment of baseline levels collected at the start of each treatment period (week 0 and week 6), the method used all measurements (baseline and follow-up in both periods) as the outcome measure, but considered the covariance between measurements within individuals (Liu GF, Lu K, Mogg R, Mallick M, Mehrotra DV. Should baseline be a covariate or dependent variable in analyses of change from baseline in clinical trials? Stat Med 2009; 28(20): 2509–30). Linear comparisons between variables representing period (first / second), measurement type (baseline / final), and treatment received (placebo / triple combination) produced an unbiased estimate of the effect of the triple combination on changes in blood pressure compared to placebo. All available data were included in the model, and no missing data were extrapolated. If a patient had missing data in one period, data from the available period were used. Sensitivity analyses were performed, including only patients with available data in both periods, to determine if treatment effects had changed.The denominator degrees of freedom were also adjusted according to Kenward and Roger (2009), which is optimal for smaller sample sizes (Kenward MG, Roger JH. An improved approximation to the precision of fixed effects from restricted maximum likelihood. Computational Statistics & Data Analysis 2009; 53(7): 2583-95).
[0261] The carry-over test used an unpaired t-test for the primary outcome measure, where order was considered as an effect. A paired t-test was used to test the time-segment effect, which compared the primary outcome measure of time segment 1 with the primary outcome measure of time segment 2 from the same patient. A sensitivity analysis was also performed using a normal paired t-test to compare the primary outcome measure between different time segments (different treatments) from the same patient without considering the baseline level of each time segment.
[0262] Continuous secondary endpoints with baseline values (e.g., day / night dynamic SBP / instruction manual 36 / 83 pages 39 CN 122272578 A DBP) were analyzed similarly to the primary endpoint. Paired t-tests were used to analyze other continuous variables for which there was no baseline value at each time period. Counts and percentages of all adverse events were reported. As a sensitivity analysis, the analysis was repeated for complete cases (i.e., complete data for each measurement time period).
[0263] Tests were performed for the interaction effects of treatment efficacy with age (<=60 years vs. >60 years), sex, and BMI (<=30 kg / m2 vs. <30 kg / m2). Subgroup analyses for each variable were also performed. All analyses were performed on SAS 9.4 (Cary, NC, USA).
[0264] Example 3: Comparative Study of Low-Dose Combination Therapy vs. Standard-Dose Monotherapy for the Treatment of Hypertension Objective The primary objective of this study was to investigate, in a double-blind, randomized, controlled trial, whether initial treatment with low-dose combination therapy would be more effective in lowering blood pressure and with fewer side effects compared to initial standard-dose monotherapy according to current guidelines in patients with hypertension. A secondary objective was to assess whether this approach was safer and had fewer side effects compared to standard care.
[0265] Study Design This was a 12-week, double-blind, randomized controlled trial (1:1) of 650 patients with grade 1 and 2 essential hypertension.Subjects were randomized via a centrally computer-based randomization service to receive either an initial therapy consisting of a triple combination therapy or an angiotensin receptor blocker (ARB) according to current Australian hypertension guidelines (with the option to add a calcium channel blocker (CCB) as needed). The primary outcome was a reduction in mean systolic blood pressure measured at 12 weeks using a standardized automated BP cuff. Secondary outcome endpoints included the proportion of subjects with controlled blood pressure at 6 and 12 weeks, ambulatory blood pressure (ABP) measurements, and tolerability / occurrence of adverse events.
[0266] The inclusion criteria for eligibility are as follows: - Adults (≥18 years old) - Treatment-naïve, or currently untreated (not in the past 4 weeks), or taking an antihypertensive medication (angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, calcium channel blocker, beta-blocker, aldosterone antagonist, alpha-blocker) - SBP 140–179 mmHg and / or DBP 90–109 mmHg recorded in two separate instances at intervals of more than one week - At least one measurement should be recorded by the researcher using an automated BP device for study, or recorded as a daily average SBP ≥135 mmHg and / or DBP ≥85 mmHg on 24-hour ambulatory BP monitoring - At least one of these measurements should be recent (within the past 12 weeks) - Daily average SBP ≥135 mmHg and / or DBP ≥85 mmHg on 24-hour ambulatory BP monitoring - Exclusion criteria for records within a randomized 12-week period are as follows: - Contraindications to telmisartan, amlodipine, or indapamide; - Evidence of secondary causes of hypertension, such as renal artery stenosis; significant renal impairment (eGRF <50); elevated serum potassium (above laboratory normal limits); - Pregnant women, breastfeeding women, and / or women of childbearing potential who do not use medically acceptable contraception (pharmacological or barrier methods) throughout the study; - Concomitant diseases, physical injuries, or mental conditions that the research team / primary care physician deems may interfere with study behavior, including outcome assessment; - Participation in concurrent interventional medical research or clinical trials. Patients in observational studies, natural history studies, and / or epidemiological studies that do not involve intervention are eligible.
[0267] - The primary care physician or other responsible physician in charge of the participant believes that the participant should not change their current monotherapy - Unable or unwilling to provide written informed consent - Unable to complete the study procedures, including 24-hour ambulatory blood pressure monitoring - There is a clear indication for combination therapy in the study. For these studies, a triple combination of each component is tested at 50% of the lowest hypertension treatment dose (LHTD) or a triple combination of each component is tested at 100% of the lowest hypertension treatment dose (LHTD).
[0268] If this study tests a triplet combination where each component is 50% of the lowest hypertension treatment dose (LHTD), the test composition is as follows. Patients meeting the inclusion criteria are randomly assigned to receive: 1) a combination pill containing the following three components—telmisartan 10 mg, amlodipine besylate 1.25 mg, and indapamide 0.625 mg; or 2) telmisartan 40 mg.
[0269] If this study tests a triplet combination where each component is 100% of the lowest hypertension treatment dose (LHTD), the test composition is as follows. Patients meeting the inclusion criteria are randomly assigned to receive: 1) a combination pill containing the following three components—telmisartan 20 mg, amlodipine besylate 2.5 mg, and indapamide 1.25 mg; or 2) telmisartan 40 mg.
[0270] Patients currently receiving monotherapy are required to discontinue their treatment while they are receiving study treatment. At 6 weeks, if blood pressure in any group was greater than 140 / 90 mmHg, amlodipine besylate (5 mg) was added by the researchers.
[0271] The primary outcome measure was the difference between groups in mean automated clinic systolic blood pressure at 12 weeks, adjusted for baseline values.
[0272] Secondary outcome measures included the following: - Intergroup differences in mean 24-hour SBP and DBP over 12 weeks of 24-hour ambulatory blood pressure measurements - Intergroup differences in mean changes in 24-hour SBP and DBP over 0 to 12 weeks - Intergroup differences in mean daytime SBP and DBP over 12 weeks - Intergroup differences in mean nighttime SBP and DBP over 12 weeks - Intergroup differences in daytime, nighttime, and 24-hour BP load (percentage of area under the blood pressure curve exceeding normal daytime, nighttime, and 24-hour values according to the NHFA Guide to Management of Hypertension 2008) - Intergroup differences in non-dipper blood pressure (nighttime BP not exceeding 10% lower than mean daytime BP according to the NHFA Guide to Management of Hypertension 2008) and blood pressure coefficient of variation (O'Brien, E., G. Parati and G. Stergiou, Hypertension, 2013. 62(6): p. 988-94).
[0273] - Other blood pressure measurements in the triplet group and control group: mean diastolic blood pressure change from baseline to 12 weeks, percentage of hypertension control at 6 and 12 weeks (SBP <140 mmHg and DBP <90 mmHg), percentage of patients requiring step-up treatment at 6 weeks, and percentage of patients with controlled blood pressure (as defined above) and no adverse events.
[0274] Intergroup differences in SBP and DBP variability - Tolerability Manual 38 / 83 pages 41 CN 122272578 A Intergroup differences in mean potassium, uric acid, blood glucose, cholesterol and fraction, ALT, AST, UACR (urine albumin / creatinine ratio), and creatinine levels.
[0275] Statistical methods for intergroup differences in participant withdrawal from treatment All analyses of study outcome measures were performed according to the intention-to-treat principle. The primary analysis of changes in systolic blood pressure (SBP) at 12 weeks was performed using analysis of covariance (ANCOVA) including the treatment group and baseline SBP as a covariate. Continuous secondary outcome measures were analyzed similarly. Additional analyses included 6-week and 12-week measurements in the longitudinal model, including treatment groups, visits, and treatment-visit interactions, as well as baseline measurements. Intra-patient correlations were modeled using generalized estimating equations. A similar approach was applied to binary endpoints (e.g., hypertension control), where log-binomial regression was used instead of linear regression. Predefined subgroup analyses were also included, defined based on baseline blood pressure, sex, age, and history of hypertension treatment. Detailed analysis plans were developed prior to unblinding.
[0276] Example 4: Pharmaceutical Composition 1 The following pharmaceutical compositions were prepared with the specified components and dosages shown in the table below.
[0277] Table 6.
[0278] Example 5: Pharmaceutical Composition 2 The following pharmaceutical compositions were prepared with the specified components and dosages shown in the table below.
[0279] Table 7. Specification 39 / 83 pages 42 CN 122272578 A
[0280] Example 6: Pharmaceutical Composition 3 The following pharmaceutical compositions were prepared with the specified components and dosages shown in the table below.
[0281] Table 8. Instructions for Use 40 / 83 pages 43 CN 122272578 A
[0282] Example 7: Comparative Study of Low-Dose Combination Therapy with Standard-Dose Monotherapy and Placebo to Assess Effects on Blood Pressure and Cholesterol in Migraine Subjects Objective To investigate whether low-dose combination therapy for lowering blood pressure and cholesterol levels would reduce BP and LDL levels and to determine the safety of the intervention in participating subjects in a double-blind, randomized factorial trial.
[0283] Study Design: A 12-week double-blind, randomized, controlled 3x3 factorial trial in migraine participants: Participants were randomized to the BP group (low-dose telmisartan, amlodipine, indapamide with standard-dose propranolol with placebo) and the cholesterol-lowering group (low-dose rosuvastatin and ezetimibe with simvastatin with placebo). There was a 4-week screening period and another 4-week post-treatment observation period.
[0284] The eligibility criteria for inclusion are as follows: Migraine (with or without typical aura) according to the IHS ICHD-3 diagnostic criteria ICHD 3b. (Instructions for use, page 41 / 83, CN 122272578 A) Migraine symptoms must have been present for at least 1 year prior to inclusion in the study, averaging 2–14 days per month over the past 3 months (90 days) based on the subject's self-report.
[0285] Migraine symptoms must have occurred before age 50. For adults aged 18 to 65, clinic SBP ≥120 mmHg and / or DBP ≥75 mmHg (average of second and third readings) must be present. There must be no clear contraindications to any of the study drugs used at the doses used in this trial. (Subjects may take other preventive and therapeutic medications, provided they do not have a contraindication to the study drug. Eligibility is also based on whether the patient is taking medications in the same class as the study drug.) Medically stable at the investigator's discretion; if taking any concomitant migraine preventive medications, a stable dose will be determined by the investigator; willingness to continue using the current migraine preventive medication during the study period; ability to take oral medications, adhere to the medication regimen, and perform the study procedures during the study period.
[0286] Exclusion criteria are as follows: Contraindications to any of the following: telmisartan, amlodipine, indapamide, rosuvastatin, ezetimibe, simvastatin, or propranolol; concomitant use of angiotensin receptor blockers, angiotensin-converting enzyme inhibitors, calcium channel blockers, diuretics, or statins.
[0287] Subjects with a clear indication for any one or more investigational drugs; subjects with a history of cluster headaches; subjects with migraine aura but no headache; subjects with brainstem aura, hemiplegic migraine, or chronic migraine according to IHS criteria; subjects with drug overuse headaches; pregnant, breastfeeding, or female patients who are not using appropriate contraception (if of childbearing age).
[0288] Chronic medical conditions that may affect the frequency of headaches (e.g., lupus) as determined by the investigator; alcohol or drug abuse in the past year; any concomitant medical or psychiatric conditions that, in the investigator's judgment, may interfere with or preclude participation in the study; abnormal creatinine or electrolyte levels at screening.
[0289] Informed consent could not be provided.
[0290] Subjects who have received botulinum toxin injections or nerve stimulation for migraines in the past three months; subjects currently or in the past three months who have participated in an interventional medical investigation or clinical trial. Subjects in observational, natural history, and / or epidemiological studies that do not involve interventions are eligible.
[0291] Study design: A 12-week double-blind, randomized, controlled 3x3 factorial trial: Participants were randomly assigned to the BP group (low-dose telmisartan, amlodipine, indapamide and standard-dose propranolol and placebo) and the cholesterol-lowering group (low-dose rosuvastatin and ezetimibe and simvastatin and placebo).There was a 4-week screening period and another 4-week post-treatment observation period.
[0292] Table 9. Instructions for Use, pages 42 / 83, CN 122272578 A
[0293] Participants were randomly assigned to the BP group (low-dose telmisartan, amlodipine, indapamide and standard-dose propranolol and placebo) and the cholesterol group (low-dose rosuvastatin and ezetimibe and simvastatin and placebo), where allocation was performed according to a computer-generated randomization schedule. Group 1 received the low-dose antihypertensive combination and the low-dose cholesterol-lowering combination (i.e., telmisartan 20 mg + amlodipine 2.5 mg + indapamide 1.25 mg + rosuvastatin 10 mg + ezetimibe 10 mg (combination N)). Group 2 received the low-dose antihypertensive combination and simvastatin (i.e., telmisartan 20 mg + amlodipine 2.5 mg + simvastatin). Group 3 received a low-dose combination of blood pressure-lowering drugs and placebo (i.e., telmisartan 20 mg + amlodipine 2.5 mg + placebo). Group 4 received a low-dose combination of cholesterol-lowering drugs and propranolol (i.e., rosuvastatin 10 mg + ezetimibe 10 mg + propranolol). Group 5 received propranolol + simvastatin. Group 6 received propranolol + placebo. Group 7 received a low-dose combination of cholesterol-lowering drugs and placebo (i.e., rosuvastatin 10 mg + ezetimibe 10 mg + placebo). Group 8 received placebo + simvastatin. Group 9 received double placebo.
[0294] All participants and research team members were unaware of the randomization except for the principal investigator and the manufacturer of the investigational product. All individual drugs were overpackaged and masked through the same packaging, labeling, and dosing schedule.
[0295] Study treatment: Low-dose antihypertensive combination = telmisartan 20 mg + amlodipine 2.5 mg + indapamide 1.25 mg, once daily; Low-dose cholesterol-lowering combination = rosuvastatin 10 mg + ezetimibe 10 mg, once daily; propranolol dose = 160 mg / day, once daily; simvastatin dose = 20 mg / day, once daily; Outcome endpoints: Blood pressure and cholesterol; Outcome endpoints: Changes in DBP and SBP; Changes in LDL; Secondary outcome endpoints: Tolerability: Intergroup differences in potential related side effects (dizziness, blurred vision, syncope / collapse / fall, ankle edema, rash, pruritus, gout, hyperkalemia, hypokalemia, hyponatremia, myalgia, insomnia, nightmares, rebound hypertension); Intergroup differences in participants dropping out of treatment; Safety: Percentage with any serious adverse events (SAE); Medication adherence: Self-reported measures, pill count; Blood pressure measurement: Instructions for use 43 / 83 pages 46 CN 122272578 A Office blood pressure was measured according to recommendations from the Australian National Heart Foundation. Participants rested in a seated position for 5 minutes, selected an appropriate cuff size, and recorded 3 blood pressure measurements using an Omron HEM907 monitor or an equivalent validated automated digital BP monitor. The principles of automated office blood pressure measurement were applied to ensure the patient was alone during blood pressure recording.
[0296] Laboratory Tests: Potassium (K+), sodium (Na+), serum creatinine, and LDL were measured at screening and at the end of the 12-week treatment follow-up.
[0297] Safety: From informed consent to the end of the follow-up period, all participants reported SAEs and adverse events of special concern (AESIs), which were reported in their case reports. AESI included: dizziness, hypotension, foot edema, headache, muscle cramps, bradycardia, flushing, hypersensitivity reactions (rash, itching), gastrointestinal discomfort, myalgia, syncope / collapse / fall, gout, insomnia, nightmares, rebound hypertension, chest tightness / chest pain, tremor / shaking, irregular heartbeat / tachycardia. Statistical methods and analysis plan: All analyses of study outcome measures were performed according to the intention-to-treat principle. Continuous outcome measures such as SBP and LDL-cholesterol at 12 weeks were analyzed using ANCOVA with treatment group and baseline values as covariates. Additional analyses included provisional measures in the longitudinal model, including treatment group, visits, and treatment-visit interactions, as well as baseline measures. Intra-patient correlations were modeled using generalized estimating equations. A similar approach was applied to binary endpoints, where log-binomial regression was used instead of linear regression. Predefined subgroup analyses, baseline BP, baseline LDL, sex, and age were also included.
[0298] Sample size determination: 60 participants were randomly assigned to each blood pressure lowering group and 60 participants were randomly assigned to each LDL lowering group. Assuming an SD of 13, the study had 80% power to detect a 7 mmHg SBP difference between groups at p=0.05; assuming an SD of 0.7 mmol / L, the study had 80% power to detect a 0.5 mmol / L LDL difference at p=0.05. Due to recruitment challenges, the full sample size was not achieved. (Instructions for Use 44 / 83, page 47, CN 122272578 A, Table 10.) Participant disposal
[0299] *One patient discontinued the study at week 4. This patient was in the BP and cholesterol placebo group. The remaining 29 participants completed the study.
[0300] Results Table 11. Adverse Events Notification 45 / 83 pages 48 CN 122272578 A Notification 46 / 83 pages 49 CN 122272578 A Notification 47 / 83 pages 50 CN 122272578 A Notification 48 / 83 pages 51 CN 122272578 A Notification 49 / 83 pages 52 CN 122272578 A
[0301] Table 12. Blood Pressure Levels at Each Visit Notification 50 / 83 pages 53 CN 122272578 A Notification 51 / 83 pages 54 CN 122272578 A
[0302] Table 13. Blood Pressure Comparison by Visit in the BP Group Notification 52 / 83 pages 55 CN 122272578 A Notification 53 / 83 pages 56 CN 122272578 A
[0303] Table 14. Subject Status Instructions 54 / 83 pages 57 CN 122272578 A
[0304] Table 15. Outcome Indicators Instructions 55 / 83 pages 58 CN 122272578 A
[0305] Table 16. BP Outcome Indicators Instructions 56 / 83 pages 59 CN 122272578 A Instructions 57 / 83 pages 60 CN 122272578 A
[0306] Table 11. Outcome Indicators (All Treatment Groups) Instructions 58 / 83 pages 61 CN 122272578 A
[0307] Table 12. Adverse Events Instructions 59 / 83 pages 62 CN 122272578 A Instructions 60 / 83 pages 63 CN 122272578 A Instructions 61 / 83 pages 64 CN 122272578 A Specification page 62 / 83 65 CN 122272578 A Specification page 63 / 83 66 CN 122272578 A Specification page 64 / 83 67 CN 122272578 A Specification page 65 / 83 68 CN 122272578 A
[0308] Other embodiments The embodiments include the following embodiments 1 to 161.
[0309] Embodiment 1. A pharmaceutical composition comprising: (a) an angiotensin II receptor blocker; (b) a diuretic; and (c) a calcium channel blocker, wherein each of (a), (b), and (c) is in a dose of about 40% to about 80% of the lowest hypertension treatment dose (LHTD) of each of (a), (b), and (c), and wherein the pharmaceutical composition further comprises at least one cholesterol-lowering active agent.
[0310] Embodiment 2. The pharmaceutical composition of Embodiment 1, wherein the pharmaceutical composition comprises a combination of blood pressure-lowering active agents, wherein the blood pressure-lowering active agent comprises an angiotensin II receptor blocker, a diuretic, and a calcium channel blocker.
[0311] Embodiment 3. The pharmaceutical composition of Embodiment 1 or 2, wherein the pharmaceutical composition is substantially free of angiotensin-converting enzyme inhibitors or pharmaceutically acceptable salts thereof.
[0312] Embodiment 4. The pharmaceutical composition of any one of Embodiments 1-3, wherein the pharmaceutical composition is substantially free of β-receptor blockers or pharmaceutically acceptable salts thereof.
[0313] Embodiment 5. A pharmaceutical composition of any one of Embodiments 1-4, wherein the pharmaceutical composition is substantially free of platelet function modifiers, serum homocysteine depressants, or combinations thereof.
[0314] Embodiment 9. A pharmaceutical composition of Embodiment 5, wherein the pharmaceutical composition is substantially free of platelet function modifiers.
[0315] Embodiment 10. A pharmaceutical composition of Embodiment 9, wherein the platelet function modifier is aspirin, ticlopidine, dipyridamole, clopidogrel, abciximab, or ibuprofen.
[0316] Embodiment 11. A pharmaceutical composition of Embodiment 9 or 10, wherein the platelet function modifier is aspirin.
[0317] Embodiment 12. A pharmaceutical composition of Embodiment 5, wherein the pharmaceutical composition is substantially free of serum homocysteine depressants.
[0318] Embodiment 13. The pharmaceutical composition of embodiment 12, wherein the serum homocysteine lowering agent is folic acid, vitamin B6, vitamin B12, or a combination thereof.
[0319] Embodiment 14. The pharmaceutical composition of embodiment 12 or 13, wherein the serum homocysteine lowering agent is folic acid.
[0320] Embodiment 15. The pharmaceutical composition of any one of embodiments 1-14, wherein the diuretic is a thiazide diuretic.
[0321] Embodiment 16. The pharmaceutical composition of embodiment 15, wherein the thiazide diuretic is a thiazide, benzylfluorothiazide, chlorothiazide, cyclopenthiazine, cyclothiazide, epithiazide, hydrochlorothiazide, hydrofluorothiazide, mebendazim, methamphetazim, porbithiazine, trichlorothiazide, or a pharmaceutically acceptable salt or hydrate thereof.
[0322] Embodiment 17. The pharmaceutical composition of Embodiment 16, wherein the thiazide diuretic is hydrochlorothiazide.
[0323] Embodiment 18. The pharmaceutical composition of any one of Embodiments 1-14, wherein the diuretic is a thiazide-like diuretic.
[0324] Embodiment 19. The pharmaceutical composition of Embodiment 18, wherein the thiazide-like diuretic is quinacrine, clopamide, chlorthalidone, mefcitabine, chlorfenapyramide, metoprazine, meteclaron, sipamide, indapamide, chlorothiazide, fenquinazole, or a pharmaceutically acceptable salt or hydrate thereof.
[0325] Embodiment 20. The pharmaceutical composition of Embodiment 19, wherein the thiazide-like diuretic is indapamide or its hydrate.
[0326] Embodiment 21. The pharmaceutical composition of Embodiment 20, wherein the thiazide-like diuretic is indapamide.
[0327] Embodiment 22. The pharmaceutical composition of embodiment 19, wherein the thiazide-like diuretic is chlorthalidone.
[0328] Embodiment 23. The pharmaceutical composition of any one of embodiments 1-14, wherein the diuretic is a loop diuretic.
[0329] Embodiment 24. The pharmaceutical composition of embodiment 23, wherein the loop diuretic is furosemide, bumetanide, ethacrynic acid, etorazoline, mozolomide, oxazolinone, pyrottanide, tenacrylic acid, torasemide, or a pharmaceutically acceptable salt or hydrate thereof.
[0330] Embodiment 25. The pharmaceutical composition of any one of embodiments 1-14, wherein the diuretic is diclofenac, amiloride, pamabromide, mannitol, acetazolamide, metronidazole, spironolactone, triamterene, or a pharmaceutically acceptable salt or hydrate thereof.
[0331] Embodiment 26. The pharmaceutical composition of any one of embodiments 1-25, wherein the calcium channel blocker is amlodipine, nifedipine, diltiazem, nimodipine, verapamil, isradipine, felodipine, nicardipine, nisoldipine, clovidipine, dihydropyridine, lercanidipine, nifedipine, cilnidipine, manidipine, miradipine, benprodil, barnidipine, nivardipine, golopamil, lidocaine, areradipine, dotazine, dipropionyl, or a pharmaceutically acceptable salt or hydrate thereof.
[0332] Embodiment 27. The pharmaceutical composition of embodiment 26, wherein the calcium channel blocker is amlodipine or a pharmaceutically acceptable salt thereof.
[0333] Embodiment 28. The pharmaceutical composition of embodiment 27, wherein the calcium channel blocker is amlodipine besylate.
[0334] Embodiment 29. The pharmaceutical composition of any one of embodiments 1-28, wherein the angiotensin II receptor blocker is irbesartan, telmisartan, valsartan, candesartan, eprosartan, olmesartan, azisartan, losartan (instructions page 67 / 83, 70 CN 122272578 A) or a pharmaceutically acceptable salt or hydrate thereof.
[0335] Embodiment 30. The pharmaceutical composition of Embodiment 29, wherein the angiotensin II receptor blocker is irbesartan.
[0336] Embodiment 31. The pharmaceutical composition of Embodiment 29, wherein the angiotensin II receptor blocker is telmisartan.
[0337] Embodiment 32. The pharmaceutical composition of any one of Embodiments 1-31, wherein each of (a), (b), and (c) is at a dose of about 40% to about 60% of the lowest hypertension treatment dose (LHTD).
[0338] Embodiment 33. The pharmaceutical composition of Embodiment 32, wherein the diuretic is a thiazide diuretic, and the dose of the thiazide diuretic is about 50% of the lowest hypertension treatment dose (LHTD) of the thiazide diuretic.
[0339] Embodiment 34. The pharmaceutical composition of Embodiment 33, wherein the thiazide diuretic is hydrochlorothiazide, and the dose of hydrochlorothiazide is about 6.25 mg.
[0340] Embodiment 35. The pharmaceutical composition of embodiment 32, wherein the diuretic is a thiazide-like diuretic, and the dose of the thiazide-like diuretic is about 50% of the lowest hypertension therapeutic dose (LHTD) of the thiazide-like diuretic.
[0341] Embodiment 36. The pharmaceutical composition of embodiment 35, wherein the thiazide-like diuretic is indapamide, and the dose of indapamide is about 0.625 mg.
[0342] Embodiment 37. The pharmaceutical composition of embodiment 35, wherein the thiazide-like diuretic is chlorothiazide, and the dose of chlorothiazide is about 12.5 mg.
[0343] Embodiment 38. The pharmaceutical composition of embodiment 32, wherein the diuretic is a loop diuretic, and the dose of the loop diuretic is about 50% of the lowest hypertension therapeutic dose (LHTD) of the loop diuretic.
[0344] Embodiment 39. The pharmaceutical composition of any one of embodiments 1-38, wherein the dose of said calcium channel blocker is about 50% of the lowest hypertension therapeutic dose (LHTD) of said calcium channel blocker.
[0345] Embodiment 40. The pharmaceutical composition of embodiment 39, wherein said calcium channel blocker is amlodipine besylate, and the dose of amlodipine besylate is about 1.25 mg.
[0346] Embodiment 41. The pharmaceutical composition of any one of embodiments 1-40, wherein said angiotensin II receptor blocker is about 50% of the lowest hypertension therapeutic dose (LHTD) of said angiotensin II receptor blocker.
[0347] Embodiment 42. The pharmaceutical composition of embodiment 41, wherein said angiotensin II receptor blocker is irbesartan, and the dose of irbesartan is about 37.5 mg.
[0348] Embodiment 43. The pharmaceutical composition of Embodiment 41, wherein the angiotensin II receptor blocker is telmisartan, and the dose of telmisartan is about 10 mg.
[0349] Embodiment 44. The pharmaceutical composition of Embodiment 32, wherein the angiotensin II receptor blocker is irbesartan, the diuretic is hydrochlorothiazide, and the calcium channel blocker is amlodipine besylate.
[0350] Embodiment 45. The pharmaceutical composition of Embodiment 44, wherein the dose of irbesartan is about 30 mg to about 45 mg, the dose of hydrochlorothiazide is about 5 mg to about 7.5 mg, and the dose of amlodipine besylate is about 1 mg to about 1.5 mg.
[0351] Embodiment 46. The pharmaceutical composition of embodiment 45, wherein the dose of irbesartan is about 37.5 mg, the dose of hydrochlorothiazide is about 6.25 mg, and the dose of amlodipine besylate is about 1.25 mg.
[0352] Embodiment 47. The pharmaceutical composition of embodiment 32, wherein the angiotensin II receptor blocker is telmisartan, the diuretic is hydrochlorothiazide, and the calcium channel blocker is amlodipine besylate.
[0353] Embodiment 48. The pharmaceutical composition of embodiment 47, wherein the dose of telmisartan is about 8 mg to about 12 mg, the dose of hydrochlorothiazide is about 5 mg to about 7.5 mg, and the dose of amlodipine besylate is about 1 mg to about 1.5 mg.
[0354] Embodiment 49. The pharmaceutical composition of embodiment 48, wherein the dose of telmisartan is about 10 mg, the dose of hydrochlorothiazide is about 6.25 mg, and the dose of amlodipine besylate is about 1.25 mg.
[0355] Embodiment 50. The pharmaceutical composition of embodiment 32, wherein the angiotensin II receptor blocker is irbesartan, the diuretic is indapamide, and the calcium channel blocker is amlodipine besylate.
[0356] Embodiment 51. The pharmaceutical composition of embodiment 50, wherein the dose of irbesartan is about 30 mg to about 45 mg, the dose of indapamide is about 0.5 mg to about 0.75 mg, and the dose of amlodipine besylate is about 1 mg to about 1.5 mg.
[0357] Embodiment 52. The pharmaceutical composition of embodiment 51, wherein the dose of irbesartan is about 37.5 mg, the dose of indapamide is about 0.625 mg, and the dose of amlodipine is about 1.25 mg.
[0358] Embodiment 53. The pharmaceutical composition of embodiment 32, wherein the angiotensin II receptor blocker is telmisartan, the diuretic is indapamide, and the calcium channel blocker is amlodipine besylate.
[0359] Embodiment 54. The pharmaceutical composition of Embodiment 53, wherein the dose of telmisartan is about 8 mg to about 12 mg, the dose of indapamide is about 0.5 mg to about 0.75 mg, and the dose of amlodipine besylate is about 1 mg to about 1.5 mg.
[0360] Embodiment 55. The pharmaceutical composition of Embodiment 54, wherein the dose of telmisartan is about 10 mg, the dose of indapamide is about 0.625 mg, and the dose of amlodipine besylate is about 1.25 mg.
[0361] Embodiment 56. The pharmaceutical composition of Embodiment 32, wherein the angiotensin II receptor blocker is telmisartan, the diuretic is chlorthalidone, and the calcium channel blocker is amlodipine besylate.
[0362] Embodiment 57. The pharmaceutical composition of embodiment 56, wherein the dose of telmisartan is about 8 mg to about 12 mg, the dose of chlorthalidone is about 10 mg to about 15 mg, and the dose of amlodipine besylate is about 1 mg to about 1.5 mg.
[0363] Embodiment 58. The pharmaceutical composition of embodiment 57, wherein the dose of telmisartan is about 10 mg, the dose of chlorthalidone is about 12.5 mg, and the dose of amlodipine besylate is about 1.25 mg.
[0364] Embodiment 59. The pharmaceutical composition of embodiment 32, wherein the angiotensin II receptor blocker is irbesartan, the diuretic is chlorthalidone, and the calcium channel blocker is amlodipine besylate.
[0365] Embodiment 60. The pharmaceutical composition of embodiment 59, wherein the dose of irbesartan is about 30 mg to about 45 mg, the dose of chlorthalidone is about 10 mg to about 15 mg, and the dose of amlodipine besylate is about 1 mg to about 1.5 mg.
[0366] Embodiment 61. The pharmaceutical composition of embodiment 60, wherein the dose of irbesartan is about 37.5 mg, the dose of chlorthalidone is about 12.5 mg, and the dose of amlodipine besylate is about 1.25 mg.
[0367] Embodiment 62. The pharmaceutical composition of any one of embodiments 1-31, wherein the doses of (a), (b), and (c) are each about 60% to about 80% of the lowest hypertension treatment dose (LHTD).
[0368] Embodiment 63. The pharmaceutical composition of embodiment 62, wherein the diuretic is a thiazide diuretic, and the dose of the thiazide diuretic is about 66% of the lowest hypertension treatment dose (LHTD) of the thiazide diuretic.
[0369] Embodiment 64. The pharmaceutical composition of Embodiment 63, wherein the thiazide diuretic is hydrochlorothiazide, and the dose of hydrochlorothiazide is about 8.25 mg.
[0370] Embodiment 65. The pharmaceutical composition of Embodiment 62, wherein the diuretic is a thiazide-like diuretic, and the dose of the thiazide-like diuretic is about 66% (LHTD) of the lowest hypertension treatment dose of the thiazide-like diuretic.
[0371] Embodiment 66. The pharmaceutical composition of Embodiment 65, wherein the thiazide-like diuretic is indapamide, and the dose of indapamide is about 0.825 mg.
[0372] Embodiment 67. The pharmaceutical composition of Embodiment 65, wherein the thiazide-like diuretic is chlorothiazide, and the dose of chlorothiazide is about 16.5 mg.
[0373] Embodiment 68. The pharmaceutical composition of Embodiment 62, wherein the diuretic is a loop diuretic, and the dose of the loop diuretic is about 66% of the lowest hypertension treatment dose (LHTD) of the loop diuretic.
[0374] Embodiment 69. A pharmaceutical composition of any one of Embodiments 62-68, wherein the dose of the calcium channel blocker is about 66% of the lowest therapeutic dose (LHTD) of the calcium channel blocker.
[0375] Embodiment 70. A pharmaceutical composition of Embodiment 69, wherein the calcium channel blocker is amlodipine besylate, and the dose of amlodipine besylate is about 1.65 mg.
[0376] Embodiment 71. A pharmaceutical composition of any one of Embodiments 62-70, wherein the dose of the angiotensin II receptor blocker is about 66% of the lowest therapeutic dose (LHTD) of the angiotensin II receptor blocker.
[0377] Embodiment 72. A pharmaceutical composition of Embodiment 71, wherein the angiotensin II receptor blocker is irbesartan, and the dose of irbesartan is about 49.5 mg.
[0378] Embodiment 73. The pharmaceutical composition of Embodiment 71, wherein the angiotensin II receptor blocker is telmisartan, and the dose of telmisartan is about 13.2 mg.
[0379] Embodiment 74. The pharmaceutical composition of Embodiment 62, wherein the angiotensin II receptor blocker is irbesartan, the diuretic is hydrochlorothiazide, and the calcium channel blocker is amlodipine besylate.
[0380] Embodiment 75. The pharmaceutical composition of Embodiment 74, wherein the dose of irbesartan is about 45 mg to about 60 mg, the dose of hydrochlorothiazide is about 7.5 mg to about 10 mg, and the dose of amlodipine besylate is about 1.5 mg to about 2 mg.
[0381] Embodiment 76. The pharmaceutical composition of Embodiment 75, wherein the dose of irbesartan is about 49.5 mg, the dose of hydrochlorothiazide is about 8.25 mg, and the dose of amlodipine besylate is about 1.65 mg.
[0382] Embodiment 77. The pharmaceutical composition of Embodiment 62, wherein the angiotensin II receptor blocker is telmisartan, the diuretic is hydrochlorothiazide, and the calcium channel blocker is amlodipine besylate.
[0383] Embodiment 78. The pharmaceutical composition of Embodiment 77, wherein the dose of telmisartan is about 12 mg to about 16 mg, the dose of hydrochlorothiazide is about 7.5 mg to about 10 mg, and the dose of amlodipine besylate is about 1.5 mg to about 2 mg.
[0384] Embodiment 79. The pharmaceutical composition of Embodiment 78, wherein the dose of telmisartan is about 13.2 mg, the dose of hydrochlorothiazide is about 8.25 mg, and the dose of amlodipine besylate is about 1.65 mg.
[0385] Embodiment 80. The pharmaceutical composition of embodiment 62, wherein the angiotensin II receptor blocker is irbesartan, the diuretic is indapamide, and the calcium channel blocker is amlodipine besylate.
[0386] Embodiment 81. The pharmaceutical composition of embodiment 80, wherein the dose of irbesartan is about 45 mg to about 60 mg, the dose of indapamide is about 0.75 mg to about 1.0 mg, and the dose of amlodipine besylate is about 1.5 mg to about 2 mg.
[0387] Embodiment 82. The pharmaceutical composition of embodiment 81, wherein the dose of irbesartan is about 49.5 mg, the dose of indapamide is about 0.825 mg, and the dose of amlodipine is about 1.65 mg.
[0388] Embodiment 83. The pharmaceutical composition of Embodiment 62, wherein the angiotensin II receptor blocker is telmisartan, the diuretic is indapamide, and the calcium channel blocker is amlodipine besylate.
[0389] Embodiment 84. The pharmaceutical composition of Embodiment 83, wherein the dose of telmisartan is about 12 mg to about 16 mg, the dose of indapamide is about 0.75 mg to about 1.0 mg, and the dose of amlodipine besylate is about 1.5 mg to about 2 mg.
[0390] Embodiment 85. The pharmaceutical composition of Embodiment 84, wherein the dose of telmisartan is about 13.2 mg, the dose of indapamide is about 0.825 mg, and the dose of amlodipine besylate is about 1.65 mg.
[0391] Embodiment 86. The pharmaceutical composition of embodiment 62, wherein the angiotensin II receptor blocker is telmisartan, the diuretic is chlorthalidone, and the calcium channel blocker is amlodipine besylate.
[0392] Embodiment 87. The pharmaceutical composition of Embodiment 86, wherein the dose of telmisartan is about 12 mg to about 16 mg, the dose of chlorthalidone is about 15 mg to about 20 mg, and the dose of amlodipine besylate is about 1.5 mg to about 2 mg.
[0393] Embodiment 88. The pharmaceutical composition of Embodiment 87, wherein the dose of telmisartan is about 13.2 mg, the dose of chlorthalidone is about 16.5 mg, and the dose of amlodipine besylate is about 1.65 mg.
[0394] Embodiment 89. The pharmaceutical composition of Embodiment 62, wherein the angiotensin II receptor blocker is irbesartan, the diuretic is chlorthalidone, and the calcium channel blocker is amlodipine besylate.
[0395] Embodiment 90. The pharmaceutical composition of embodiment 89, wherein the dose of irbesartan is about 45 mg to about 60 mg, the dose of chlorthalidone is about 15 mg to about 20 mg, and the dose of amlodipine besylate is about 1.5 mg to about 2 mg.
[0396] Embodiment 91. The pharmaceutical composition of embodiment 90, wherein the dose of irbesartan is about 49.5 mg, the dose of chlorthalidone is about 16.5 mg, and the dose of amlodipine besylate is about 1.65 mg.
[0397] Embodiment 92. The pharmaceutical composition of any one of embodiments 1-91, wherein the dose of any one of the angiotensin II receptor blocker, diuretic, and calcium channel blocker is replaced by about 80% to about 250% of the lowest hypertension treatment dose (LHTD) of the angiotensin II receptor blocker, diuretic, or calcium channel blocker.
[0398] Embodiment 93. The pharmaceutical composition of embodiment 92, wherein the dose of the angiotensin II receptor blocker is replaced by about 80% to about 250% of the lowest hypertension therapeutic dose (LHTD) of the angiotensin II receptor blocker.
[0399] Embodiment 94. The pharmaceutical composition of embodiment 92, wherein the dose of the diuretic is replaced by about 80% to about 250% of the lowest hypertension therapeutic dose (LHTD) of the diuretic.
[0400] Embodiment 95. The pharmaceutical composition of embodiment 92, wherein the dose of the calcium channel blocker is replaced by about 80% to about 250% of the lowest hypertension therapeutic dose (LHTD) of the calcium channel blocker.
[0401] Embodiment 96. The pharmaceutical composition of any one of the angiotensin II receptor blocker, diuretic and calcium channel blocker is replaced with about 80% to about 150% of the lowest hypertension treatment dose (LHTD) of the angiotensin II receptor blocker, diuretic or calcium channel blocker.
[0402] Embodiment 97. The pharmaceutical composition of Embodiment 96, wherein the dose of the angiotensin II receptor blocker is replaced by about 80% to about 150% of the lowest hypertension treatment dose (LHTD) of the angiotensin II receptor blocker.
[0403] Embodiment 98. The pharmaceutical composition of Embodiment 97, wherein the dose of the angiotensin II receptor blocker is replaced by about 100% of the lowest hypertension treatment dose (LHTD) of the angiotensin II receptor blocker.
[0404] Embodiment 99. The pharmaceutical composition of Embodiment 98, wherein the dose of the diuretic is replaced by about 80% to about 150% of the lowest hypertension treatment dose (LHTD) of the diuretic.
[0405] Embodiment 100. The pharmaceutical composition of Embodiment 99, wherein the dose of the diuretic is replaced by about 100% of the lowest hypertension treatment dose (LHTD) of the diuretic.
[0406] Embodiment 101. The pharmaceutical composition of embodiment 96, wherein the dose of the calcium channel blocker is replaced by about 80% to about 150% of the lowest hypertension therapeutic dose (LHTD) of the calcium channel blocker described on page 74 of CN 122272578 A, specification 71 / 83.
[0407] Embodiment 102. The pharmaceutical composition of embodiment 101, wherein the dose of the calcium channel blocker is replaced by about 100% of the lowest hypertension therapeutic dose (LHTD) of the calcium channel blocker.
[0408] Embodiment 103. The pharmaceutical composition of any one of embodiments 92-95, wherein the dose of any one of the angiotensin II receptor blocker, diuretic, and calcium channel blocker is replaced by about 150% to about 250% of the lowest hypertension therapeutic dose (LHTD) of the angiotensin II receptor blocker, diuretic, or calcium channel blocker.
[0409] Embodiment 104. The pharmaceutical composition of embodiment 103, wherein the dose of the angiotensin II receptor blocker is replaced by about 150% to about 250% of the lowest hypertension treatment dose (LHTD) of the angiotensin II receptor blocker.
[0410] Embodiment 105. The pharmaceutical composition of embodiment 104, wherein the dose of the angiotensin II receptor blocker is replaced by about 200% of the lowest hypertension treatment dose (LHTD) of the angiotensin II receptor blocker.
[0411] Embodiment 106. The pharmaceutical composition of embodiment 103, wherein the dose of the diuretic is replaced by about 150% to about 250% of the lowest hypertension treatment dose (LHTD) of the diuretic.
[0412] Embodiment 107. The pharmaceutical composition of embodiment 106, wherein the dose of the diuretic is replaced by about 200% of the lowest hypertension treatment dose (LHTD) of the diuretic.
[0413] Embodiment 108. The pharmaceutical composition of Embodiment 103, wherein the dose of the calcium channel blocker is replaced by about 150% to about 250% of the lowest hypertension therapeutic dose (LHTD) of the calcium channel blocker.
[0414] Embodiment 109. The pharmaceutical composition of any of Embodiment 108, wherein the dose of the calcium channel blocker is replaced by about 200% of the lowest hypertension therapeutic dose (LHTD) of the calcium channel blocker.
[0415] Embodiment 110. The pharmaceutical composition of any of Embodiments 1-91, wherein the dose of any two of the angiotensin II receptor blocker, diuretic, and calcium channel blocker is replaced by about 80% to about 250% of the lowest hypertension therapeutic dose (LHTD) of the angiotensin II receptor blocker, diuretic, or calcium channel blocker.
[0416] Embodiment 111. The pharmaceutical composition of embodiment 110, wherein the dose of the angiotensin II receptor blocker is replaced by about 80% to about 250% of the lowest hypertension therapeutic dose (LHTD) of the angiotensin II receptor blocker.
[0417] Embodiment 112. The pharmaceutical composition of embodiment 110, wherein the dose of the diuretic is replaced by about 80% to about 250% of the lowest hypertension therapeutic dose (LHTD) of the diuretic.
[0418] Embodiment 113. The pharmaceutical composition of embodiment 110, wherein the dose of the calcium channel blocker is replaced by about 80% to about 250% of the lowest hypertension therapeutic dose (LHTD) of the calcium channel blocker.
[0419] Embodiment 114. The pharmaceutical composition of any one of embodiments 110-113, wherein the dose of any two of the angiotensin II receptor blocker, diuretic, and calcium channel blocker is replaced by about 80% to about 150% of the lowest therapeutic dose (LHTD) of the angiotensin II receptor blocker, diuretic, or calcium channel blocker.
[0420] Embodiment 115. The pharmaceutical composition of embodiment 114, wherein the dose of the angiotensin II receptor blocker is replaced by about 80% to about 150% of the lowest therapeutic dose (LHTD) of the angiotensin II receptor blocker.
[0421] Embodiment 116. The pharmaceutical composition of embodiment 115, wherein the dose of the angiotensin II receptor blocker is replaced by about 100% of the lowest therapeutic dose (LHTD) of the angiotensin II receptor blocker.
[0422] Embodiment 117. The pharmaceutical composition of embodiment 114, wherein the dose of the diuretic is replaced with about 80% to about 150% of the lowest hypertension treatment dose (LHTD) of the diuretic.Instructions for Use, Pages 72 / 83, 75, CN 122272578 A
[0423] Embodiment 118. The pharmaceutical composition of Embodiment 117, wherein the dose of the diuretic is replaced with about 100% of the lowest hypertension therapeutic dose (LHTD) of the diuretic.
[0424] Embodiment 119. The pharmaceutical composition of Embodiment 114, wherein the dose of the calcium channel blocker is replaced with about 80% to about 150% of the lowest hypertension therapeutic dose (LHTD) of the calcium channel blocker.
[0425] Embodiment 120. The pharmaceutical composition of Embodiment 119, wherein the dose of the calcium channel blocker is replaced with about 100% of the lowest hypertension therapeutic dose (LHTD) of the calcium channel blocker.
[0426] Embodiment 121. The pharmaceutical composition of any one of embodiments 110-113, wherein the dose of any two of the angiotensin II receptor blocker, diuretic, and calcium channel blocker is replaced by about 150% to about 250% of the lowest hypertension treatment dose (LHTD) of the angiotensin II receptor blocker, diuretic, or calcium channel blocker.
[0427] Embodiment 122. The pharmaceutical composition of embodiment 121, wherein the dose of the angiotensin II receptor blocker is replaced by about 150% to about 250% of the lowest hypertension treatment dose (LHTD) of the angiotensin II receptor blocker.
[0428] Embodiment 123. The pharmaceutical composition of embodiment 122, wherein the dose of the angiotensin II receptor blocker is replaced by about 200% of the lowest hypertension treatment dose (LHTD) of the angiotensin II receptor blocker.
[0429] Embodiment 124. The pharmaceutical composition of embodiment 121, wherein the dose of the diuretic is replaced by about 150% to about 250% of the lowest hypertension therapeutic dose (LHTD) of the diuretic.
[0430] Embodiment 125. The pharmaceutical composition of embodiment 124, wherein the dose of the diuretic is replaced by about 200% of the lowest hypertension therapeutic dose (LHTD) of the diuretic.
[0431] Embodiment 126. The pharmaceutical composition of embodiment 121, wherein the dose of the calcium channel blocker is replaced by about 150% to about 250% of the lowest hypertension therapeutic dose (LHTD) of the calcium channel blocker.
[0432] Embodiment 127. Any pharmaceutical composition of embodiment 126, wherein the dose of the calcium channel blocker is replaced by about 200% of the lowest hypertension therapeutic dose (LHTD) of the calcium channel blocker.
[0433] Embodiment 128: A pharmaceutical composition comprising: (a) telmisartan; (b) a thiazide-like diuretic; and (c) a calcium channel blocker, wherein each of (a), (b), and (c) is at about 80% to about 150% of the lowest therapeutic dose for hypertension (LHTD), and wherein said pharmaceutical composition further comprises at least one cholesterol-lowering active agent.
[0434] Embodiment 129: The pharmaceutical composition of Embodiment 128, wherein said pharmaceutical composition is substantially free of angiotensin-converting enzyme inhibitors or pharmaceutically acceptable salts thereof, beta-blockers or pharmaceutically acceptable salts thereof, platelet function modifiers, serum homocysteine lowering agents, or combinations thereof.
[0435] Embodiment 130: The pharmaceutical composition of Embodiment 128 or 129, wherein the thiazide-like diuretic is quetiapine, clopamine, chlorthalidone, mefcitabine, chlorfenapyramide, metoprazine, meteclaron, sipamide, indapamide, chlorothiazide, fenquinazole, or a pharmaceutically acceptable salt or hydrate thereof.
[0436] Embodiment 131: The pharmaceutical composition of Embodiment 130, wherein the thiazide-like diuretic is indapamide or its hydrate.
[0437] Embodiment 132: The pharmaceutical composition of Embodiment 131, wherein the thiazide-like diuretic is indapamide.
[0438] Embodiment 133: A pharmaceutical composition of any one of Embodiments 128-132, wherein the calcium channel blocker is amlodipine, nifedipine, diltiazem, nimodipine, verapamil, isradipine, felodipine, nicardipine, sodipine, clovidipine, dihydropyridine, lercanidipine, nifedipine, cinidipine, manidipine, miradipine, benprodil, barnidipine, nivardipine, golopamil, lidocaine, areradipine, dotazine, dipropionylene, or a pharmaceutically acceptable salt or hydrate thereof.
[0439] Embodiment 134: A pharmaceutical composition of Embodiment 133, wherein the calcium channel blocker is amlodipine or a pharmaceutically acceptable salt thereof.
[0440] Embodiment 135: The pharmaceutical composition of Embodiment 134, wherein the calcium channel blocker is amlodipine besylate.
[0441] Embodiment 136: The pharmaceutical composition of any one of Embodiments 128-135, wherein each of (a), (b), and (c) is at about 80% to about 120% of the lowest hypertension treatment dose (LHTD).
[0442] Embodiment 137: The pharmaceutical composition of any one of Embodiments 128-136, wherein the dose of the thiazide-like diuretic is about 100% of the lowest hypertension treatment dose (LHTD) of the thiazide-like diuretic.
[0443] Embodiment 138: The pharmaceutical composition of Embodiment 137, wherein the thiazide-like diuretic is indapamide, and the dose of indapamide is about 1.25 mg.
[0444] Embodiment 139: The pharmaceutical composition of any one of Embodiments 128-138, wherein the dose of the calcium channel blocker is about 100% of the lowest hypertension therapeutic dose (LHTD) of the calcium channel blocker.
[0445] Embodiment 140: The pharmaceutical composition of Embodiment 139, wherein the calcium channel blocker is amlodipine besylate, and the dose of amlodipine besylate is about 2.5 mg.
[0446] Embodiment 141: The pharmaceutical composition of any one of Embodiments 128-139, wherein the dose of the angiotensin II receptor blocker is about 100% of the lowest hypertension therapeutic dose (LHTD) of the angiotensin II receptor blocker.
[0447] Embodiment 142: A pharmaceutical composition of any one of Embodiments 128-140, wherein the angiotensin II receptor blocker is telmisartan, and the dose of telmisartan is about 100% of the lowest hypertension treatment dose (LHTD) of telmisartan.
[0448] Embodiment 143: A pharmaceutical composition of Embodiment 142, wherein the dose of telmisartan is about 20 mg.
[0449] Embodiment 144: A pharmaceutical composition of Embodiment 136, wherein the thiazide-like diuretic is indapamide, the calcium channel blocker is amlodipine besylate, and the angiotensin II receptor blocker is telmisartan.
[0450] Embodiment 145: A pharmaceutical composition of Embodiment 144, wherein the dose of telmisartan is about 16 mg to about 24 mg, the dose of indapamide is about 1 mg to about 1.5 mg, and the dose of amlodipine besylate is about 2 mg to about 3 mg.
[0451] Embodiment 146: The pharmaceutical composition of Embodiment 145, wherein the dose of telmisartan is about 20 mg, the dose of indapamide is about 1.25 mg, and the dose of amlodipine besylate is about 2.5 mg.
[0452] Embodiment 147: The pharmaceutical composition of any one of Embodiments 1-146, wherein (a), (b), and (c) are provided in one formulation.
[0453] Embodiment 148: The pharmaceutical composition of any one of Embodiments 1-146, wherein (a), (b), and (c) are each provided in a separate formulation.
[0454] Embodiment 149: The pharmaceutical composition of any one of Embodiments 1-146, wherein two of (a), (b), and (c) are provided in one formulation.
[0455] Embodiment 150: The pharmaceutical composition of any one of Embodiments 1-149, wherein the pharmaceutical composition is in the form of a pill, tablet, or capsule.
[0456] Embodiment 151. A pharmaceutical composition of any one of Embodiments 1-150, wherein the pharmaceutical composition is suitable for oral administration as per the instructions for use on page 74 / 83 of the specification, CN 122272578 A.
[0457] Embodiment 152: A method of treating hypertension in a subject of need, comprising administering to the subject a pharmaceutical composition of any one of Embodiments 1-151.
[0458] Embodiment 153. The method of Embodiment 152, wherein the treatment results in a systolic blood pressure (SBP) below about 140 mmHg.
[0459] Embodiment 154. The method of Embodiment 151 or 152, wherein the treatment results in a reduction in systolic blood pressure (SBP) of about 10 mmHg or more.
[0460] Embodiment 155. The method of any one of Embodiments 151-154, wherein the treatment results in a diastolic blood pressure (DBP) below about 90 mmHg.
[0461] Embodiment 156. The method of any one of embodiments 151-155, wherein the treatment results in a reduction of diastolic blood pressure (DBP) of about 5 mmHg or more.
[0462] Embodiment 157. The method of any one of embodiments 151-156, wherein the treatment results in a reduction of systolic blood pressure (SBP) greater than that obtained using the lowest complete hypertension treatment dose of any one of the pharmaceutical compositions (a), (b), and (c).
[0463] Embodiment 158. The method of any one of embodiments 151-157, wherein the treatment results in a reduction of diastolic blood pressure (DBP) greater than that obtained using the lowest complete hypertension treatment dose of any one of the pharmaceutical compositions (a), (b), and (c).
[0464] Embodiment 159. The method of any one of embodiments 151-158, wherein the treatment results in higher long-term tolerability and a reduced risk of side effects or adverse reactions compared to treatment using the lowest complete hypertension treatment dose of any one of the pharmaceutical compositions (a), (b), and (c).
[0465] Embodiment 160. The method of any one of Embodiments 151-159, wherein the treatment is initial or first-line treatment for hypertension.
[0466] Embodiment 161. The method of any one of Embodiments 151-160, wherein the subject has not received any prior hypertension therapy prior to treatment.
[0467] In some or any one of the above embodiments, the at least one cholesterol-lowering active agent is selected from NPC1L1 inhibitors, statins, or combinations thereof.
[0468] In some or any one of the above embodiments, the at least one cholesterol-lowering active agent is selected from NPC1L1 inhibitors, statins, or combinations thereof.
[0469] In some or any of the above embodiments, the at least one cholesterol-lowering active agent is a combination of an NPC1L1 inhibitor and a statin.
[0470] In some or any of the above embodiments, the at least one cholesterol-lowering active agent is selected from ezetimibe, rosuvastatin, or a combination thereof.
[0471] In some or any of the above embodiments, the at least one cholesterol-lowering active agent is a combination of ezetimibe and rosuvastatin.
[0472] In some or any of the above embodiments, the dose of ezetimibe is about 10 mg, and the dose of rosuvastatin is about 10 mg.
[0473] In some or any of the above embodiments, (a), (b), and (c) are provided in a single formulation.
[0474] In some or any of the above embodiments, (a), (b), (c), and the at least one cholesterol-lowering active agent are provided in a single formulation.
[0475] In some or any of the above embodiments, (a), (b), (c) and the at least one cholesterol-lowering active agent are provided in separate formulations.
[0476] Embodiments include the following embodiments P1 to P99.
[0477] Embodiment P1. A pharmaceutical composition comprising: (a) an angiotensin II receptor blocker; (b) a diuretic; and (c) a calcium channel blocker, wherein each of (a), (b), and (c) is in a dose of about 40% to about 80% of the lowest therapeutic dose of hypertension (LHTD), and wherein the pharmaceutical composition further comprises at least one cholesterol-lowering active agent.
[0478] Embodiment P2. The pharmaceutical composition of Embodiment P1, wherein the pharmaceutical composition is substantially free of angiotensin-converting enzyme inhibitors or pharmaceutically acceptable salts thereof, β-blockers or pharmaceutically acceptable salts thereof, platelet function modifiers, serum homocysteine lowering agents, or combinations thereof.
[0479] Embodiment P3. The pharmaceutical composition of embodiment P1 or P2, wherein the diuretic is a thiazide-like diuretic.
[0480] Embodiment P4. The pharmaceutical composition of embodiment P3, wherein the thiazide-like diuretic is quetiapine, clopamid, chlorthalidone, mefcitabine, chlorfenapyramide, metoprazine, meteclaron, sipamid, indapamid, chlorothiazide, fenquinazole, or a pharmaceutically acceptable salt or hydrate thereof.
[0481] Embodiment P5. The pharmaceutical composition of embodiment P4, wherein the thiazide-like diuretic is indapamid or its hydrate.
[0482] Embodiment P6. The pharmaceutical composition of embodiment P5, wherein the thiazide-like diuretic is indapamid.
[0483] Embodiment P7. A pharmaceutical composition of any one of Embodiments P1-P6, wherein the calcium channel blocker is amlodipine, nifedipine, diltiazem, nimodipine, verapamil, isradipine, felodipine, nicardipine, nisoldipine, clovidipine, dihydropyridine, lercanidipine, nifedipine, cilnidipine, manidipine, miradipine, benprodil, barnidipine, nivardipine, golopamil, lidocaine, areradipine, dotazine, dipropionylene, or a pharmaceutically acceptable salt or hydrate thereof.
[0484] Embodiment P8. A pharmaceutical composition of any one of Embodiments P1-P7, wherein the calcium channel blocker is amlodipine or a pharmaceutically acceptable salt thereof.
[0485] Embodiment P9. A pharmaceutical composition of any one of Embodiments P1-P8, wherein the calcium channel blocker is amlodipine besylate.
[0486] Embodiment P10. A pharmaceutical composition of any one of Embodiments P1-P9, wherein the angiotensin II receptor blocker is irbesartan, telmisartan, valsartan, candesartan, eprosartan, olmesartan, azilsartan, losartan, or a pharmaceutically acceptable salt or hydrate thereof.
[0487] Embodiment P11. A pharmaceutical composition of any one of Embodiments P1-P10, wherein the angiotensin II receptor blocker is telmisartan.
[0488] Embodiment P12. A pharmaceutical composition of any one of Embodiments P1-P11, wherein each of (a), (b), and (c) is at about 40% to about 60% of the lowest therapeutic dose of hypertension (LHTD).
[0489] Embodiment P13. A pharmaceutical composition of any one of embodiments P1-P12, wherein the diuretic is a thiazide-like diuretic, and the dose of the thiazide-like diuretic is about 50% of the lowest hypertension therapeutic dose (LHTD) of the thiazide-like diuretic.
[0490] Embodiment P14. A pharmaceutical composition of any one of embodiments P1-P13, wherein the thiazide-like diuretic is indapamide, and the dose of indapamide is about 0.625 mg.
[0491] Embodiment P15. A pharmaceutical composition of any one of embodiments P1-P14, wherein the dose of the calcium channel blocker is about 50% of the lowest hypertension therapeutic dose (LHTD) of the calcium channel blocker.
[0492] Embodiment P16. The pharmaceutical composition of any one of embodiments P1-P15, wherein the calcium channel blocker is amlodipine besylate and the dose of amlodipine besylate is about 1.25 mg.
[0493] Embodiment P17. A pharmaceutical composition of any one of Embodiments P1-P16, wherein the dose of the angiotensin II receptor blocker is about 50% of the lowest hypertension therapeutic dose (LHTD) of the angiotensin II receptor blocker.
[0494] Embodiment P18. A pharmaceutical composition of any one of Embodiments P1-P17, wherein the angiotensin II receptor blocker is telmisartan, and the dose of telmisartan is about 10 mg.
[0495] Embodiment P19. A pharmaceutical composition of any one of Embodiments P1-P18, wherein the angiotensin II receptor blocker is telmisartan, the diuretic is indapamide, and the calcium channel blocker is amlodipine besylate.
[0496] Embodiment P20. The pharmaceutical composition of embodiment P19, wherein the dose of telmisartan is about 8 mg to about 12 mg, the dose of indapamide is about 0.5 mg to about 0.75 mg, and the dose of amlodipine besylate is about 1 mg to about 1.5 mg.
[0497] Embodiment P21. The pharmaceutical composition of embodiment P19, wherein the dose of telmisartan is about 10 mg, the dose of indapamide is about 0.625 mg, and the dose of amlodipine besylate is about 1.25 mg.
[0498] Embodiment P22. A pharmaceutical composition comprising: (a) telmisartan; (b) a thiazide-like diuretic; and (c) a calcium channel blocker, wherein each of (a), (b), and (c) is at a dose of about 80% to about 150% of the lowest hypertension treatment dose (LHTD), and wherein the pharmaceutical composition further comprises at least one cholesterol-lowering active agent.
[0499] Embodiment P23. The pharmaceutical composition of embodiment P22, wherein the pharmaceutical composition is substantially free of angiotensin-converting enzyme inhibitors or pharmaceutically acceptable salts thereof, beta-blockers or pharmaceutically acceptable salts thereof, platelet function modifiers, serum homocysteine depressants, or combinations thereof.
[0500] Embodiment P24. The pharmaceutical composition of embodiment P22 or P23, wherein the diuretic is a thiazide-like diuretic.
[0501] Embodiment P25. The pharmaceutical composition of embodiment P24, wherein the thiazide-like diuretic is quinacrine, clopamide, chlorthalidone, mefcitabine, chlorfenapyramide, metoprazine, meteclaron, sipamide, indapamide, chlorothiazide, fenquinazole, or a pharmaceutically acceptable salt or hydrate thereof.
[0502] Embodiment P26. The pharmaceutical composition of embodiment P25, wherein the thiazide-like diuretic is indapamide or its hydrate.
[0503] Embodiment P27. The pharmaceutical composition of embodiment P26, wherein the thiazide-like diuretic is indapamide.
[0504] Embodiment P28. A pharmaceutical composition of any one of Embodiments P22-P27, wherein the calcium channel blocker is amlodipine, nifedipine, diltiazem, nimodipine, verapamil, isradipine, felodipine, nicardipine, nisoldipine, clovidipine, dihydropyridine, lorcanidipine, nicardipine, cilnidipine, manidipine, miradipine, benprodil, barnidipine, nivardipine, golopamil, lidocaine, areradipine, dotazine, dipropionylene, or a pharmaceutically acceptable salt or hydrate thereof.
[0505] Embodiment P29. A pharmaceutical composition of any one of Embodiments P22-P28, wherein the calcium channel blocker is amlodipine or a pharmaceutically acceptable salt thereof.
[0506] Embodiment P30. The pharmaceutical composition of any one of embodiments P22-P29, wherein the calcium channel blocker is amlodipine besylate.
[0507] Embodiment P31. The pharmaceutical composition of any one of embodiments P22-P30, wherein the doses of (a), (b), and (c) are each about 80% to about 120% of the lowest hypertension treatment dose (LHTD).
[0508] Embodiment P32. The pharmaceutical composition of any one of embodiments P22-P31, wherein the dose of the thiazide-like diuretic is about 100% of the lowest hypertension treatment dose (LHTD) of the thiazide-like diuretic.
[0509] Embodiment P33. The pharmaceutical composition of any one of embodiments P22-P32, wherein the thiazide-like diuretic is indapamide, and the dose of indapamide is about 1.25 mg.
[0510] Embodiment P34. The pharmaceutical composition of any one of embodiments P22-P33, wherein the dose of said calcium channel blocker is about 100% of the lowest hypertension treatment dose (LHTD) of said calcium channel blocker.
[0511] Embodiment P35. The pharmaceutical composition of any one of embodiments P22-P34, wherein said calcium channel blocker is amlodipine besylate, and the dose of amlodipine besylate is about 2.5 mg.
[0512] Embodiment P36. The pharmaceutical composition of any one of embodiments P22-P35, wherein said angiotensin II receptor blocker is telmisartan, and the dose of telmisartan is about 100% of the lowest hypertension treatment dose (LHTD) of telmisartan.
[0513] Embodiment P37. The pharmaceutical composition of any one of embodiments P22-P36, wherein said angiotensin II receptor blocker is telmisartan, and the dose of telmisartan is about 20 mg.
[0514] Embodiment P38. A pharmaceutical composition of any one of Embodiments P22-P37, wherein the thiazide-like diuretic is indapamide, the calcium channel blocker is amlodipine besylate, and the angiotensin II receptor blocker is telmisartan.
[0515] Embodiment P39. A pharmaceutical composition of Embodiment P38, wherein the dose of telmisartan is about 16 mg to about 24 mg, the dose of indapamide is about 1 mg to about 1.5 mg, and the dose of amlodipine besylate is about 2 mg to about 3 mg.
[0516] Embodiment P40. A pharmaceutical composition of Embodiment P39, wherein the dose of telmisartan is about 20 mg, the dose of indapamide is about 1.25 mg, and the dose of amlodipine besylate is about 2.5 mg.
[0517] Embodiment P41. The pharmaceutical composition of any of the preceding embodiments, wherein the at least one cholesterol-lowering active agent is selected from NPC1L1 inhibitors, statins, or combinations thereof.
[0518] Embodiment P42. The pharmaceutical composition of any of the preceding embodiments, wherein the at least one cholesterol-lowering active agent is a combination of an NPC1L1 inhibitor and a statin.
[0519] Embodiment P43. The pharmaceutical composition of any of the preceding embodiments, wherein the at least one cholesterol-lowering active agent is ezetimibe, rosuvastatin, or a combination thereof.
[0520] Embodiment P44. The pharmaceutical composition of any of the preceding embodiments, wherein the at least one cholesterol-lowering active agent is a combination of ezetimibe and rosuvastatin.
[0521] Embodiment P45. The pharmaceutical composition of Embodiment P43 or P44, wherein the dose of ezetimibe is about 10 mg, and wherein the dose of rosuvastatin is about 10 mg.
[0522] Embodiment P46. A method for treating at least one of hypertension and dyslipidemia in a subject in need, comprising administering to the subject a pharmaceutical composition of any of the preceding embodiments.
[0523] Embodiment P47. A method for treating a combination of hypertension and dyslipidemia in a subject in need, the specification of which is 78 / 83 pages, 81 CN 122272578 A, comprises administering to the subject a pharmaceutical composition of any of the preceding embodiments.
[0524] Embodiment P48. The method of embodiment 46 or 47, wherein the method is a first-line therapy.
[0525] Embodiment P49. A method of treating hypertension and / or dyslipidemia in a subject in need, comprising administering to the subject: (a) an angiotensin II receptor blocker; (b) a diuretic; and (c) a calcium channel blocker, wherein each of (a), (b), and (c) is at a dose of about 40% to about 80% of the lowest therapeutic dose for hypertension (LHTD), and wherein said method further comprises at least one cholesterol-lowering agent.
[0526] Embodiment P50. The method of Embodiment P49, wherein said method substantially excludes angiotensin-converting enzyme inhibitors or pharmaceutically acceptable salts thereof, beta-blockers or pharmaceutically acceptable salts thereof, platelet function modifiers, serum homocysteine lowering agents, or combinations thereof.
[0527] Embodiment P51. The method of Embodiment P49 or P50, wherein said diuretic is a thiazide-like diuretic.
[0528] Embodiment P52. The method of embodiment P51, wherein the thiazide-like diuretic is quetiapine, clopamine, chlorthalidone, mefcitabine, chlorfenapyramide, metoprazine, meteclaron, sipamide, indapamide, chlorothiazide, fenquinazole, or a pharmaceutically acceptable salt or hydrate thereof.
[0529] Embodiment P53. The method of embodiment P52, wherein the thiazide-like diuretic is indapamide or its hydrate.
[0530] Embodiment P54. The method of embodiment P53, wherein the thiazide-like diuretic is indapamide.
[0531] Embodiment P55. The method of any one of embodiments P49-P54, wherein the calcium channel blocker is amlodipine, nifedipine, diltiazem, nimodipine, verapamil, isradipine, felodipine, nicardipine, nisoldipine, clovidipine, dihydropyridine, lorcanidipine, nicardipine, cilnidipine, manidipine, miradipine, benprodil, barnidipine, nivardipine, golopamil, lidocaine, areradipine, dotalizine, dipropionylene, or a pharmaceutically acceptable salt or hydrate thereof.
[0532] Embodiment P56. The method of any one of embodiments P49-P55, wherein the calcium channel blocker is amlodipine or a pharmaceutically acceptable salt thereof.
[0533] Embodiment P57. The method of any one of embodiments P49-P56, wherein the calcium channel blocker is amlodipine besylate.
[0534] Embodiment P58. The method of any one of Embodiments P49-P57, wherein the angiotensin II receptor blocker is irbesartan, telmisartan, valsartan, candesartan, eprosartan, olmesartan, azilsartan, losartan, or a pharmaceutically acceptable salt or hydrate thereof.
[0535] Embodiment P59. The method of any one of Embodiments P49-P58, wherein the angiotensin II receptor blocker is telmisartan.
[0536] Embodiment P60. The method of any one of Embodiments P49-P59, wherein the doses of (a), (b), and (c) are each about 40% to about 60% of the lowest hypertension treatment dose (LHTD).
[0537] Embodiment P61. The method of any one of Embodiments P49-P60, wherein the diuretic is a thiazide-like diuretic, and the dose of the thiazide-like diuretic is about 50% of the lowest hypertension treatment dose (LHTD) of the thiazide-like diuretic.
[0538] Embodiment P62. The method of any one of Embodiments P49-P61, wherein the thiazide-like diuretic is indapamide (page 79 / 83, CN 122272578 A), and the dose of indapamide is about 0.625 mg.
[0539] Embodiment P63. The method of any one of embodiments P49-P62, wherein the dose of the calcium channel blocker is about 50% of the lowest hypertension therapeutic dose (LHTD) of the calcium channel blocker.
[0540] Embodiment P64. The method of any one of embodiments P49-P63, wherein the calcium channel blocker is amlodipine besylate, and the dose of amlodipine besylate is about 1.25 mg.
[0541] Embodiment P65. The method of any one of embodiments P49-P64, wherein the dose of the angiotensin II receptor blocker is about 50% of the lowest hypertension therapeutic dose (LHTD) of the angiotensin II receptor blocker.
[0542] Embodiment P66. The method of any one of embodiments P49-P65, wherein the angiotensin II receptor blocker is telmisartan, and the dose of telmisartan is about 10 mg.
[0543] Embodiment P67. The method of any one of embodiments P49-P66, wherein the angiotensin II receptor blocker is telmisartan, the diuretic is indapamide, and the calcium channel blocker is amlodipine besylate.
[0544] Embodiment P68. The method of embodiment P67, wherein the dose of telmisartan is about 8 mg to about 12 mg, the dose of indapamide is about 0.5 mg to about 0.75 mg, and the dose of amlodipine besylate is about 1 mg to about 1.5 mg.
[0545] Embodiment P69. The method of embodiment P67, wherein the dose of telmisartan is about 10 mg, the dose of indapamide is about 0.625 mg, and the dose of amlodipine besylate is about 1.25 mg.
[0546] Embodiment P70. A method of treating hypertension and / or dyslipidemia in a subject in need, comprising administering to the subject: (a) telmisartan; (b) a thiazide-like diuretic; and (c) a calcium channel blocker, wherein each of (a), (b), and (c) is at about 80% to about 150% of the lowest hypertension treatment dose (LHTD), and wherein said method further comprises at least one cholesterol-lowering active agent.
[0547] Embodiment P71. The method of Embodiment P70, wherein said method substantially excludes angiotensin-converting enzyme inhibitors or pharmaceutically acceptable salts thereof, beta-blockers or pharmaceutically acceptable salts thereof, platelet function modifiers, serum homocysteine lowering agents, or combinations thereof.
[0548] Embodiment P72. The method of Embodiment P70 or P71, wherein said diuretic is a thiazide-like diuretic.
[0549] Embodiment P73. The method of embodiment P72, wherein the thiazide-like diuretic is quetiapine, clopamine, chlorthalidone, mefcitabine, chlorfenapyramide, metoprazine, meteclaron, sipamide, indapamide, chlorothiazide, fenquinazole, or a pharmaceutically acceptable salt or hydrate thereof.
[0550] Embodiment P74. The method of embodiment P73, wherein the thiazide-like diuretic is indapamide or its hydrate.
[0551] Embodiment P75. The method of embodiment P74, wherein the thiazide-like diuretic is indapamide.
[0552] Embodiment P76. The method of any one of embodiments P70-P75, wherein the calcium channel blocker is amlodipine, nifedipine, diltiazem, nimodipine, verapamil, isradipine, felodipine, nicardipine, nisoldipine, clovidipine, dihydropyridine, lorcanidipine, nicardipine, cilnidipine, manidipine, miradipine, benprodil, barnidipine, nivardipine, golopamil, lidocaine, areradipine, dotazine, dipropionyl, or a pharmaceutically acceptable salt or hydrate thereof.
[0553] Embodiment P77. The method of any one of embodiments P70-P76, wherein the calcium channel blocker is amlodipine or a pharmaceutically acceptable salt thereof. Specification 80 / 83 pages 83 CN 122272578 A
[0554] Embodiment P78. The method of any one of embodiments P70-P77, wherein the calcium channel blocker is amlodipine besylate.
[0555] Embodiment P79. The method of any one of embodiments P70-P78, wherein the doses of (a), (b), and (c) are each about 80% to about 120% of the lowest hypertension treatment dose (LHTD).
[0556] Embodiment P80. The method of any one of embodiments P70-P79, wherein the dose of the thiazide-like diuretic is about 100% of the lowest hypertension treatment dose (LHTD) of the thiazide-like diuretic.
[0557] Embodiment P81. The method of any one of Embodiments P70-P80, wherein the thiazide-like diuretic is indapamide, and the dose of indapamide is about 1.25 mg.
[0558] Embodiment P82. The method of any one of Embodiments P70-P81, wherein the dose of the calcium channel blocker is about 100% of the lowest hypertension treatment dose (LHTD) of the calcium channel blocker.
[0559] Embodiment P83. The method of any one of Embodiments P70-P82, wherein the calcium channel blocker is amlodipine besylate, and the dose of amlodipine besylate is about 2.5 mg.
[0560] Embodiment P84. The method of any one of Embodiments P70-P83, wherein the angiotensin II receptor blocker is telmisartan, and the dose of telmisartan is about 100% of the lowest hypertension treatment dose (LHTD) of telmisartan.
[0561] Embodiment P85. The method of any one of Embodiments P70-P84, wherein the angiotensin II receptor blocker is telmisartan, and the dose of telmisartan is about 20 mg.
[0562] Embodiment P86. The method of any one of Embodiments P70-P85, wherein the thiazide-like diuretic is indapamide, the calcium channel blocker is amlodipine besylate, and the angiotensin II receptor blocker is telmisartan.
[0563] Embodiment P87. The method of Embodiment P86, wherein the dose of telmisartan is about 16 mg to about 24 mg, the dose of indapamide is about 1 mg to about 1.5 mg, and the dose of amlodipine besylate is about 2 mg to about 3 mg.
[0564] Embodiment P88. The method of embodiment P87, wherein the dose of telmisartan is about 20 mg, the dose of indapamide is about 1.25 mg, and the dose of amlodipine besylate is about 2.5 mg.
[0565] Embodiment P89. The method of any one of embodiments P49-P88, wherein the at least one cholesterol-lowering active agent is selected from NPC1L1 inhibitors, statins, or combinations thereof.
[0566] Embodiment P90. The method of any one of embodiments P49-P89, wherein the at least one cholesterol-lowering active agent is a combination of NPC1L1 inhibitors and statins.
[0567] Embodiment P91. The method of any one of the preceding embodiments, wherein the at least one cholesterol-lowering active agent is ezetimibe, rosuvastatin, or a combination thereof.
[0568] Embodiment P92. The method of any one of embodiments P49-P90, wherein the at least one cholesterol-lowering active agent is a combination of ezetimibe and rosuvastatin.
[0569] Embodiment P93. The method of Embodiment P91 or P92, wherein the dose of ezetimibe is about 10 mg, and wherein the dose of rosuvastatin is about 10 mg.
[0570] Embodiment P94. The method of any one of Embodiments P49-P93, wherein (a), (b), (c) and the at least one cholesterol-lowering active agent are provided in a single formulation.
[0571] Embodiment P95. The method of any one of Embodiments P49-P93, wherein (a), (b), (c) and the at least one cholesterol-lowering active agent are provided in at least two separate formulations.
[0572] Embodiment P96. The method of any one of Embodiments P49-P93, wherein (a), (b), (c) and at least two of the at least one cholesterol-lowering active agent are provided in a single formulation.
[0573] Embodiment P97. The method of any one of embodiments P49-P93, wherein (a), (b), (c) and at least three of the at least one cholesterol-lowering active agent are provided in a single formulation.
[0574] Embodiment P98. The method of embodiment P97, wherein the at least one cholesterol-lowering active agent is a combination of ezetimibe and rosuvastatin.
[0575] Embodiment P99. The method of embodiment P98, wherein (a), (b), (c) are provided in a single formulation, and the combination of ezetimibe and rosuvastatin is provided in another formulation.
[0576] In one aspect, a pharmaceutical composition is provided comprising at least two of the following: (a) an angiotensin II receptor blocker; (b) a diuretic; and (c) a calcium channel blocker, wherein each of (a), (b), and (c) is at a dose of about 40% to about 80% of the lowest therapeutic dose of hypertension (LHTD), wherein the pharmaceutical composition further comprises at least one cholesterol-lowering active agent.
[0577] In another aspect, a pharmaceutical composition is provided comprising at least three of the following: (a) an angiotensin II receptor blocker; (b) a diuretic; and (c) a calcium channel blocker, wherein each of (a), (b), and (c) is at a dose of about 40% to about 80% of the lowest therapeutic dose for hypertension (LHTD), wherein the pharmaceutical composition further comprises at least one cholesterol-lowering active agent. In another aspect, a pharmaceutical composition is provided comprising at least two of the following: (a) telmisartan; (b) a thiazide-like diuretic; and (c) a calcium channel blocker, wherein each of (a), (b), and (c) is at a dose of about 80% to about 150% of the lowest therapeutic dose for hypertension (LHTD), wherein the pharmaceutical composition further comprises at least one cholesterol-lowering active agent.
[0578] In another aspect, a pharmaceutical composition is provided comprising at least two of the following: (a) telmisartan; (b) a thiazide-like diuretic; and (c) a calcium channel blocker, wherein each of (a), (b), and (c) is at a dose of about 80% to about 150% of the lowest therapeutic dose (LHTD), wherein the pharmaceutical composition further comprises at least one cholesterol-lowering active agent.
[0579] In another aspect, a pharmaceutical composition is provided comprising at least three of the following: (a) telmisartan; (b) a thiazide-like diuretic; and (c) a calcium channel blocker, wherein each of (a), (b), and (c) is at a dose of about 80% to about 150% of the lowest therapeutic dose (LHTD), wherein the pharmaceutical composition further comprises at least one cholesterol-lowering active agent.
[0580] In some embodiments, (a), (b), and (c) are provided in a single formulation, and the combination of ezetimibe and rosuvastatin is provided in another formulation.
[0581] In another aspect, this document also provides a method for treating at least one of hypertension and dyslipidemia in a subject in need, comprising administering a pharmaceutical composition disclosed in some or any of the above embodiments. In an improvement, this method is a first-line therapy.
[0582] In another aspect, this document also provides a method for treating a combination of hypertension and dyslipidemia in a subject in need, comprising administering a pharmaceutical composition disclosed in some or any of the above embodiments. In an improvement, this method is a first-line therapy.
[0583] While preferred embodiments of the present disclosure have been shown and described herein, it will be apparent to those skilled in the art that these embodiments are provided by way of example only. Many variations, alterations, and substitutions will occur to those skilled in the art without departing from the scope of this disclosure. It should be understood that various alternatives to the embodiments of the present disclosure described herein may be employed in carrying out this disclosure. The scope of this disclosure is intended to be defined by the appended claims, and thereby covers the methods and structures within the scope of those claims and their equivalents.Instruction manual, page 83 / 83, 86 CN 122272578 A, Figure 1; Instruction manual, Figure 1 / 3, page 87 CN 122272578 A, Figure 2; Instruction manual, Figure 2 / 3, page 88 CN 122272578 A, Figure 3; Instruction manual, Figure 3 / 3, page 89 CN 122272578 A. Abstract: Provided herein are pharmaceutical compositions that are useful for the treatment of hypertension comprising an angiotensin II receptor blocker, a diuretic, and a calcium channel blocker.
Claims
1. A pharmaceutical composition comprising: (a) Telmisartan; (b) Indapamide; and (c) Amlodipine besylate; The dosage of telmisartan is 8-12 mg or 12-16 mg; the dosage of indapamide is 0.5-0.75 mg or 0.75-1.0 mg; the dosage of amlodipine besylate is 1-1.5 mg or 1.5-2 mg; and the pharmaceutical composition further comprises one or more cholesterol-lowering active agents.
2. The pharmaceutical composition according to claim 1, wherein the dose of indapamide is about 0.625 mg.
3. The pharmaceutical composition according to claim 1 or 2, wherein the dose of amlodipine besylate is 1 to 1.5 mg.
4. The pharmaceutical composition according to claim 1 or 2, wherein the dose of amlodipine besylate is 1.5 to 2 mg.
5. The pharmaceutical composition according to any one of the preceding claims, wherein the dose of telmisartan is about 10 mg.
6. The pharmaceutical composition according to any one of the preceding claims, wherein the dose of indapamide is about 0.625 mg, the dose of amlodipine besylate is 1.5-2 mg, and the dose of telmisartan is about 10 mg.
7. A pharmaceutical composition comprising: (a) Telmisartan; (b) Indapamide; and (c) Amlodipine besylate; The dosage of telmisartan is 16-30 mg, 16-24 mg, 18-22 mg, or 30-50 mg; the dosage of indapamide is 1-1.875 mg, 1-1.5 mg, 1.125-1.375 mg, or 1.875-3.125 mg; the dosage of amlodipine besylate is 2-3.75 mg, 2-3 mg, 2.25-2.75 mg, or 3.75-6.25 mg; and the pharmaceutical composition further comprises one or more cholesterol-lowering active agents.
8. The pharmaceutical composition according to claim 7, wherein the dose of amlodipine besylate is 2-3.75 mg.
9. The pharmaceutical composition according to claim 7 or 8, wherein the dose of amlodipine besylate is 2-3 mg.
10. The pharmaceutical composition according to any one of claims 7-9, wherein the dose of amlodipine besylate is 2.25-2.75 mg.
11. The pharmaceutical composition according to any one of claims 7-10, wherein the dose of amlodipine besylate is 3.75-6.25 mg.
12. The pharmaceutical composition according to any one of claims 7-11, wherein the dose of indapamide is about 1.25 mg.
13. The pharmaceutical composition according to any one of claims 7-12, wherein the dose of telmisartan is about 20 mg.
14. The pharmaceutical composition according to any one of claims 7-13, wherein the dose of indapamide is about 1.25 mg, the dose of amlodipine besylate is 2 mg-3.75 mg, and the dose of telmisartan is about 20 mg.
15. The pharmaceutical composition according to claim 1 or 7, wherein the pharmaceutical composition is a pill, tablet or capsule.
16. The pharmaceutical composition according to any one of the preceding claims, wherein the one or more cholesterol-lowering drugs are rosuvastatin, ezetimibe, or a combination thereof.
17. The pharmaceutical composition according to claim 16, wherein one or more cholesterol-lowering active agents are rosuvastatin.
18. The pharmaceutical composition according to claim 16 or 17, wherein the dose of rosuvastatin is 10 mg.
19. The pharmaceutical composition according to claim 16, wherein one or more cholesterol-lowering active agents are ezetimibe.
20. The pharmaceutical composition according to claim 16 or 19, wherein the dose of ezetimibe is 10 mg.
